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Developmental speech and language disorders
Normal and abnormal speech and language development
Most children acquire speech and language skills quickly in the first few years of life, in a 
way that seems almost effortless. For example, a typical two-and-a-half year old toddler can 
already speak over 1000 words and understand even more1, without having received any 
formal teaching. Interestingly, the acquisition of spoken language appears to be specific to 
our species; no other living animal demonstrates this capacity2. In humans, interaction via 
language is crucial for socio-emotional development and academic performance3. The ability 
to acquire speech and language skills forms the basis for many other areas of development. 
In some children, the development of speech and language skills is not that straightforward 
and uncomplicated. Such problems may be first recognized at toddler age, when a child 
starts talking later than other children or has difficulties understanding language. However, 
language impairments can also become apparent only at a later age. Language problems 
at a young age might be short-lived; a subset of so-called ‘late talkers’ or ‘late bloomers’ 
catch-up completely and do not have any difficulties in the long term4. Nonetheless, in a 
significant proportion of children, deficits do not resolve spontaneously5. If the problems 
persist and are not the obvious result of another primary cause, such as deafness, traumatic 
brain injury or insufficient language exposure, the child might have a developmental speech 
or language disorder, that is a neurobiological disorder characterized by impaired speech 
and/or language development.
Terminology and categorization
Although the existence of developmental speech and language disorders is not questioned, 
there are many different ideas on terminology and criteria used to define them. Especially for 
language impairments, several different names have been used over time, including specific 
language impairment, developmental dysphasia and developmental language disorder. 
Because language disorders are at the interface of different medical and educational 
professions, inconsistent naming and categorization can lead to confusion and inconsistency 
in clinical and research practices6,7.
Two well-known diagnostic manuals contain definitions for developmental speech and 
language disorders: the Diagnostic and Statistical Manual of Mental disorders (DSM) and 
the International Classification of Diseases (ICD). Importantly, both classification systems 
do not always reflect the diagnoses given or the terminology used in practice by speech 
and language therapists7. The current version of the DSM, DSM-5, contains the category 
communication disorders, with the following subcategories: language disorder, social 
(pragmatic) communication disorder, speech sound disorder and childhood-onset fluency 
disorder (stuttering)8. In DSM-5, verbal dyspraxia is listed in the subcategory speech sound 




and language which contains several subcategories (e.g. phonological disorder, expressive 
language disorder, mixed receptive-expressive language disorder and apraxia). 
Although the terminology of communication disorders represents an ongoing topic 
of debate, results of a recent Delphi study, performed within the international and 
multidisciplinary CATALISE consortium, recommend the adoption of the consensus English 
term developmental language disorder (abbreviated as DLD)9. In the Netherlands, since 
2014 the same label (in Dutch: taalontwikkelingsstoornis, commonly abbreviated as TOS) 
has been widely used by speech therapists, as well as all care and education organizations 
involved10. For developmental speech disorders, the term commonly used in the literature 
is speech sound disorders (in the Netherlands: spraakontwikkelingsstoornis; developmental 
speech disorder). These labels are used as umbrella terms for a heterogeneous category of 
children who have errors in speech production that significantly impact intelligibility. 
In this thesis, the term developmental speech and language disorders is used to refer 
to children diagnosed with a DLD and/or a speech sound disorder. This encompasses all 
developmental speech and language disorders as referred to in DSM-V and ICD-10, with 
the exception of stuttering (fluency disorders). Figure 1 shows a schematic overview of the 
terms and classification as used in this thesis. 




Prevalence of developmental speech and language disorders
The prevalence of developmental speech and language disorders amongst children is not 
exactly known, and can vary widely depending on, for example, the age of the child and the 
diagnostic criteria that are used. The most cited study that estimated prevalence was a USA-
based population study of monolingual children (i.e. children who were proficient in only 
one language) around five years of age, in which a DLD was identified in ~7% of the sample 
11. Another study in Sweden reported that the vast majority of the 5-6% of children who 
screened positive in a language screening at 2.5 years of age, later fulfil criteria for DLD when 
assessed by a speech therapist5. In the Netherlands the precise number of children with 
developmental speech and language disorders is unknown, as no systematic registration is in 
place. It is known that there we 84,000 children under ten years old  with DLD who received 
speech therapy from a local speech therapist in 2017, while 4,900 such children received 
multidisciplinary treatment in a Cluster 2 setting12. Systematic terminology, clear diagnostic 
guidelines and diagnostic registration systems are needed in order to provide more accurate 
estimates of the prevalence of developmental speech and language disorders and of the 
various subtypes within this heterogeneous group of disorders. 
Clinical features
Children with developmental speech and language disorders can have problems with various 
aspects of speech and/or language, with differing levels of severity. While the relationships 
between speech and language are complex, we here present a general framework that is 
helpful for approaching heterogeneity within speech and language disorders. In general, 
language is defined by the complex ability of using and understanding words and sentences 
(independent of the modality used to express those), speech is the process of shaping 
meaningful vocalisations. 
According to this framework, on a language level, different facets and associated problems 
can be categorized9,10, including but not limited to the following:
• Phonology: the organization of speech sounds into categories. An example of this is 
phonological awareness problems; when a child has problems with correctly identifying 
units of spoken language.
• Syntax and morphosyntax: the rules and principles that determine the structure of 
sentences and how words within a sentence are modified depending on the context. A 
child can have both expressive problems with syntax (e.g. use of short sentences only 
or problems with correct conjugation of verbs), but receptive language impairments 
affecting syntax can also occur (e.g. not understanding different sentence structures 
correctly).
• Semantics: the area concerned with the meaning of words and sentences. A child can for 




• Pragmatics: a topic concerning how language is used appropriately in a given context. 
Examples of pragmatic language problems include saying unrelated or inappropriate 
things in a certain situation, or trouble with understanding social communication 
cues. Of note, pragmatics and semantics interact in important ways; a child might 
misunderstand the intended meaning of a sentence because he or she lacks the 
necessary pragmatic abilities and come up with the wrong inference.
On a speech level, different types of speech problems and disorders can be characterized as 
well4,13. Using speech observation and specific speech tasks and tests, a speech therapist can 
distinguish between different underlying processes that lead to speech problems. Different 
classification systems of speech disorders are being used, based on e.g. etiological and/or 
linguistic approaches13. Examples of problems that can be defined on a speech level are: 
• Phonological problems: These happen when a child does not understand and/or 
correctly use the rules for sounds of a language, leading to phonological error patterns, 
see also the description in previous paragraph (phonological problems can influence 
speech and language processes). 
• Phonetic articulation problems: These include substitutions or distortions of the same 
sound in different situations (e.g. in isolation, verbs and sentences; during imitations 
and spontaneous speech). Articulation problems lead to mispronunciation (e.g. lisping).
• Motor speech problems: These include problems with planning, programming and 
execution. For example, childhood apraxia of speech (CAS) is a developmental speech 
disorder that is the result of planning and coordination difficulties.
There is no international consensus about inclusion criteria for developmental speech 
and language disorders and diagnostic test procedures, and a lot of variation exists not 
only between countries but also within countries14. Using a discrepancy criterion for IQ 
(referred to as cognitive referencing), in which non-verbal IQ should be higher than the 
language scores, does not seem to contribute to better diagnosis10. In short, one can infer a 
developmental speech or language disorder if there are significant language and/or speech 
impairments, in the absence of a clear primary cause such as hearing loss, brain injuries, 
low non-verbal intelligence or language deprivation, and if problems endure into middle 
childhood and beyond, with a serious impact on everyday social interactions9,10. 
Specific language and speech problems can be present in distinct combinations, and with 
different problems being most prominent. Over the years, many attempts have been 
made to create separate profiles or subgroups, but no agreement has been reached on 
the definition of clear clusters or profiles9,10. All in all, it is most important to realize that 
even with consistent terminology and categorization, developmental speech and language 
disorders will always be heterogeneous disorders that include a wide range of speech and 




Diagnosis, treatment and prognosis
Systematic screening is important to identify children with possible speech and language 
impairments at a young age. Although some young children might catch up and not have a 
developmental speech or language disorder later in life, it is important to start monitoring 
and instigate treatment as early as possible. A wait-and-see approach can place young 
children at risk for life-long problems15; late talkers are generally thought to need at least 
watchful surveillance16. 
A developmental speech or language disorder diagnosis is made by a speech therapist, 
ideally in consultation with a multidisciplinary team, to not only assess speech/language 
capacities but also medical, psychological and environmental factors10. Testing of speech and 
language capacities is usually performed using a combination of observation, normalized 
speech and language tests, and spontaneous language analysis10. The testing procedure and 
tests chosen depend on many different factors, including but not limited to the age and 
capacities of the individual being tested, the language spoken and the test characteristics 
(e.g. the test reliability and validity). Examples of currently used tests in the Netherlands are 
the Schlichting tests for Language Comprehension17 and Language Production-II18, the Dutch 
version of the Peabody Picture Vocabulary test-III19, the Clinical Evaluation of Language 
Fundamentals (CELF-4-NL)20 and the Dutch Nonspeech Test (NNST)21. In addition to direct 
assessments, scoring checklists or scales are often used that can be filled in by parents and/
or therapists such as ICS-NL and CCC. After thorough assessment, a subsequent therapeutic 
plan can be devised, depending on the profile of problems and their severity, as different 
types of therapies and treatment strategies exist4. In short, language therapy can be defined 
as specific intensive stimulation to improve aspects of language22, in order to reach goals 
not just focused on the disorder but on improving communication and participation10. 
Most children receive treatment from a local speech therapist. In more severe cases 
specialized ambulatory support or education in a special education setting for children with 
communication difficulties might be necessary.
The long-term prognosis of a developmental speech or language disorder can vary. Some 
children do not have any speech/language problems at a later age10, but for many children the 
problems persist later in life and can significantly affect social and societal participation23,24. 
Other neurodevelopmental disorders: clinical overlap and differences
Developmental speech and language disorders form a subgroup within the larger group 
of neurodevelopmental disorders with regard to categorization in the DSM-5. In fact, 
developmental speech and language disorders often co-occur with other developmental 
disorders or difficulties, including Attention Deficit Hyperactivity Disorder (ADHD), motor 
impairments, developmental dyslexia and autism spectrum disorder7,25. The presence of 
other developmental disorders might complicate diagnosis and intervention strategies for 




On the other hand, problems with speech and/or language can also reflect a broader 
underlying neurodevelopmental disorder. The best-known example of this may be the 
co-occurrence of  language problems in the context of autism spectrum disorder. Verbal 
children with autism spectrum disorder can have language impairments that appear similar 
to those in children with DLD26. Speech and language deficits can also be observed in 
childhood epilepsy disorders27. Specifically, Landau-Kleffner syndrome is a disorder of the 
epilepsy-aphasia spectrum in which children with previously normal development show 
language regression with a typical profile, together with nocturnal EEG abnormalities and 
rare seizures27,28. Finally, speech and language problems can also occur in the context of 
broader cognitive impairments, as in intellectual disability.
In the early literature on speech and language disorders, much emphasis was put on the 
idea of specificity, e.g. a person could not be diagnosed with a DLD if this individual was also 
diagnosed with an autism spectrum disorder. Using exclusionary factors rather than inclusion 
factors has led to major issues in categorization of these disorders, and this approach does 
not fit with knowledge on underlying pathogenic mechanisms, a topic further discussed in 
Chapter 9 of this thesis.
Genetics of developmental speech and language disorders
Heritability 
It has been known for a long time that developmental speech and language disorders tend 
to run in families29; a positive family history is a clear risk factor for developing a DLD9,10. 
Yet, familial occurrence alone does not prove a genetic origin. Shared environment could 
also lead to familial clustering of DLD. It is known that environmental factors play an 
important role in normal speech and language development, because after all, a child will 
not learn a language without being exposed to it30. However, it is not entirely clear what 
role environmental factors exactly play in the development of developmental speech and 
language disorders.
Twin studies provide one means for disentangling contributions of genetic and environmental 
factors, and can give insights into the heritability of a trait. Heritability is defined as the 
proportion of phenotypic variance that can be attributed to genetic differences. As 
monozygotic twins have virtually identical genomes, while dizygotic twins on average share 
about 50% of polymorphic alleles, the co-occurrence of a disorder in monozygotic twins 
compared with that in dizygotic twins enables estimation of its heritability. For developmental 
speech and language disorders, several twin studies have shown that heritability is high (at 
least 0.5)31-33, although such estimates might vary depending on inclusion criteria and cut-off 
values for speech or language impairments used34. 
Thus, it is clear from family and twin data that developmental speech and language 
disorders are strongly influenced by genetics. In addition, genetic factors also make a strong 
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contribution to normal variation in speech and language development, as assessed with 
a range of quantitative tests35. Nevertheless, it is important to point out that the concept 
‘language’ itself is not encoded in our genes. Rather, our DNA and the genetic variance that 
it harbours are important in shaping the human brain in such a way that it is able to use 
speech and language, sometimes referred to as the ‘language-ready’ brain.
Inheritance patterns: multifactorial and Mendelian inheritance
The concept of heritability is useful for demonstrating that there is a genetic influence on a 
trait, but it does not reveal anything about the likely mode(s) of inheritance. In the context 
of speech and language disorders, it is important to distinguish between multifactorial and 
Mendelian inheritance patterns. 
Multifactorial inheritance means that a disorder or trait is the outcome of multiple 
genetic and environmental factors. On a genetic level, this means that many DNA variations 
contribute to the risk of developing the disorder, and that different combinations of different 
common variants can give rise to the same phenotype. These variants may have a range of 
sizes at the genomic level, as well as variable modes of influence, but they are generally 
common polymorphisms, each with a small effect size. Most recognised in this context are 
single nucleotide polymorphisms (SNPs); single base pair changes found at a frequency 
of >1% in the general population. Disorders with a multifactorial inheritance pattern are 
referred to as complex diseases. For complex disorders, it is not possible to perform a single 
DNA test on an individual level and determine the exact risk of developing the disorder. In 
this case, it is necessary to compare extremely large groups of people with and without the 
disorder of interest, to give adequate statistical power for tracking down specific genetic 
risk loci (e.g. SNPs). It has now become standard practice to analyse such large samples for 
association using millions of SNPs spread throughout the genome - these types of studies 
are called case-control ‘genome wide association screens’ (GWAS). Beyond case-control 
designs, similar approaches can be used to test SNPs for association with quantitative 
traits (i.e. continuously varying phenotypes) again requiring very large sample sizes to give 
sufficient power for detecting small effect sizes via a GWAS design.
Studies of developmental speech and language disorders indicate that much of the 
underlying genetic architecture is indeed complex and multifactorial. Several GWAS efforts 
have been undertaken, and some interesting genetic loci have been identified36-39, but these 
studies have often been underpowered and not all of them used a replication cohort to 
confirm findings. Moreover, independent replication studies of the strongest findings are 
still scarce. Larger systematic studies are needed to better understand the complex genetic 
background of developmental speech and language disorders.
On the other hand, there is Mendelian inheritance. A Mendelian (also known as monogenic) 




transmission pattern that follows Mendel’s principles. Typically, Mendelian disorders are 
caused by rare genetic variants with a large effect size. Examples of Mendelian inheritance 
patterns are autosomal dominant (as seen in e.g. Marfan syndrome), autosomal recessive 
(e.g. cystic fibrosis), X-linked dominant (e.g. Rett syndrome) and X-linked recessive (e.g. red-
green colour blindness).
Over the past decade, an increasing number of reports have identified Mendelian causes 
of developmental speech and language disorders. It is currently unknown what proportion 
of cases of developmental speech and language disorders may be explained by Mendelian 
causes, and what proportion is multifactorial. Nonetheless, it is well established that 
studying Mendelian forms of disorder is a powerful way for gaining insights into aetiology. 
This thesis focuses specifically on Mendelian causes of developmental speech and language 
disorders, and the prospects of using recent developments in DNA sequencing technologies 
for advancing our understanding of their biology.
FOXP2: the first Mendelian link to developmental speech and language disorders
Until the introduction of new genetic techniques in the last decade, identifying the gene 
responsible for a disease of interest was generally very labour- and time-intensive. Often, 
a method termed positional cloning was used, in which the segregation of the phenotype 
of interest was studied in a large family, or in multiple families with the same phenotype. 
It was this approach that led to the discovery of FOXP2, the first gene to be implicated in a 
Mendelian form of speech and language disorder.
FOXP2 was originally identified in 2001, through genetic studies of a large three-generational 
family with CAS as the core phenotype, and a complex suite of deficits in expressive and 
receptive language with varying degrees of severity40,41. While the affected individuals did 
not have intellectual disability, they had on average lower nonverbal IQ than their unaffected 
family members41. Fifteen (about half) of the family members in different generations were 
diagnosed with this disorder, clearly fitting a Mendelian (autosomal dominant) inheritance 
pattern, facilitating a positional cloning approach. After using linkage mapping to determine 
the most likely chromosomal location of the putative etiological variant (chromosome 
7q31.2)42, and identification of an unrelated individual with CAS and a balanced chromosomal 
translocation disrupting this same region, FOXP2 was established as the gene responsible40. 
A single base pair substitution within FOXP2 turned out to perfectly co-segregate with the 
disorder in the family of interest42. In the years following publication of these first cases 
of FOXP2 mutation, more children with variants disrupting the gene have been identified, 
including different missense and truncating variants, as well as microdeletions encompassing 
the whole locus43. Although speech and language problems are still the most prominent 
feature of the FOXP2-associated disorder, other neurodevelopmental features reported in 




FOXP2 has since been the focus of interest for many studies of genetic pathways involved 
in speech and language. The FOXP2 gene encodes the FOXP2 protein, a member of the 
forkhead-box family of transcription factors with important roles in regulating the expression 
of other genes45, and is highly expressed in several regions of the developing brain, including 
the cortex, striatum, thalamus and cerebellum46. For example, it has been shown that mice 
with cortex-specific disruptions of Foxp2 show deficits in social behaviour and cognitive 
flexibility47,48, and disruption of FoxP2 in area X (a brain region involved in vocal learning) 
affects song development and song production in zebra finches49. All in all, in vitro and in 
vivo studies on FOXP2 function have led to important insights beyond the  FOXP2-associated 
human disorder50.  
There is no doubt that rare disruptive FOXP2 variants can cause a developmental speech and 
language disorder, with CAS as a prominent feature. Nonetheless, this does not mean that 
most children with CAS have a pathogenic FOXP2 disruption. In fact, although the frequency 
of FOXP2 variants in cohorts of children with CAS has not yet been systematically assessed, 
it is likely that pathogenic variants in FOXP2 can only be found in a very small minority of 
children with CAS43. The reason for this is that there are likely many more genes in which 
pathogenic variants can cause CAS, resulting in genetic heterogeneity, a concept further 
explained later in this chapter. Until today FOXP2 is the only gene recorded as associated 
with a specific speech and language disorder in the OMIM (Online Mendelian Inheritance in 
Man) database, where the phenotype associated with FOXP2 variants is indexed as Speech-
language disorder-1 (MIM 602081). 
Chromosomal abnormalities in developmental speech and language disorders
When discussing different types of genetic variation, a distinction is often made between 
variants at the chromosomal level and at the  nucleotide (base pair) level. Chromosomal 
aberrations include aneuploidies (gain or loss of chromosomes; e.g. trisomy 21) and 
copy number variants (CNVs). CNVs are gains or losses of chromosomal material (>1,000 
nucleotides), e.g. a 22q11 microdeletion, which is a deletion involving a part (band 11) of 
the long arm (q-arm) of chromosome 22. In addition to aneuploidies and CNVs, many other 
complex chromosomal rearrangements can occur: e.g. translocations, inversions, etc. 
Large chromosomal aberrations (>5Mb) can be detected using karyotyping, a technique 
in which the chromosomes are made visible under a microscope. Using karyotyping, a 
study published in 1980 showed an increased prevalence of numerical chromosomal 
abnormalities in a cohort of children with specific speech and language delays: four out of 
88 tested children had a whole chromosome aneuploidy (47XXY, 47XYY, 48XXYY and mosaic 
trisomy 21)51. This finding was confirmed in a more recent study using genome-wide SNP 
genotype data, in which a higher prevalence of sex chromosome aneuploidies was found 
in a cohort of children with speech/language delays and a cohort of children with specific 




abnormalities, as well as chromosomal translocations have all been reported in individuals 
with speech or language disorders, e.g. reciprocal translocations affecting FOXP242,53,54. 
Since the introduction of microarray platforms, including array CGH (comparative genomic 
hybridization) and SNP arrays, it is now possible to easily perform genome-wide CNV 
screens with high resolution55,56. A small number of cohort studies have been published in 
which CNV testing was done in children with developmental speech and language disorders, 
with overlapping conclusions but also conflicting evidence in terms of the enrichment of 
different types of CNVs in individuals with DLD. Laffin et al. identified different possibly 
pathogenic CNVs using array CGH in a USA-based cohort of children with CAS, including a 
16p11.2 deletion57. Simpson et al. used SNP genotyping (in combination with CNV calling) 
to show an enrichment of common CNVs in children with DLD from the United Kingdom, 
not driven by large or de novo variants58. A de novo variant is a variant (SNV or CNV) that 
is present in an individual but not in either parent. Finally, Kalnak et al. similarly used SNP 
arrays to call CNVs in Swedish children with a DLD and typically developing children, but in 
this case reported an enrichment for rare and de novo CNVs in the DLD group59. 
For the broader field of neurodevelopmental disorders, the introduction of microarrays 
in research and diagnostic settings has led to the identification and characterization of 
many new microdeletion and duplication syndromes, and thus provided many affected 
individuals with a molecular diagnosis60,61. One of the best characterized CNVs is the 16p11.2 
deletion, which constituted a risk factor in several different cohort studies of children with 
developmental speech and language disorders57,59 and in studies of individuals with CAS62-64. 
A prospective study in 55 individuals with a 16p11.2 deletion showed that the majority of 
individuals had CAS, as well as receptive and expressive language impairments65. However, 
although speech and language problems are often a prominent feature of this microdeletion 
syndrome, the phenotype is not speech/language-specific, as a wide spectrum of additional 
features can be present in affected individuals, including autism spectrum disorders, mild 
intellectual disability and seizures66. Other CNVs have been associated with speech and/or 
language delays, e.g. 15q11.2 deletion or duplication67,68, 7q11.23 duplication69 and 1p21.3 
deletion. Individuals with these deletions or duplications often show prominent speech and/
or language impairments, but again the syndromes are not limited to the speech/language 
domain and often show highly variable expressivity, which is further discussed in the last 
paragraph of this chapter.
In summary, most chromosomal abnormalities found in children with speech and language 
disorders are not speech- or language-specific, but often associated with a broad range of 
other possible neurodevelopmental impairments. Nevertheless, it is clear that CNVs can be 
the cause developmental speech and language disorders, and that these pathogenic CNVs 
are more present in children with developmental speech and language disorders compared 




Not long after the introduction of high resolution microarrays, next generation sequencing 
(NGS) methods became widely available70. NGS is a collective name for all techniques 
involving massive parallel sequencing. In short, these techniques have made it possible 
to read out the sequence of nucleotides of a very large number of DNA fragments at the 
same time, at costs that have become lower and lower as methods have advanced.. Due 
to the introduction of NGS, it is now possible to analyse entire genomes at a base pair 
resolution with relative ease, for example to search for disease-causing single nucleotide 
variants. Perhaps the most common current use of NGS techniques in human genetics is 
for sequencing of whole exomes (where the exome is defined as all coding genes within the 
genome) and genomes.
The advantages of these new sequencing techniques are numerous. With exome and 
genome sequencing it is now much more feasible to identify Mendelian disorders caused 
by single nucleotide variants, obviating the need for a prior hypothesis about the specific 
gene involved. This is especially important for disorders that are less recognizable and/
or phenotypes that can be caused by a single variant in many different genes (genetically 
heterogeneous disorders). These advances have led to highly improved diagnostic 
possibilities for patients with various kind of disorders, as the number of new candidate 
genes and associated disorders has expanded very rapidly and is still growing71. Altogether, 
the widespread introduction of NGS in research and diagnostic practices has greatly 
contributed to our knowledge on disease genes and associated inheritance mechanisms, 
and also on proteins, pathways and pathogenic mechanisms involved in disease.
Exome sequencing is now implemented in diagnostic practices for many developmental 
disorders, such as intellectual disability and autism spectrum disorder, and has been 
demonstrated to outperform chromosome microarrays as a first-tier clinical diagnostic test 
for unexplained neurodevelopmental disorders72. Not only has the use of NGS confirmed 
the extreme genetic heterogeneity for these disorders, it has also revealed the significance 
of de novo variants. It is estimated that more than 40% of individuals with a severe 
neurodevelopmental disorder has a disease-causing de novo variant in the coding region 
of a gene73. 
Single nucleotide variants in developmental speech and language disorders
In contrast to several other neurodevelopmental disorders, for the field of developmental 
speech and language disorders, genetic testing and especially diagnostic exome/genome 
sequencing is not yet common practice. In a research setting, a few studies have been 
published in which NGS has been used to investigate developmental speech or language 
disorder cohorts: three studies in children with CAS, and one in a cohort of children with 
DLD. The first study on CAS used exome sequencing in a cohort of ten affected children74. 




was hampered by missing information on variant frequencies in control populations and 
inheritance status. Moreover, although the authors sequenced the whole exome, they 
prioritized most of their analysis on prior “candidate genes” from the earlier (limited) 
literature, leading them to propose variants in those genes as potentially pathogenic, 
that have subsequently turned out to be benign. Another NGS study on CAS used whole 
genome sequencing in nineteen unrelated individuals, a cohort partially overlapping with 
the previously mentioned exome sequencing study75. Three de novo likely pathogenic 
variants were found in three probands, affecting the genes CHD3, SETD1A and WDR5, and 
five additional pathogenic or likely pathogenic variants in other probands where parental 
information was unavailable for determining inheritance status. A very recent study that 
used NGS in a CAS cohort consisting of 34 children is in line with these results, as likely 
pathogenic SNVs or CNVs were found in 11 out of 34 probands (32%)76. These latter two 
studies show the potential of NGS for investigating developmental speech disorders, and 
highlight that in a significant number of cases these disorders can be caused by a high 
penetrance variant disrupting a single gene. 
For DLD, only one NGS study has been published so far, in which exome sequencing in a 
research setting was performed in 43 unrelated probands with severe specific language 
impairment77. Though different potentially pathogenic variants in several genes were 
identified, pathogenicity is still unclear for many of those. The contribution of de novo 
variants and more general of Mendelian disorders in children with DLD remains to be 
explored. 
Interestingly, pathogenic variants that have been reported in the speech/language cohort 
studies described above have often been found in known disease genes or in candidate genes 
for a broader group of neurodevelopmental disorders, as other individuals with variants in 
the same gene do not always have prominent speech or language problems. Moreover, in 
several different newly characterized neurodevelopmental disorders, impairments in speech 
and language appear frequently as part of the clinical spectrum of associated disorders.
It is hard to classify all disease genes based on the involvement of speech and language 
problems, as most studies do not assess and/or describe these capacities in a standardized 
manner. However, for some genes the link with speech and language problems is clear: e.g. 
when prominent speech/language disorders are recurrently reported in genotype-driven 
disorder characterization studies, and when rare variants in the same gene are found in NGS 
studies of speech and/or language disorder cohorts. A notable example is the SETBP1 gene. 
Loss-of-function variants in this gene cause a neurodevelopmental disorder, commonly 
referred to as SETBP1 disorder, that is characterized by severe expressive speech and/or 
language problems, in combination with mild intellectual disability78,79. Similarly, variants 
affecting KAT6A cause a neurodevelopmental disorder that can vary in severity, but speech 
problems and more specifically CAS, are prominent80. These are just two examples of a 
Chapter 1
22
potentially large group of genes in which variants can give rise to impairments in speech 
and language development. A more systematic use of NGS to study developmental speech 
and language impairments, coupled to a more systematic characterization of phenotypes, 
is needed.
Genetic heterogeneity and variable expressivity
Two concepts are extremely important for understanding the genetic background of 
Mendelian inherited speech and language disorders: genetic heterogeneity and variable 
expressivity.
In Mendelian disorders, a DNA variant in a single gene can be enough to cause a phenotype. 
This does not mean that individuals with the phenotype always share the same underlying 
genetic cause. For some phenotypes there is this 1:1 relationship with the gene involved, 
for example the disease cystic fibrosis is always caused by variants in the CFTR gene. But for 
many phenotypes or disorders there is genetic heterogeneity, which means that the same 
phenotype in different individuals can be caused by specific variants in different genes. For 
example Noonan syndrome, a clinically recognizable neurodevelopmental phenotype, can 
be caused by pathogenic variants in >10 different genes81. Genetic heterogeneity can be even 
more extreme, depending on the phenotype of interest. For intellectual disability, over 1500 
different Mendelian disease genes are already known82. Research so far on developmental 
speech and language disorders also points to significant genetic heterogeneity75,76,83. This 
means that unbiased genetic screens are preferred, as it is extremely hard to select specific 
disease-causing genes as candidates  based only on the phenotype. 
Variable expressivity is another important concept in this context. If a SNV or CNV is 
pathogenic, this means that the variant is disease-causing. But this does not mean that 
it always leads to exactly the same clinical features or the same severity of disorder. For 
many Mendelian neurodevelopmental disorders considerable variable expressivity has 
been shown, which means that the phenotype amongst individuals carrying the same 
variant might differ. For developmental speech and language disorders an example is the 
16p11.2 deletion related disorder. While there is no doubt that this deletion is pathogenic, 
the resulting clinical features can vary substantially: between different families with this 
deletion, and even between affected individuals within the same family66. While one family 
member might have CAS, another person can have a mild intellectual disability and a third 
person might have prominent features of autism spectrum disorder. Some individuals who 
carry a pathogenic SNV or CNV may not display  any phenotype at all. This phenomenon is 
referred to as incomplete penetrance. 
All in all, when interpreting NGS data for Mendelian speech and language disorders in a 
clinical or research context, it is important to realize that these disorders can be caused 
by a very large number of different SNVs and CNVs in different individuals, and that these 




Aim, relevance and outline of this thesis
Aim and relevance of this thesis
At present, not much is known about the molecular genetic basis of developmental 
speech and language disorders. Although these disorders are considered to mostly reflect 
a multifactorial etiology, there is increasing evidence for an important additional role for 
Mendelian causes. NGS techniques are now frequently used to identify molecular causes in 
several neurodevelopmental disorders, which has led to a large increase in knowledge on 
underlying genetic mechanisms. In contrast, the use of NGS in developmental speech and 
language disorders so far is very limited, and as a consequence, the genetic architecture 
underlying these disorders is incompletely understood.
The aim of this thesis is to investigate Mendelian causes of developmental speech and 
language disorders by NGS techniques. By integrating NGS data, phenotyping data and 
functional data from protein-specific laboratory assays, our goal is to better understand the 
genetic background of these disorders and gain knowledge to improve clinical care.
A better understanding of the role of Mendelian causes in developmental speech and 
language disorders is highly important, as it might provide families with improved genetic 
counseling on recurrence risks, and on possible additional associated features, and provide 
Figure 2: Genetic heterogeneity and variable expressivity
a) Genetic heterogeneity in developmental speech and language disorders: the same phenotype in different  
 individuals can be caused by specific variants in different genes  
b) Variable Expressivity of Mendelian neurodevelopmental disorders: individuals carrying the same variant might 
 have different phenotypes
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guidance to specific intervention options for speech and language therapists. In general, if 
NGS results from studies of children with speech and language impairments indicate a larger 
role for Mendelian factors, this would show the need for offering genetic testing via NGS 
in children with these disorders. NGS results obtained through studying unique patients 
with abnormal developmental phenotypes have already been shown to be an inexhaustible 
resource of information on molecular pathways and pathogenic mechanisms involved in 
normal and abnormal neurodevelopmental processes. 
Outline of this thesis
In Chapter 2, we characterize a series of rare variants in the MED13 gene, after the initial 
finding of a missense variant of unknown significance in a child with a DLD. We show that 
pathogenic variants in MED13 can cause a neurodevelopmental disorder with associated 
speech and language disorders.
In Chapter 3, we describe how one variant of interest in a child with a DLD has led to the 
identification of POU3F3-associated disorder. POU3F3, also known as Brain-1, is a well-
known gene in the context of brain development. W show how different variants disrupt 
the transcription factor activity of the encoded protein, and lead to a neurodevelopmental 
disorder with prominent speech and language impairments and a characteristic facial 
phenotype.
For Chapter 4, a genome sequencing result from a research project in children with CAS was 
the starting point for the characterization of pathogenic CHD3 variants in a larger series of 
patients. We found that specific missense variants in this gene disrupt ATPase activity and 
chromatin remodeling functions of the encoded protein. With this study, we implicate CHD3 
variants in a disorder characterized by intellectual disability, macrocephaly and impaired 
speech and language.
In Chapter 5, we characterized several missense variants in WDR5, after the identification of 
a de novo variant in this gene in a child with a developmental speech disorder (CAS). We show 
how the amino acids involved in these variants cluster in the three-dimensional structure of 
the WDR5 protein, and characterize the phenotypic spectrum of this neurodevelopmental 
disorder with variable expressivity.
The study in Chapter 6 started with an interesting missense variant in FOXP4. We 
demonstrate that, similar to its gene family members FOXP1 and FOXP2, heterozygous 
variants in FOXP4 cause a neurodevelopmental phenotype with associated developmental 
speech and language difficulties.
In Chapter 7 we delineate speech, language, oral motor and neuropsychological phenotypes 




clinical overlap and highly recurrent features. On the other, we show that speech problems 
can differ between individuals, and that the severity of clinical features is highly variable. 
Chapter 8 describes our study design for the GENTOS study, a prospective cohort study in 
which we plan to perform whole-genome sequencing using a trio approach in 50 individuals 
with a severe developmental speech and language disorder and their parents. The aim of 
this study is to determine the diagnostic yield for rare (Mendelian) genetic causes in DLD.
And finally, in Chapter 9, we summarize the research in this thesis, and discuss how the 
results from our studies have increased our understanding of rare pathogenic variants and 
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Many genetic causes of developmental delay and/or intellectual disability 
(DD/ID) are extremely rare, and robust discovery of these requires both large-
scale DNA sequencing and data sharing. Here we describe a GeneMatcher 
collaboration which led to a cohort of 13 affected individuals harboring protein-
altering variants, 11 of which are de novo, in MED13; the only inherited variant 
was transmitted to an affected child from an affected mother. All patients had 
intellectual disability and/or developmental delays, including speech delays 
or disorders. Other features that were reported in two or more patients 
include autism spectrum disorder, attention deficit hyperactivity disorder, 
optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart 
abnormalities, and dysmorphisms. Six affected individuals had mutations that 
are predicted to truncate the MED13 protein, six had missense mutations, 
and one had an in-frame-deletion of one amino acid. Out of the seven 
nontruncating mutations, six clustered in two specific locations of the MED13 
protein: an N-terminal and C-terminal region. The four N-terminal clustering 
mutations affect two adjacent amino acids that are known to be involved in 
MED13 ubiquitination and degradation, p.Thr326 and p.Pro327. MED13 is a 
component of the CDK8-kinase module that can reversibly bind Mediator, 
a multi-protein complex that is required for Polymerase II transcription 
initiation. Mutations in several other genes encoding subunits of Mediator 
have been previously shown to associate with DD/ID, including MED13L, a 







The introduction of next-generation sequencing techniques has rapidly improved the 
identification of genes that associate with rare disease. Although developmental delay (DD) 
and intellectual disability (ID) are relatively common1, there is extreme genetic heterogeneity 
among affected patients and a large fraction of patients with DD/ID remain refractory to 
diagnosis2. In unsolved cases, the understanding of gene–disease relationships has greatly 
benefited from collaboration between clinical genetics teams (Sobreira et al. 2015). In fact, 
many recently discovered DD/ID genes have come from “matchmaking”3-5, where websites 
such as GeneMatcher6 facilitate the comparison of patients with rare genotypes and 
phenotypes across the world.
Here we present the results of a collaboration facilitated by GeneMatcher 6 in which multiple 
clinical and research groups independently identified individuals with DD/ID and related 
phenotypes with rare protein-altering variation in MED13. This genotype-driven approach 
enabled us to characterize the phenotypes and mutational spectrum of a cohort of 13 
patients, each with a likely pathogenic variant in MED13.
Although MED13 has not been previously linked to a disorder, it is a paralog of MED13L, 
mutations of which have been found to cause ID, speech impairment and heart defects7-9. 
The gene products MED13 and MED13L are mutually exclusive components of the reversible 
CDK8-module of the Mediator complex, a multi-protein complex that is required for the 
expression of all protein-coding genes10,11. In this study, we show that variants in MED13 
are also associated with a neurodevelopmental disorder, and delineate the corresponding 
phenotypic features and mutational spectrum.
Materials and methods
Informed consent
Informed consent to publish de-identified data was obtained from all patients, either as 
part of the diagnostic workflow or as part of a research study12. Informed consent to publish 
clinical photographs was also obtained when applicable. Informed consent matched the 
local ethical guidelines.
Exome/genome sequencing
In patients A, B, D, E, F, G, I, K, L and M, whole exome sequencing and variant filtering 
were performed as previously published13-17. In patient C, targeted Sanger sequencing was 
performed to confirm the presence of the MED13 variant (L131*) that was first identified in 
patient B. For patient H, whole genome sequencing was performed using Illumina’s HiSeq 
X ten platform. Sequencing reads were mapped against the hs37d5 reference using GATK. 
Variants were called using GATK’s Haplotype Caller. Variants were filtered using frequencies 
from the ExAC and gnomAD databases (mean allele frequency < 0.003) and for conservation 
using PhastCons (> 0.5) and PhyloP (> 4). For patient J, whole genome sequencing, variant 
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prioritization, and Sanger validation were performed as previously described12. In each 
patient, the observed MED13 mutation was considered to be the most likely contributor 
to the phenotype, and no additional pathogenic or likely pathogenic variants were found.
Three‑dimensional modeling
Protein modeling was performed as previously described18. Modeling of MED13 interacting 
with FBXW7 was performed using PDB 2OVQ, replacing molecule C with the MED13 amino 
acids 321–330. Binding energy was calculated following each patient variant insertion and 
energy minimization using AMBER14 force field (http://ambermd.org) in YASARA.
RNA isolation
2.5 mL of blood was collected in PAXgene RNA tubes (PreAnalytiX #762165) according to the 
manufacturer’s instructions and stored short-term at − 20 °C. RNA was isolated using a PAX 
gene Blood RNA Kit (Qiagen #762164) according to the manufacturer’s instructions. Isolated 
RNA was quantified by Qubit® (Thermo Fisher #Q32855).
cDNA synthesis
First strand synthesis of cDNA was performed from 150 ng of RNA isolated from blood using 
Superscript™ III (Thermo Fisher #18080044) according to manufacturer’s instructions using 
random primers (Invitrogen #48190011) for +/− RT reactions. The products were diluted 
1:10 in water before use in qPCR reactions.
qPCR
qPCR was performed according to manufacturer’s protocols using Taqman gene expression 
master mix (ThermoFisher #4369016) and FAM-MGB Taqman probes directed against MED13 
(ThermoFisher Hs01080701_m1 catalog #4331182) and GAPDH (ThermoFisher #4352934E). 
qPCR reactions were carried out in a QuantStudio 6 Flex Real-Time PCR system (Applied 
Biosystems) using 40 cycles of amplification. Raw CT values were obtained, normalized first 
to the GAPDH loading control, and then to the proband. We tested an additional loading 
control [AGPAT-data not shown (ThermoFisher Hs00965850_g1; catalog #4331182)], but 
the data were like those normalized to GAPDH.
Sanger sequencing
cDNA template was amplified using primers to the region of interest: 5'-CGA GGC TCT TAT 
GGA ACT GAT GAA TC-3' (forward) and 5'-GAT CCA TCG TGC TTT CAG ACA CAT C-3' (reverse). 
No amplification was observed in the no RT condition. PCR conditions were: 500 nM primers, 
3% DMSO, 1x Phusion HF (NEB #M0531L), 0.5 μL cDNA template, and cycling at (98 °C, 30 s), 
(98 °C, 10 s; 60 °C, 30 s; 72 °C, 45 s)x35, (72 °C, 7 m), (4 °C, ∞). The additional reverse primer 
5'-AAA TGC TTC ATT GTT ACC GTC AGC T-3' and the additional forward primers 5'-TCC AAA 
AGA AAC GAT GTG AGT ATG CAG-3', 5'-CTC TCT TCA GCC AGT TCT TCA GGA T-3', 5'-ACA ATT 
TCA TAA AAT GGC TGG CCG A-3', 5'-CGA GGC TCT TAT GGA ACT GAT GAA TC-3', 5'-GTG CTT 
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TCT CCA TTT GCT CTT CCT T-3' were used for sequencing, along with the primers used for 
amplification from cDNA. Chromatograms were quantified using ab1PeakReporter (Thermo 
Fisher).
Western Blot
Whole blood was collected using cell processing tubes (BD #362760), isolated according 
to the manufacturer’s instructions, and stored in liquid nitrogen in CTS™ Synth-a-Freeze® 
Medium (Thermo Fisher # A13713-01) until use. As a control for antibody specificity, MED13 
was knocked down in neural precursor cells (clone BC1, MTI-GlobalStem #GSC-4311) by 
generating stable lines using puromycin selection expressing shRNA against MED13 (Sigma 
Aldrich # SHCLNG-NM_005121; TRCN0000234904) compared to a GFP shRNA control in the 
same vector (Addgene # 30323). Cell pellets were processed using the NE-PER™ (Thermo 
Fisher #78833) nuclear and cytoplasmic extraction kit according to the manufacturer’s 
instructions, and nuclear extracts were used for the blot shown (whole cell extracts, even at 
very high concentrations, did not produce sufficient signal). 60 μg of protein was loaded for 
patient blood samples, and 15 μg of protein was loaded for neural precursor cell samples. 
Blots were blocked for 1 h at room temperature in LICOR blocking buffer (LICOR #927-
40000), then blots were probed (with washes in PBS-T (0.05% Tween-20) and a secondary 
probe for 1 h after each primary probe) with 1:250 rabbit anti-MED13 (Bethyl #A301-277A) 
for 3 days at 4 °C, 1:1,000 mouse anti-HDAC2 (clone 3F3, SCBT #sc-81599) overnight at 4 °C 
as a loading control, and 1:1000 rabbit anti-HSP90 (abcam #ab115660) overnight at 4 °C as 
an additional loading control. Secondary probes were used at 1:20,000 (LICOR #926-32211 
and #926-68070). Three other primary antibodies were tested for MED13, but did not show 
sufficient signal to detect MED13 in blood despite detecting MED13 in neural precursor 
nuclear lysates: Bethyl #278A, Abcam #ab49468, and Abcam #ab76923 (data not shown).
Statistical enrichment of MED13 variants in DD/ID cohorts
We compared the frequency of observed de novo MED13 variation identified in two large 
sequencing cohorts to the expected frequency of variation in MED13 based on its gene 
specific mutation rate (Samocha et al. 2014) using an Exact Poisson Test in R 49.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We collected detailed clinical information of 13 patients with rare, protein-altering MED13 
variants. Eleven variants were confirmed to be de novo, and one patient (patient B) inherited 
the variant from her mother who is also affected (patient C). Phenotypic data summarizing 
the spectrum of features of this cohort of 13 patients are shown in Table 1.
All patients had developmental delays with varying severity and course. In the patients that 
underwent formal intelligence testing, total IQ levels varied from 85 (lower range of normal 
IQ) to an IQ between 35 and 50 (moderate ID). Five patients had an Autism Spectrum Disorder 
(ASD), and three patients were diagnosed with Attention Deficit Hyperactivity Disorder 
(ADHD). All patients had speech delays and/or disorders, with delayed milestones in speech 
and language development. While several patients had expressive and receptive language 
problems, in the majority of patients, speech production was significantly more impaired 
than language comprehension. Three patients (patient A, K and M) showed characteristics 
of speech apraxia, a developmental speech disorder in which affected individuals have 
difficulties accurately programming the motor sequences required to produce fluent speech. 
Patient A had a mild ID, but showed speech apraxia with a mixed receptive and expressive 
language disorder, and limited verbal expression at the age of 8 years. Patient M had a non-
verbal IQ of 70 with a severe speech/language disorder. Her expressive speech was severely 
affected, with signs of speech apraxia. At the age of 8 years she only used single words and 
very short sentences. Patient K developed some speech capabilities, but showed regression 
at the age of 13 months and has since remained non-verbal.
Seven of 13 patients showed delays in motor development, most of which affected at least 
the gross motor skills (6 of 7), although one patient was reported to have only fine motor 
delays. Three patients had hypotonia (patient E, F and G). One patient (patient H) developed 
severe drugresistant myoclonic-atonic epilepsy at 4 years of age with generalized clonic, 
myoclonic, atonic, tonic and atypical absence seizures. MRI screening of this patient showed 
a small abnormality in the left occipital lobe of his brain that did not correspond to the 
electrophysiological onset or the semiology of his seizures. In other patients, MRI scans 
were not performed or showed no clear abnormalities, except for mild frontal atrophy in 
patient M.
Eight patients (62%) presented with eye or vision abnormalities. Two patients (patients L 
and M) presented with Duane anomaly, a congenital type of strabismus that is characterized 
by non-progressive horizontal ophtalmoplegia and retraction of the globe with attempted 
adduction, together with narrowing of the palpebral fissure19. One patient (patient G) had 
strabismus, two patients had astigmatism (patient A and I), and one patient (patient E) had 
congenital nystagmus. While only one patient (patient D) had a visual impairment, three 
patients had optic nerve abnormalities: pale optic nerves in patient D, papilledema in 
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patient G, and in patient E outer retinal atrophy temporal to both optic discs was reported 
with relatively small optic nerves on a MRI-scan.
Several other interesting phenotypes were observed in at least two patients in the cohort. 
Four patients presented with chronic obstipation (patients C, E, G and M). Two patients had 
conductive hearing loss (patients F and L). Two patients had congenital heart abnormalities: 
a mildly dilated aortic root and pulmonary artery (both improving over time) in patient 
F, and a subaortic stenosis in patient J. Two patients were reported to have chronic sleep 
issues (patient J and K).
Overlapping facial characteristics were reported, including widely spaced eyes with narrow 
palpebral fissures and peri-orbital fullness, a broad and high nasal bridge, full nasal tip, 
synophrys, a flat philtrum and a wide mouth with thin upper lip (Fig. 1).
Variants and predicted consequences
The MED13 transcript (NM_005121.2) encodes a large protein consisting of 2174 amino 
acids (NP_005112.2). The Pfam database characterizes two domains within the MED13 
protein: an N-terminal domain (aa 11–383) and a C-terminal domain (aa 1640–2163), as 
shown in Fig. 2a. Analysis of conservation across the length of the protein indicates several 
highly conserved residues that lie between these two domains (Fig. 2b).
All 12 unique variants found in our patients are absent from the gnomAD database20 and 
TOPMED Bravo database (https://bravo.sph.umich.edu/freeze3a/hg19/) and are predicted 
to be highly deleterious by CADD v1.321, with scores ranging from 20.5 to 41 (Table 1). 
Six patients had five unique variants that are predicted to be truncating: three nonsense 
mutations (p.Leu131* in Patients B and C, p.Leu582* in Patient I and p.Arg1400* in Patient J) 
and two frameshift variants leading to a premature stop codon (p.Pro42Leufs*6 in patient A 
and p.Thr1496Metfs*11 in Patient K). The remaining variants include six missense variants 
and a single amino acid deletion. These seven variants form two apparent clusters: one in 
the N-terminal conserved phosphodegron domain and the other in the C-terminal domain 
(Fig. 2a). These seven variants were all found to lie within motifs that are highly conserved 
between MED13 and MED13L (Fig. 2b) and affect sites under high codon selection (Fig. 2c). 
These missense variants and the in-frame deletion are each located on surface-exposed 
sites within a three-dimensional model of the MED13 protein (Fig. 3). The four mutations 
that cluster in the N-terminal domain affect two adjacent amino acids (p.Thr326 and 
p.Pro327) that are known to be part of a conserved phosphodegron that is required for 
binding with SCF-Fbw7 ubiquitin ligase for degradation22. Using interaction data from Davis 
et al. and PDB structure 2OVQ, which has Fbw7 interacting with a similar motif as MED13, 
we modeled this interaction for MED13 followed by insertion of each variant and calculation 
of binding energy. All four variants (p.Thr326Ile, p.Thr326del, p.Pro327Ser, p.Pro327Gln) 
are predicted to alter the phosphorylation and Fbw7 interaction with drastic decreases in 
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binding energy to Fbw7 (Figure S1). The two missense changes clustering in the C-terminal 
portion of the protein (p.Gln2060Lys and p.Ala2064Val; in patients L and M, respectively) 
were also studied in more detail. One of the changes (p.Ala2064Val) is predicted to be 
structurealtering through increasing hydrophobic collapse, secondary structure formation, 
and increasing aliphatic index of a surface exposed linear motif. This results in a decrease of 
the regions linear interacting peptide potential that is highly conserved and likely functional 
(Figure S2). The remaining missense variant (p.Pro540Thr in Patient H) lies within a highly 
conserved linear motif centered near amino acid 538 (Fig. 2b); it results in the formation 
of a high probability Casein Kinase 1 phosphorylation motif, which could lead to additional 
interaction with proteins containing forkhead- associated domains when analyzed through 
the ELM database23 (Fig. 3).
Effects of truncating MED13 mutation on transcript and protein levels
As truncating mutations often lead to nonsense-mediated decay and haploinsufficiency, we 
aimed to examine the effects of a truncating MED13 mutation on levels of MED13 transcript 
and MED13 protein. We performed RT-PCR on cDNA transcribed from RNA of patient J, who 
was heterozygous for a nonsense mutation (c.4198C > T; p.Arg1400*). We compared the 
MED13 transcript level of the patient to her biological parents and two healthy controls (Fig. 
4a). No differences in MED13 transcript levels were detectable between the affected patient 
and the unaffected parents or controls (One-way ANOVA p = 0.5913). Sanger sequencing 
Figure 1: Facial phenotypes of seven individuals with a MED13 variant
Facial phenotypes of seven individuals with a MED13 variant. Overlapping facial characteristics include peri-orbital 
fullness, narrow palpebral fissures, a broad and high nasal bridge, full nasal tip, synophrys, flat philtrum, wide 
mouth and a thin upper lip.
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of cDNA amplicons from the child demonstrated the presence of the aberrant transcript 
in the child (Fig. 4b), at ~ 70% levels relative to the normal transcript (Fig. 4c). To assess 
the effect of the nonsense mutation on protein levels, a western blot was performed on 
nuclear extracts from mononuclear blood cells of the patient and controls (Fig. 4d). While 
full-length MED13 protein was present in the patient (and in the controls), no truncated 
MED13 protein product could be detected. The MED13 protein level of the patient was not 
clearly different compared with the MED13 protein level of the father.
Enrichment of de novo MED13 variants in DD/ID cohorts
We quantified the extent of enrichment of de novo variants in MED13 within DD/ID-affected 
probands. We used only the two largest cohorts considered within this study, each of which 
yielded at least two de novo MED13 variants. Five patients described here (A, E, F, I, and 
K) come from a cohort of 11,149 affected individuals, and two patients, one of which is 
described here (patient L), were identified within the Deciphering Developmental Disorders 
(DDD) study of 4293 trios24. Both studies suggest a rate close to 1 de novo variant affecting 
MED13 per ~ 2200 DD/ID-affected individuals. When comparing the number of observed 
de novo mutations in MED13 to the expected number based on the gene specific mutation 
rate of MED13 for missense, splicesite, nonsense and frameshift mutations [6.237 × 10−5 
per chromosome25], we find evidence for a significant enrichment among DD/ID-affected 
individuals (7 variants in 30,884 alleles; p = 0.00371).
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Figure 2: Analysis of mutations: location, conservation and codon usage of variant sites
(a) Identified mutations are shown within a linear representation of the MED13 protein, consisting of 2174 amino acids. 
Missense mutations and the in-frame deletion are shown in blue, and nonsense and frameshift mutations in green. 
Six of the seven non-truncating mutations in our MED13 cohort cluster in two small regions within the N-terminal and 
C-terminal domains of the MED13 protein. Affected amino acids p.Thr326 and p.Pro327 and are part of a conserved 
phosphodegron (CPD), which is shown in orange. Two LxxLL nuclear receptor-binding motifs are also noted. (b) Analysis 
of conservation throughout the protein was performed using amino acid selection scores as previously published 18, 
using a 21 codon sliding window for both MED13 and MED13L aligned such that the most selected motifs of a 
protein are identified as peaks. The center of each highly conserved linear motif is labeled and those containing 
variants described in this paper are boxed. (c) Codon usage throughout evolution for the locations of all missense 
mutations and the in-frame deletion. All five sites are under high selection with multiple synonymous (Syn, gray) 
amino acids in 352 open reading frames (ORFs) of MED13 and MED13L with only a single nonsynonymous (Nonsyn, 
red) change. Numbers indicate instances where ORFs in other species deviate from the conserved codon usage. Of 
note, for three locations (326, 327 and 540) the codon used differs between MED13 and MED13L with the amino 
acid conserved. In these cases, numbers indicate where ORFs in other species deviate from conserved codon usage 
in their respective ortholog.
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Figure 3: Location of missense mutations and in-frame deletion in threedimensional structure of MED13 and 
conservation of affected amino acids
A full model of MED13 protein created with I-TASSER modeling was combined with 152 species sequences for 
MED13 using ConSurf mapping. Amino acid coloring is as followed: gray = not conserved, yellow = conserved 
hydrophobic, green = conserved hydrophilic, red = conserved polar acidic, blue = conserved polar basic, magenta 
= conserved human variants of interest. A zoomed in view of the three different affected regions are shown, along 
with amino acid alignments from MED13 and MED13L. An asterisk (*) indicates 100% conservation in all sequences 
and a colon (:) indicates functional conservation. Linear motifs mapped with the Eukaryotic Linear Motif tool are 
shown below sites for 326–327 and 540.




By molecular and clinical characterization of a cohort of 13 patients with variants in MED13, 
we here provide evidence for a new neurodevelopmental disorder. This MED13-associated 
syndrome is characterized by DD/ ID with speech delay and/or speech disorders. Additionally 
a broad spectrum of other common features is seen, including ASD, ADHD, various 
eye abnormalities and mild facial dysmorphisms. Based on the phenotypes of patients 
presented here, we do not yet see a clear genotype- phenotype correlation between type 
and location of the mutations and severity of clinical features. However, it is notable that 
the two patients with Duane anomaly have a missense mutation in a similar location in 
the C-terminal domain of the MED13 protein, and that the optic nerve abnormalities are 
reported in patients with mutations affecting residues p.Thr326 or p.Pro327 only.
MED13 is a component of the CDK8-kinase module, which can reversibly bind the 
Mediator complex. Mediator is a multi-protein complex that is required for assembly and 
stabilization of the pre-initiation complex, which is essential for transcription initiation26,27. 
The core function of Mediator is to transmit signals from various transcription factors to 
RNA polymerase II (Pol II)28. Binding of the CDK8-module to Mediator has been reported to 
prevent the association of Mediator with the Pol II preinitiation complex, thus preventing 
transcription initiation and/or re-initiation. In this way, the CDK8-module is considered a key 
molecular switch in Pol II mediated transcription29. MED13, as well as the other subunits of 
the CDK8-module, are known to be critical regulators of developmental gene expression 
programs in Drosophila, zebrafish and C. elegans30,31. MED13, or its paralog MED13L, forms 
a direct connection of the CDK8 module with the core Mediator complex32, and protein 
turnover of MED13 (or MED13L) may be critical in modulating the pools of Mediator-CDK8 
kinase complex in cells22,29,33.
Three missense mutations (p.Thr326Ile, p.Pro327Ser and p.Pro327Gln) and one in-frame-
deletion (p.Thr326del) in our cohort are likely to affect MED13 protein turnover due to their 
location within a conserved phosphodegron. This phosphodegron is recognized by the SCF-
Fbw7 ubiquitin ligase, which targets the MED13 protein for ubiquitination and degradation22. 
In fact, it has already been shown that a specific amino acid substitution at position 326 in 
MED13 (p.Thr326Ala) leads to impaired binding of Fbw7 to the phosphodegron of MED13/
MED13L, thus preventing MED13/MED13L ubiquitination and degradation22. Therefore, a 
variant at this position may lead to increased levels of MED13 protein in the cell. As Fbw7 
is proposed to target only MED13 or MED13L proteins that are bound to the core Mediator 
complex22, these mutations may have an effect on the CDK8 module-Mediator association 
and subsequently on transcription regulation. The potential effects of the p.Pro540Thr 
missense variant are also intriguing. Protein modeling suggests that this variant could 
introduce an additional Casein Kinase 1 phosphorylation site, thus potentially increasing 
interactions with forkhead-associated domains involved in protein–protein interactions.
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Figure 4: Analysis of transcript and protein levels in patient with nonsense mutation
(a) Level of MED13 transcript was measured by qPCR and normalized to GAPDH and proband (patient J). No differences 
were detectable between groups (One-way ANOVA p = 0.5913). An additional loading control (AGPAT) produced very 
similar results (data not shown). (b) Representative Sanger traces from cDNA amplicons demonstrating the presence 
of the variant in the proband, and absence in the father and mother. (c) Quantification of the chromatograms of all 
Sanger sequences reveals less signal from the base on the mutant allele (p < 0.0001 by paired t-test compared to the 
wildtype base signal by trace). The father and mother do not have any signal at the mutant base above the level of noise. 
(d) Western blot for MED13 (and HSP90 and HDAC2 as loading controls) from nuclear extracts of patient peripheral 
blood mononuclear cells or a neural precursor cell line (present to demonstrate antibody specificity with a 
knockdown (KD) control). If the nonsense mutation resulted in a stable protein, a product at approximately 150 
kDa would be expected, which is not present. No protein was recoverable from the blood sample from the mother.
We also observed five unique mutations predicted to truncate MED13. In assessments of 
RNA and protein levels in Patient J and her unaffected parents, the variant transcript was 
detected in the proband but no truncated protein could be observed. While these results 
are inconclusive with regards to the molecular mechanism of pathogenicity in this particular 
proband, loss-of-function mechanisms remain an attractive possibility. Patterns of variation 
in MED13 in human population databases indicate that MED13 is relatively intolerant to 
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loss-of-function variation; MED13 has a Rare Variant Intolerance Score (RVIS) that ranks 
among the top 1.66% of all genes34 and an ExAC pLI score of 1.0020.
We show an enrichment of de novo MED13 mutations compared to what is expected under 
a null model (p = 0.00371) in two large ID/DD patient cohorts. We acknowledge that this 
p value does not exceed a genomewide evidence threshold and by itself proves association. 
However, the enrichment p value does not account for five de novo variants described here 
from smaller cohorts that were discovered independent of, and prior to, assessment of 
the statistical evidence from the larger cohorts. We also observed clustering of missense 
mutations in our cohort, which by itself is an argument for pathogenicity35. Additionally, 
independent genetic studies also support the disease relevance of variation in MED13. 
There is one report of an 800-kb microdeletion including MED13 and five other genes 
in a patient with moderate ID, short stature, mild dysmorphisms, and hearing loss36; 
the authors proposed MED13 as the most likely causal candidate gene. Additionally, a 
de novo frameshift (p.Pro286Leufs*86) and a de novo variant that likely affects splicing 
(D + 3; c.814+3A>G) were observed in a cohort of 2508 probands with ASD37, and three rare 
protein-altering variants in MED13 (p.Ala418Thr, p.Arg512*, p.Tyr1649*) were also found in 
a separate ASD cohort38.
Other Mediator subunits, including other CDK8-kinase module-associated disease 
genes, have been associated with various neurodevelopmental disorders. Variants in 
MED12 have been associated with ID syndromes with congenital abnormalities, including 
Opitz-Kaveggia syndrome (MIM 305,450)39, Lujan-Fryns syndrome (MIM 309,520)40 
and X-linked Ohdo syndrome (MIM 300,896)41. Mutations in MED12 have also been 
associated with intellectual disability. In addition to ID and speech delays both MED12 
patients and several MED13 probands described here present with eye abnormalities (eye 
movement disorders, and abnormalities of the retina and optic nerves)42,43 and chronic 
obstipation43,44. In addition to the MED12 subunit, a disruption of CDK19 was reported in a 
patient with ID, microcephaly and congenital retinal folds45.
It is of particular relevance to this study that variation in the MED13-paralog MED13L has 
been shown to cause a neurodevelopmental disorder as well46. Given the similar molecular 
roles for MED13 and MED13L, we aimed to compare and contrast phenotypes presented 
by both groups of individuals using information provided in the literature. The main 
phenotypic characteristics of MED13L-associated syndrome are (borderline) ID with delayed 
speech and language development, and a variable spectrum of other features including 
autism, hypotonia, characteristic facial features and heart defects7-9,47,48. Many of these 
features clearly overlap with the phenotypes in our MED13 cohort. However, similar to the 
heterogeneity observed here in patients with MED13 variation, the spectrum of phenotypes 
observed among MED13L mutation carriers is quite broad. The identification and detailed 
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phenotyping of additional patients with MED13 and MED13L mutations is needed to 
elucidate the complete spectrum of associated features, and to reveal the similarities and 
differences between the two syndromes.
We believe that the data presented in this study coupled to the additional evidence available 
from other studies strongly support the conclusion that rare protein-altering variation in 
MED13 underlie a new neurodevelopmental disorder. Key results from this study include: a 
significant enrichment of de novo mutations in MED13 within ID/DD cohorts (p = 0.00371); 
the clustering and conservation levels of the positions affected by the observed missense 
variation (Fig. 2a, b); the computationally predicted deleteriousness of the observed 
mutations (Table 1; Fig. 3, Fig. S1); and the overlap of phenotypic features among the 13 
patients presented here, including speech difficulties (13/13), intellectual disability (at least 
9/13), and eye or vision problems (8/13). Supporting evidence from other studies include: 
the existence of mutations affecting MED13 in at least six independent families affected 
by pediatric neurodevelopmental disorders; the intolerance of MED13 to mutations 
in the general human population (pLI = 1.00, RVIS score of 1.66%); and the previously 
established disease-associations of several other Mediator subunits, including MED13L, a 
functionally related paralog of MED13. While the precise pathogenic mechanisms have yet 
to be elucidated—some of the mutations observed here are predicted to stabilize MED13 
protein while others are predicted to lead to loss-offunction— we find it highly likely that 
mutational disruption of normal MED13 function leads to disease, adding MED13 to the list 
of Mediator-associated, in particular CDK8-kinase module-associated, neurodevelopmental 
disorders.
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Figure S1: Analysis of variants at position 326-327 in relation to Fbw7-interaction 
The interaction of MED13 with Fbw7 was modeled, by using PDB structure 2OVQ and amino acids 321-330 of 
the MED13 protein. All four different variants in our cohort that affect this binding region (T326I, T326del, P327S, 
P327Q) were subsequently inserted in the model, and binding energy was calculated using AMBER14 force field 
(http://ambermd.org/) in YASARA. All four variants are predicted to alter the phosphorylation and Fbw7 interaction 
with a severe decrease in binding energy to Fbw7 (PNG 2012 KB).
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Figure S2: Structural packing of MED13 and variants at amino acid position 2060-2064 
(a) MobiDB breakdown (http://mobidb.bio.unipd.it/Q9UHV7/predictions) for MED13 showing structural disorder 
(orange) from various databases, linear interacting peptides (LIPs, green) helical prediction (pink), beta sheet 
prediction (light orange), and rigidity (magenta). The 2060-2064 region is boxed in red with low prediction of 
disorder and a predicted LIP from 2060-2070, suggesting this highly conserved surface exposed region has a high 
potential to form secondary structure when bound to some unknown protein binding partner. (b) Jpred4 secondary 
structure predictions(Drozdetskiy et al. 2015) showing predicted changes in secondary structures, with a score 
of 9 being most likely to form secondary structure at each residue. p.Ala2064Val has highest probability to form 
stable secondary structure (average residue score of 7.05 compared to the wild type WT 5.6 and p.Gln2060Lys 
of 5.7). A variant increasing secondary structure would decrease formation rates with the unknown binding 
partner, thus likely resulting in loss of binding. (c) Aliphatic index score(Ikai 1980) showing p.Ala2064Val to increase 
thermostability of the linear motif. An increase in intrinsic thermostability likely decreases formation rates with the 
unknown binding partner similar to secondary structure predictions. (d) Location and effect of the two missense 
mutations p.Gln2060Lys and p.Ala2064Val shown on our predicted models for the region (PNG 351 KB).
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POU3F3, also referred to as Brain-1, is a well-known transcription factor involved 
in the development of the central nervous system, but it has not previously 
been associated with a neurodevelopmental disorder. Here, we report the 
identification of 19 individuals with heterozygous POU3F3 disruptions, most 
of which are de novo variants. All individuals had developmental delays and/or 
intellectual disability and impairments in speech and language skills. Thirteen 
individuals had characteristic low-set, prominent, and/or cupped ears. Brain 
abnormalities were observed in seven of eleven MRI reports. POU3F3 is an 
intronless gene, insensitive to nonsense-mediated decay, and 13 individuals 
carried protein-truncating variants. All truncating variants that we tested 
in cellular models led to aberrant subcellular localization of the encoded 
protein. Luciferase assays demonstrated negative effects of these alleles on 
transcriptional activation of a reporter with a FOXP2-derived binding motif. 
In addition to the loss-of-function variants, five individuals had missense 
variants that clustered at specific positions within the functional domains, 
and one small in-frame deletion was identified. Twomissense variants showed 
reduced transactivation capacity in our assays, whereas one variant displayed 
gain-of-function effects, suggesting a distinct pathophysiological mechanism. 
In bioluminescence resonance energy transfer (BRET) interaction assays, all 
the truncated POU3F3 versions that we tested had significantly impaired 
dimerization capacities, whereas all missense variants showed unaffected 
dimerization with wild-type POU3F3. Taken together, our identification and 
functional cell-based analyses of pathogenic variants in POU3F3, coupled with 






POU3F3 (MIM: 602480) encodes a member of class III of the POU family of transcription 
factors. These proteins all carry a characteristic POU domain that binds with high affinity to 
a specific octamer (5'-ATGCAAAT-3') or closely related DNA sequences in the enhancers and 
promoters of various different target genes1. The importance of POU3F3 for the developing 
brain is reflected in its original name Brain-1 (Brn1)2. Best known as a marker of upper- 
layer projection neurons in the cortex3, POU3F3 is implicated in the regulation of many 
key processes in the development of the central nervous system; these processes include 
cortical neuronal migration4, upper-layer specification and production, and neurogenesis5–7. 
However, the phenotypic consequences of pathogenic germline variants in human POU3F3 
are currently unknown.
We identified a de novo missense variant disrupting POU3F3 in a female with a severe 
developmental speech and language disorder, autism spectrum disorder, and mild 
intellectual disability. This variant was absent in control databases and affected a highly 
conserved amino acid, and in silico analyses consistently predicted deleterious effects on the 
function of the encoded protein. In addition, we noted a case report describing a de novo 
chromosome 2q12.1 deletion in a male with intellectual disability; in the report, POU3F3 
haploinsufficiency was discussed as a possible pathogenic mechanism8. Chromosome 
6q16.1 deletions that span the closely related, co-expressed ortholog, POU3F2 (also known 
as Brn2; MIM: 600494), cause a neurodevelopmental disorder with obesity9. Moreover, it 
has been shown that FOXP2 (MIM: 605317), disruptions of which cause a developmental 
speech disorder (speech language disorder-1; MIM: 602081), contains an intronic binding 
site for POU3F210,11.
We used matchmaking initiatives such as Gene- Matcher12 and the Decipher Database13 to 
identify additional individuals with rare germline variants in POU3F3. Here, we delineate the 
characteristic phenotypic features and mutational spectrum of a cohort of 19 individuals 
with pathogenic variants in POU3F3. Nearly all (17 out of 19) individuals had a de novo 
variant in the gene, and all variants were identified via exome sequencing with a trio 
approach. One person (individual 18) had inherited the variant from an affected mother 
(individual 19); in this family, exome sequencing had been performed in the proband and 
the mother only (duo approach).
The phenotypes of all 19 individuals with POU3F3 variants were systematically assessed and 
analyzed. A summary of the most common phenotypic characteristics is shown in Table 1, 
and more details per individual can be found in Table S1. All individuals with a POU3F3 
variant in our cohort (19/19; 100%) had developmental delays (DD) and/or an intellectual 
disability (ID). The level of functioning was broad, ranging from severe ID in two individuals 
to borderline intellectual functioning (WPPSI-IQ 77) in one individual. For individuals in 
which the severity of ID and/or DD was known, the majority (8/10; 80%) had a borderline to 
moderate level of ID and/or DD.
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Given that the first proband in our study (individual 3 in Table S1) had a severe developmental 
speech and language disorder, we paid special attention to the speech and language 
capacities across the entire cohort. All individuals with POU3F3 variants had delayed 
speech and language development, often with a delayed onset of producing first words. 
In two children who spoke their first words at an appropriate age, a halt in development 
or regression of speech in the first years of life was reported. Although both receptive and 
expressive language problems were reported, in many children expressive speech capacities 
were more impaired than language comprehension. Almost all individuals received or had 
received speech therapy, and commonly reported speech-related problems were oral motor 
problems, word finding problems, and social communication issues. In addition to this, 
drooling was reported in 9/14 individuals (64%), and open mouth behavior was seen in four 
individuals.






Feature Amount Amount Amount Percentage
Development
Developmental delay (DD) and/or intellectual 
disability (ID)
6/6 13/13 19/19 100%
Borderline or mild ID 2/6 3/13 5/19 26%
Moderate ID 1/6 2/13 3/19 16%
Severe ID 2/6 0/13 2/19 11%
DD or ID, severity unknown 1/6 8/13 9/19 47%
Speech delay or disorder 6/6 13/13 19/19 100%
Autism Spectrum Disorder (ASD) diagnosis 1/6 6/13 7/19 37%
Neurology
Abnormalities reported on brain MRI 3/4 4/7 7/11a 64%
Hypotonia 3/5 7/13 10/18a 56%
Epilepsy 2/6 0/13 2/19 11%
Drooling 2/5 7/9 9/14a 64%
Other features
Cupped and/or low-set ears 3/6 13/13 16/19 84%
Vision problems 2/6 8/13 10/19 53%
Sleeping problems (often waking up at night) 1/5 4/9 5/14a 36%
Cryptorchidism 0/1 3/10 3/11b 27% of males
A more detailed overview of phenotypic features per individual can be found in Table S1.
a Feature not assessed or not known for all 19 individuals in the cohort.
b Feature only applicable to the 11 males in the cohort. 
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Many individuals had autism-like features, and a formal diagnosis of autism spectrum 
disorder (ASD) was made in 7/19 individuals (37%). Although 3/19 (16%) individuals reached 
their motor milestones in time, most had delays in both fine and gross motor development. 
Hypotonia was reported in 10/18 individuals (56%). The two individuals with severe ID 
each had a form of epilepsy: Lennox- Gastaut syndrome with tonic-clonic seizures in one 
individual and a severe seizure disorder with myoclonic seizures, drop attacks, absences, 
and tonic-clonic seizures in the other. In both individuals, capillary hemangiomas were 
reported; this feature is not present in the rest of the cohort. Magnetic resonance imaging 
(MRI) revealed cerebral atrophy in both individuals; additionally, white matter cysts were 
present in one of them. In total, brain anomalies were reported in 7 of the 11 individuals 
(64%) in which a brain MRI was performed. Anomalies observed in at least two individuals 
were delayed myelination, cerebral atrophy, and corpus callosum abnormalities.
No significant additional congenital abnormalities were noted in our collected cohort of 19 
individuals. Vision problems, which mainly included (mild) refraction errors and strabismus, 
were reported in 10/19 individuals (53%). Hearing loss was present in one individual, and 
narrow auditory canals were reported in two other individuals. Although growth parameters 
were generally normal, small hands with short and broad digits, especially broad thumbs, as 
well as flat feet and high-arched feet were reported in some of the individuals. Five children 
(5/14; 36%) had sleeping problems at a young age, waking up several times per night. Three 
of the eleven males (27%) had cryptorchidism.
A comparison of facial features revealed a striking overlap in dysmorphisms in individuals 
with POU3F3 variants. The cupped, prominent, and often low-set ears, present in 16 of the 
19 individuals (84%), were most remarkable. Other common facial features included full 
lips, an openmouth appearance, a broad and bulbous nasal tip, hypertelorism, epicanthal 
folds, and peri-orbital fullness (Figure 1).
The types of POU3F3 variants in our cohort were diverse and included nonsense variants, 
frameshift variants, missense variants, and an in-frame deletion of five amino acids. All 
variants in this study are annotated with respect to the GenBank: NM_006236.2 transcript. 
None of the identified variants were present in the gnomAD database. The pLI-score of 
POU3F3 in gnomAD is 0.89, and no high-confidence truncating variants in this gene are 
present in this dataset, indicating that POU3F3 is especially intolerant for loss-of-function 
variance. In 13 of the 19 individuals, we found 12 different nonsense or frameshift variants, 
predicted to truncate POU3F3. For most genes, when such variants arise, the post-
transcriptional surveillance mechanism of nonsense-mediated mRNA decay (NMD) helps 
to prevent translation of aberrant truncated versions of proteins14. In mammalian cells 
this surveillance mechanism is tightly linked to pre-mRNA splicing15. Because POU3F3 is an 
intronless gene, aberrant transcripts with truncating variants are insensitive toNMD and 
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so will still be expressed. These truncating variants were distributed widely across POU3F3 
(Figure 2A) and are thus predicted to yield truncated proteins of a range of different sizes.
Five individuals in our cohort had a missense variant. All were located in one of the two 
known functional domains of POU3F3: the POU-specific (POU-S) domain and the POU-
homeobox (POU-H) domain (Figure 2A). Even with this relatively small number of missense 
variants, a clear clustering was seen: two unrelated individuals had an identical de novo 
missense variant (c.1085G>T, [p.Arg362Leu]), and another two individuals had missense 
variants that affected the same amino acid (c.1219C>G, [p.Arg407Gly] and c.1220G>T, 
[p.Arg407Leu]). One individual had a c.1367A>G, (p.Asn456Ser) substitution. In addition to 
the missense variants, one individual had an in-frame deletion (c.992_1006del, [p.Gln331_
Lys335del]), which removes five amino acids from within the POU-specific domain of the 
encoded protein. For all the missense variants and the in-frame deletion, highly conserved 
residues are affected (Figure 2B). All the missense variants of our cohort are predicted to be 
pathogenic by both PolyPhen- 2 and SIFT and have high CADD scores (range 26.9–32.0; Table 
S1). We also visualized the non-truncating variants in a tolerance landscape of POU3F3 by 
using the MetaDome web server. The tolerance landscape was computed as a missense over 
synonymous ratio, on the basis of single nucleotide variants in gnomAD in the proteincoding 
part of POU3F3. All the non-truncating variants were located in regions of the protein that 
are extremely intolerant to missense variation (Figure S1).
The two known functional domains of POU3F3, connected via a flexible linker, are both 
required for site-specific DNA binding with high affinity16. The POU-S domain forms four 
alpha-helices; several direct and sequence-specific hydrogen bonds are made between 
residues in the third helix and the DNA17. In the POU-H domain, the third helix is also 
responsible for sequence-specific DNA-binding. Two of the missense variants, c.1085G>T, 
(p.Arg362Leu) and c.1367A>G, (p.Asn456Ser), affect residues that are located in the third 
helix of the POU-S domain and the POU-H domain, respectively (Figure 2B).
We used three-dimensional protein modeling to further investigate the potential functional 
impact of the identified non-truncating variants. The PDB file PDB: 2XSD18 (POUdomain 
of POU3F1 bound to DNA) provided a template for modeling the DNA-binding region of 
POU3F3, which spans amino acids 316–466 (Figure 2C). Thismodel revealed that two of the 
amino acids (Arg362 and Asn456) that are substituted in our cohort are directly involved 
in binding the major groove of target DNA, consistent with the prior literature on other 
POU proteins16,17. In our model, Arg362 forms hydrogen bonds with a guanine base in the 
DNA of the transcription-factor binding site (Figure S2). Substitution of a leucine residue at 
this point of the protein is predicted to abolish DNA-binding. Similarly, Asn456 is directly 
involved in DNA-binding by forming hydrogen bonds with adenine, an interaction that will 
be disrupted by a substitution of serine at this position (Figure S2).
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Figure 1: Facial Features of Ten Individuals with a Pathogenic POU3F3 Variant 
(a) All individuals in this picture have cupped and/or prominent and often low-set ears, except for individual 
4. Other overlapping features are full lips, an open-mouth appearance, thick ear helices, a broad and bulbous 
nasal tip, hypertelorism, epicanthal folds, and periorbital fullness. (b) Magnification of the ear abnormalities in 
individuals 1, 9, 12, 13, 14, and 16, respectively.
The remaining two missense variants that we identified are located at position 407 on the 
edge of the homeodomain and at the flexible linker in our linear representation of POU3F3 
(Figure 2B). In the three-dimensional model, Arg407 lies in the flexible linker between 
both POU domains, but it is unclear what impact a substitution at this point would have 
on protein function (Figure 2C). Lastly, the in-frame deletion in our cohort is located in 
the POU-S domain. Although the amino acids that are deleted do not directly bind to DNA 
themselves, it is likely that their loss will alter domain structure and indirectly disturb DNA-
binding capacities.
To assess the potential functional effects of the POU3F3 variants, we performed a variety 
of complementary cellbased assays. We expressed a representative set of nine POU3F3 
variants, as well as wild-type (WT) POU3F3, as fusions to YFP tags in HEK293 cells. The set of 
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POU3F3 variants included all four missense variants, the in-frame deletion, and four of the 
truncating variants. Immunoblot analysis showed that all the expressed YFP-fusion proteins 
had the expected molecular weights (Figure S3).
Figure 2: Facial Features of Ten Individuals with a Pathogenic POU3F3 Variant 
(a) Linear representation of POU3F3 (Uni- Prot: P20264) showing the location of variants from unrelated families 
in this cohort. There are twelve truncating variants (blue), five missense variants (red), and one in-frame deletion 
(magenta). POU-S (orange) is the POU-specific domain, and POU-H (green) is the POUhomeodomain. The shown 
NLS (nuclear localization signal) prediction is derived from cNLS Mapper27. An overview with mutation details per 
subject is provided in Table S1. (b) Alignment of part of the POU3F3 amino acid sequence (using ClustalW) with 
orthologous sequences from the following species: Mus musculus, Danio rerio, Drosophila melanogaster, and 
Caenorhabditis elegans. Helix boundaries are defined as previously described16. (c) Three-dimensional modeling 
of the functional domains of POU3F3 binding to a target DNA sequence (yellow). Amino acids that are affected 
by the missense variants are shown in red (wild-type side chains are depicted), and the location of the in-frame 
deletion is shown in magenta. A more detailed picture for two missense variants, p.Arg362Leu and p.Asn456Ser, 
can be found in Figure S2.
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We assessed the subcellular localization of the mutant proteins by using direct fluorescence 
imaging (Figure 3). Although two missense variants (p.Arg407Leu and p.Arg407Gly) map 
within a computationally predicted nuclear localization signal (NLS) motif (Figure 2A), none of 
the missense variants disturbed subcellular localization in this assay. All four tested proteins 
with a missense variant were located in the nucleus in a similar manner to WT. However, 
all the other tested constructs showed abnormalities in subcellular localization patterns 
compared to WT. For three truncating constructs (c.196_197delinsT, [p.Asp66Serfs*26], 
c.668C>A, [p.Ser223*], and c.1197delG, [p.Ile400Serfs*16]), aberrant cytoplasmic expression 
was noted, in addition to the normal nuclear expression of the protein. For two of these 
constructs (p.Ser223* and p.Ile400Serfs*16) we observed protein aggregates just around 
the nuclear membrane in a subset of cells, possibly indicating degradation of mutant protein 
(Figures 3 and S4). Aberrant localization patterns within the nucleus were observed for the 
c.1284C>A, (p.Cys428*) and c.992_1006del, (p.Gln331_Lys335del) proteins, and the former 
showed small nuclear aggregates in a minority of cells (Figures 3 and S4).
We next investigated whether the variants affect the transcription factor activity of the 
encoded protein. POU3F3 belongs to the POU family of transcription factors and is known 
to share important roles in neurodevelopment with its close paralog POU3F25,6. In vitro 
experiments suggest that POU3F2 is able to activate an intronic binding site in FOXP210,11, a 
gene that has been implicated in a rare neurodevelopmental disorder mainly characterized 
by severe speech problems (MIM: 602081)19. We hypothesized that POU3F3 might also be 
able to activate transcription via this binding site within FOXP2. To test this hypothesis, we 
performed luciferase assays in which a YFP-fusion protein with POU3F3 or POU3F2 was 
expressed together with a Firefly luciferase construct containing the conserved FOXP2 
binding site (Figure S5), as well as a Renilla luciferase construct, providing a normalization 
control (Figure 4A). POU3F3 was able to increase luciferase expression as strongly as POU3F2; 
there was a six-fold increase in expression compared to the negative control (Figure 4B). 
This finding indicates that the known intronic binding site for POU3F2 can also serve as a 
functional binding site for POU3F3.
We used the same luciferase assay to compare our POU3F3 variant constructs with the 
POU3F3 WT construct. All four POU3F3 constructs with truncating variants showed a 
severe impairment in transcriptional activation function (Figure 4C). The relative luciferase 
expression for these variants was similar to that for the negative control (a YFP-expression 
vector without POU3F3), consistent with the complete or partial loss of the DNA-binding 
POU domains of POU3F3. Three of the non-truncating variants (p.Arg362Leu, p.Asn456Ser, 
and p.Gln331_Lys335del) showed partial transactivation capacity that was significantly 
lower than that of the WT construct. The p.Arg407Leu variant led to a significant increase 
in relative luciferase expression compared to the WT construct. No significant difference 
compared to WT was seen for the other missense variant at this position (p.Arg407Gly). In 
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summary, all variants except for the p.Arg407Gly substitution led to significantly disturbed 
transactivation capabilities in our assays.
POU proteins are well known to have highly conserved dimerization properties10. They 
bind to target genes as monomers or dimers and can form either homo-dimers or hetero- 
dimers involving other family members20. To investigate whether the variants in our cohort 
affected the dimerization capacities of POU3F3, we used bioluminescence resonance energy 
transfer (BRET), a sensitive live-cell assay, to test putative protein-protein interactions.21 In 
our assays, the bioluminescent donor construct encodes a Renilla luciferase (RLuc) fusion 
protein, and the fluorescent acceptor construct encodes a protein fused to YFP. If the 
proteins of interest are in close proximity, energy transfer can take place from donor to 
Figure 3: Subcellular Localization
(Direct fluorescence imaging of HEK293 cells expressing YFP-POU3F3 fusion proteins carrying different variants 
found in our cohort (green). The nuclei are stained with DAPI (blue). The scale bar ¼ 10mm. Pictures showing the 
aberrant subcellular localization patterns in a larger amount of cells for the variants p.Gln331_Lys335del, p.S223*, 
p.Ile400Serfs*16, and p.Cys428* can be found in Figure S4.
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acceptor. We tested the ability of each mutant protein to form dimers with WT POU3F3 
(Figure 5A) and with itself (Figure 5B). In these experiments the missense variants showed 
generally intact dimerization capacity, although the interactions for the p.Asn456Ser variant 
were slightly decreased. Two variants that are predicted to cause an early truncation of 
POU3F3 (p.Asp66Serfs*26 and p.Ser223*) showed a complete loss of dimerization capacity 
in both conditions. The two other truncating constructs (p.Ile400Serfs*16 and p.Cys428*) 
showed a less severe decrease, although the dimerization capacity was still significantly 
different from that of the WT construct. The p.Gln331_Lys335 protein showed impaired 
dimerization with WT POU3F3 but normal capacities for forming homo-dimers.
All in all, the results of our clinical and molecular characterization show that diverse 
variants at different locations within POU3F3 lead to a neurodevelopmental disorder with 
overlapping symptoms. When comparing genotypes and phenotypes within the cohort, 
several findings are of interest. First, two individuals (individuals 1 and 2) have a distinct 
and more severe phenotype compared to the rest of the cohort; this phenotype includes 
Figure 4: Luciferase Assays
(a) Expression constructs used in the luciferase assays: a YFP-fused POU3F3 or POU3F2 construct with a CMV 
promoter; a Firefly luciferase reporter construct with a minimal promoter and a preceding intronic FOXP2-derived 
binding site; and a control construct with Renilla luciferase under control of a TK promoter. (b) Results of luciferase 
assays with WT POU3F3 and WT POU3F2 and the reporter construct with the FOXP2-derived binding site. Values are 
expressed relative to the control and represent the mean5SD of three independent experiments, each performed 
in triplicate (**** ¼ p < 0.0001 and NS ¼ not significant, using one-way ANOVA and a post-hoc Tukey’s test). 
(c) Results of luciferase assay withWT POU3F3 and nine constructs with POU3F3 variants. Values are expressed 
relative to the control and represent the mean5SD of three independent experiments, each performed in triplicate 
(*** ¼ p < 0.001; **** ¼ p < 0.0001; and NS ¼ not significant when compared to WT POU3F3 using one-way ANOVA 
and a post-hoc Dunnett’s test).
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severe ID, epilepsy, and capillary hemangiomas. These individuals are unrelated but 
have an identical p.Arg362Leu variant. In luciferase assays, this variant showed impaired 
transcription- activation capacity, but it was not lower than that observed for other mutant 
constructs. Although the reason for the more severe and distinct phenotype associated with 
the p.Arg362Leu variant remains unclear, a dominantnegative effect is one possibility, given 
that the mutant protein showed normal subcellular localization and dimerization capacities 
in our assays.
Second, several pathogenic POU3F3 variants appear to be associated with characteristic 
facial features, especially the prominent, often cupped, and low-set ears. These ear 
abnormalities were reported independently in all individuals with a truncating variant 
and in the individuals with the p.Arg362Leu and p.Gln331_Lys335del variant (Figure 1 and 
Table S1). Prominent ears were also reported in the previously published individual with a 
microdeletion that included POU3F3.8 The cupped or prominent ears are not present in the 
three individuals with the missense variants p.Arg407Leu, p.Arg407Gly, and p.Asn456Ser. 
The two missense variants affecting amino acid Arg407 did not show loss-of-function effects 
in our luciferase assay; in fact, p.Arg407Leu showed evidence of a possible gain-of-function. 
The p.Asn456Ser variant had a mild loss-of-function effect on transcriptional activity. These 
results suggest that both loss-of-function and gain-of-function mechanisms of different 
severity might lead to neurodevelopmental disorders with differences on a phenotypic level.
Although the missense variants at positions Arg362 and Asn456 mediate DNA-binding in 
the major groove, this is not the case for Arg407. This residue is located in the flexible linker 
between the POU-domains. POU3F2 and POU3F3 are known to be flexible in terms of spacing 
preference16, meaning that they can bind to short binding motifs that are separated by 0, 2, 
or 3 bp, in contrast to other POU proteins that have more fixed preferences. Findings from a 
study of POU3F2 suggest that the highly conserved arginine residue at a position analogous 
to POU3F3 residue 407 is one of the residues that form a critical region in regulating the 
spacing preference of the protein16. Binding activity experiments showed that mutation of 
this critical region on the edge of the flexible linker and the homeodomain leads to less 
flexibility in spacing preference for the POU protein16.
The missense variants p.Arg407Gly and p.Arg407Leu show different effects in our luciferase 
assay: although p.Arg407Gly did not show any difference compared with theWT POU3F3 
construct, the p.Arg407Leu variant showed a gain-of-functioneffect. It isunclearwhythese 
twodifferent variants affecting the same Arg407 residue show different effects on 
transactivation capacity and how this relates to pathogenic mechanisms. Possibly, the 
missense variants at Arg407 alter the spacing properties of the encoded POU3F3 protein, 
and the alteration might affect transcriptional activation depending on the characteristics 
of the binding site. The architecture of regulatory DNA sites has been shown to influence 
the structure and organization of POU dimerization, interaction with other proteins, and 
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DNA-binding properties and can therefore be critical in determining the functionality of a 
transcription factor18,22.
Figure 5: Bioluminescence Resonance Energy Transfer Assays
(a) Bioluminescence resonance energy transfer (BRET) assays to measure interactions between WT POU3F3 and 
mutant POU3F3 constructs. Bars represent the corrected mean BRET ratio 5 SD of three independent experiments 
performed in triplicate (**** ¼ p < 0.0001; * ¼ p < 0.05; and NS ¼ not significant when compared to WT using one-
way ANOVA and a post-hoc Tukey’s test). The NLSdonor construct is a Renilla luciferase construct with a nuclear 
localization signal. (b) BRET assays to measure homodimerization capacity of each mutant POU3F3 construct. Bars 
represent the corrected mean BRET ratio 5 SD of three independent experiments performed in triplicate (**** ¼ 
p < 0.0001; *** ¼ p < 0.001; and NS ¼ not significant when compared to WT using one-way ANOVA and a posthoc 
Tukey’s test)
POU3F3 is highly similar to POU3F2; it has nearly identical (98.7%) amino acid sequences for 
the POU domains and the flexible linker. The main differences are found within the N-terminal 
region, which contains homopolymeric repeats that can function as transcriptional 
activation domains1,23. POU3F3 and POU3F2 share some roles and have partially redundant 
functions in cortical development4,5. Nonetheless, our study and the previously published 
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study on POU3F2 haploinsufficiency9 underscore the fact that two functional copies of both 
POU3F3 and POU3F2 are required for normal neurodevelopment. Microdeletions that span 
POU3F2 have been shown previously to cause a neurodevelopmental disorder with obesity9. 
In contrast to this POU3F2-related disorder, pathogenic variants in POU3F3 do not seem to 
be associated with obesity, because this feature is only reported in one of the 19 individuals 
in our cohort. In addition to the microdeletions encompassing POU3F2, a single de novo 
missense variant in POU3F2 has recently been reported, but the specific location of this 
variant does not correspond to any variant reported here for POU3F324.
Our functional data indicate that a known POU3F2 regulatory site mapping within the 
FOXP2 locus11 can also be bound by POU3F3. By using this binding site, we could develop 
luciferase-based assays to index the transactivation capacities of POU3F3 proteins carrying 
different etiological variants. Nevertheless, it remains undetermined whether pathogenic 
POU3F2 and/or POU3F3 variants actually have a significant impact on FOXP2 expression 
in the proper genomic context in vivo. Future studies (for example by directly testing for 
FOXP2 misregulation in individuals with pathogenic POU3F3 variants) might shed light on 
whether putative functional links between the different genes have physiological relevance 
for the speech and language impairments observed in the associated neurodevelopmental 
disorders25.
We emphasize that exome sequencing coverage is variable for POU3F3; the 5' half of 
the gene has poor coverage and the 3' part has good coverage26. So if the characteristic 
facial phenotype as shown in Figure 1 is recognized in an individual with an overlapping 
neurodevelopmental phenotype, it might be prudent to re-assess any existing next-
generation-sequencing data and/or perform targeted sequencing of POU3F3. The specific 
variants identified in this study were all covered by a sufficient number of allele counts in 
gnomAD, and none of these alleles were found in this large dataset26.
In conclusion, we have shown that pathogenic POU3F3 variants cause a neurodevelop-
mental disorder with a broad phenotypic spectrum that includes ID and/or DD, speech 
and language problems, hypotonia, and autism spectrum disorder. Most individuals 
have mild to moderate delays in neurodevelopment, but a distinct phenotype of severe 
ID and epilepsy is also reported in two individuals with an identical missense variant. 
Although most variants result in loss-of-function effects on the transactivation capacities of 
POU3F3, other possible pathogenic mechanisms cannot be excluded. By showing the effects 
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Figure S1: Non-truncating variants visualised in tolerance landscape of POU3F3 
Tolerance landscape of the POU3F3 protein based on transcript NM_006236.2 (ENST00000361360.2) visualized 
via the MetaDome web server1. The tolerance landscape is computed based on single nucleotide variants present 
in the gnomAD database. It is calculated as a missense over synonymous ratio in a sliding window of 21 residues 
over the entire POU3F3 protein. The green and blue peaks correspond to regions more tolerant to missense 
variation, and the red valleys indicate intolerant regions. The locations of the non-truncating variants in our cohort 
are displayed within the tolerance landscape of POU3F3. All these variants are located in regions that are highly 
intolerant to missense variation.
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Figure S2: Three-dimensional visualisation for the p.(Arg362Leu) and p.(Asn456Ser) variants 
A detailed visualization of the three-dimensional modeling analysis for the two missense variants affecting amino 
acids that directly bind to the major groove of DNA . Wild-type residues are shown in blue, while substitutions 
(caused by variants) are shown in magenta. DNA is depicted in yellow.
a) Arg362 (blue) is able to form hydrogen bonds with guanine in the DNA binding site. This binding is disturbed by 
substitution into leucine (magenta).
b) Asn456 (blue) is able to form hydrogen bonds with adenine in the DNA binding site. This binding is disturbed by 





Figure S3: Immunoblot analysis 
Western blot analysis of whole-cell lysates expressing eleven different YFP-tagged constructs, probed with an anti-
EGFP antibody: wild-type POU3F3, nine different POU3F3 variants and wild-type POU3F2. The immunoblot was 
stripped and then re-probed with beta-actin as a loading control. All different expressed YFP-fusion proteins are 
visible at the expected molecular weights.
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Figure S4: Aberrant subcellular localization patterns in a subset of cells for four variants 
a) Direct fluorescence imaging of cells expressing YFP-tagged variants of the POU3F3 protein: wild-type POU3F3, 
and POU3F3 with the p.(Ser223*) variant and the p.(Ile400Serfs*16) variant. In addition to the cytoplasmic 
localization of the p.(Ser223*) variant, both variant conditions show perinuclear aggregates in a subset of cells. 
Nuclei are stained with DAPI (blue). Scale bar = 10μm.
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b) Direct fluorescence imaging of cells expressing YFP-tagged variants of the POU3F3 protein: wild-type POU3F3, 
and POU3F3 with the p.(Gln331_Lys335del) variant and the p.(Cys428*) variant. Both variant conditions show an 
aberrant localization pattern within the nucleus in a subset of cells. Nuclei are stained with DAPI (blue). Scale bar 
= 10μm.
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Figure S5: POU3F3 binding site in intronic region of FOXP2 
This figure shows the ~300bp region of intron 8 of FOXP2 (chr7:114,289,482-114,289,778 (hg19/GRCh37)), that 
was cloned into a luciferase reporter vector to investigate transcriptional activation. The previously described 
POU3F2 consensus binding site2 is shown in red.
Supplemental Material and Methods
Research subjects
Informed consent was obtained from all participating families. For all pictures of probands 
in this study, specific consent to publish clinical photographs was obtained. All procedures 
in this study matched the local ethical guidelines of the participating centres, and are in 
accordance with the Declaration of Helsinki. Probands with possible pathogenic POU3F3 
variants were found using the GeneMatcher website3, the Decipher Database4 and 
matchbox5, and table S1 contains details on which specific matchmaking platform was used 
to identify each individual.
Exome sequencing, variant filtering and annotation
Exome sequencing and variant filtering were performed as previously described6-17. In 
individuals 1-17, whole exome sequencing and variant filtering was performed using a 
trio approach, in which sequencing was performed in the proband and both parents. In 
individual 18 and 19, whole exome sequencing was performed with a duo approach, in 
which the proband (individual 18) and the mother (individual 19) were sequenced. In all 
individuals, the POU3F3 variant was considered to be the most likely variant contributing 
to the phenotype, and there were no additional pathogenic or likely pathogenic variants 
reported. Additional variants (SNVs and CNVs) considered to be possibly pathogenic and/or 
to possibly contribute to the phenotype, are listed in Table S1. All variants in this study are 
annotated with respect to the NM_006236.2 transcript.
Cell culture and transfection
Human embryonic kidney cells 293 (HEK293) cells were grown in Dulbecco’s Modified Eagle’s 
Medium (Gibco) that was supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin mix (both Gibco). The cells were cultured at 37°C in an incubator with 5% 
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CO2. Transient transfection was performed with GeneJuice Transfection Reagent (Merck 
MilliPore) according to the manufacturer’s instructions.
Cloning of DNA constructs and site‑directed mutagenesis
A synthetic clone of wildtype POU3F3 cDNA with flanking restriction sites EcoR1 and Xba1 in 
a pUC57-vector was synthesized by GenScript. The POU3F3 insert was subcloned using the 
EcoR1/Xba1 restriction sites into a modified pLuc and pYFP vector as previously described 18.
Variants in POU3F3 constructs were created using site-directed mutagenesis (SDM) with 
the QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to the manufacterer’s 
instructions. The following mutated constructs were created (corresponding SDM primers in 
parentheses; F = Forward primer, R = Reverse primer): p.Arg362Leu (F: 5’-ACCACCATCTG-
CCTCTTCGAGGCCCTG-3’; R: ’-CAGGGCCTCGAAGAGGCAGATGGTGGT-3’), p.Arg407Gly (F: 5’-CAG-
GGCCGCAAGGGCAAGAAGCGGA- 3’; R: 5’-TCCGCTTCTTGCCCTTGCGGCCCTG-3’), p.Arg407Leu (F: 
5’- CAGGGCCGCAAGCTCAAGAAGCGGACC-3’; R: 5’-GGTCCGCTTCTTGAGCTTGCGGCCCTG-3’), 
p.Asn456Ser (F: 5’-GCGGGTCTGGTTCTGCAGTCGGCGCCA-3’; R: 5’-TGGCGCCGACTGCAGAAC-
CAGACCCGC-3’), p.Gln331_Lys335del (F: 5’-CCTGCGTGAAGCCCAGCTTGAACTGCTTGG-3’; R: 
5’- CCAAGCAGTTCAAGCTGGGCTTCACGCAGG-3’), p.Asp66Serfs (F: 5’-GCCTACCGGGGGTC-
CCGTCCTCTGT- 3’; R: 5’-ACAGAGGACGGGACCCCCGGTAGGC-3’), p.Ser223* (F: 5’- CCGGGCT-
GCTAGTAGAGCAGACTCTGC-3’; R: 5’-GCAGAGTCTGCTCTACTAGCAGCCCCG-3’), p. Ile400Serfs (F: 
5’-GCGCCGCGATTTGTCGATGCTTGTGGGG-3’; R: 5’- CCCCACAAGCATCGACAAATCGCGGCGC-3’) 
and p.Cys428* (F: 5’- CACTTCCTCAAGTGACCCAAGCCCTCCGC-3’; R: 5’-GCGGAGGGCTTGGGT-
CACTTGAGGAAGTG-3’). 
After SDM, variants were validated using Sanger sequencing, and POU3F3 inserts were 
subcloned into new pLuc and pYFP vectors. An ‘empty YFP-vector’ (modified pYFP expression 
vector without POU3F3 insert) was used as a control construct for the luciferase assays.
POU3F2 cDNA was cloned into TOPO vector using the following primers: 5’- 
GAGGATCCTGGCGACCGCAGCGTCTAACCAC-3’ (Forward primer) and 
5’- GATCTAGATTACTGGACGGGCGTCTGCACCCCG-3’ (Reverse primer). 
The POU3F2 insert was then subcloned into modified pLuc and pYFP vectors (as previously 
described; 18) using BamHI and XbaI restriction sites.
To create the firefly reporter construct for luciferase assays, the previously described 
POU3F2 binding site in FOXP2 (Figure S5) was cloned into TOPO from gDNA using the 
following primers: 5'- CTCGAGTAGGCACTGACTGAGAAAATC-3' (Forward primer) and 5'- 
AGATCTATATGTAAAAGAATAGTGCCT-3' (Reverse primer). The binding site was then subcloned 
into a p.GL4.23 vector (Promega) using the restriction sites BglII and XhoI. Control constructs 
used in the BRET assays (pYFP-vector with NLS-insert, and pRLuc-vector with NLSinsert) 
were made as previously described18. All constructs were validated by Sanger sequencing.




HEK293 cells were seeded on poly-D-lysine (Sigma) coated coverslips, and transfected 
after 24 hours. At 36 hours post-transfection, the cells were fixed by incubation in 4% 
Paraformaldehyde (Electron Microscopy Sciences) for ten minutes at room temperature. 
Coverslips were mounted onto slides using Vectashield mounting medium for fluorescence 
with DAPI (Vector). The proteins of interest were expressed as fusion proteins to YFP. 
Fluorescence images were obtained with an Axiovert A-1 fluorescence microscope and ZEN 
imaging software (Zeiss).
BRET assay
HEK293 cells were transfected 24 hours after plating in 96 well plates, with pairs of Renilla 
luciferase and YFP fusion proteins, as previously described18. Luciferase substrate (EnduRen; 
Promega) was added at 60μM 36 hours post-transfection. After four hours of incubation, 
the emission was measured using a TECAN F200 PRO or M200 PRO microplate reader using 
the Blue1 and Green1 filter sets. To determine the YFP-fusion protein expression level, 
fluorescence measurements were taken using a filter and a dichroic mirror suitable for green 
fluorescent protein (GFP) fluorescence (excitation 480nm, emission 535nm). The corrected 
BRET ratio was obtained using the following formula [Green1(experimental condition)/Blue1(experimental 
condition)] - [Green1(control condition)/Blue1(control condition)]. The BRET assay set-up that was used for this 
study is discussed in more detail in Deriziotis et al.18
Luciferase assay
HEK293 cells were transfected 24 hours after seeding in 96 well plates with the firefly 
luciferase reporter construct (2μl of 36nM), a pGL4.74 (hRluc/TK) Renilla Reniformis luciferase 
construct (2μl of 36nM; Promega) and a YFP-expression construct or empty YFP-expression 
vector (6μl of 36nM). Firefly luciferase and Renilla luciferase activities were measured 36 
hours post-transfection using the Dual-Luciferase Reporter Assay System (Promega) and a 
TECAN F200 PRO microplate reader.
Western blotting
Whole cell lysates were collected 40 hours post-transfection by treatment with RIPA buffer 
(Cell Signaling Technology) supplemented with 0.1mM PMSF (Sigma), Protease Inhibitor 
Cocktail (Roche) and 1mM DTT (Sigma). Cells were lysed for 30 minutes at 4°C followed by 
centrifugation for 10 minutes at 13,000rpm at 4°C. Laemmli buffer (Bio-Rad) was added to 
the supernatants, and the proteins were loaded on 4-15% Mini Protean-TGX Precast Gels 
(Bio-Rad) and transferred onto polyvinylidene fluoride membranes (Bio-Rad). Membranes 
were blocked in 5% milk in PBS-T (Phospate Buffered Saline supplemented with 0.1% Tween) 
for 1.5h at room temperature and then probed with 1:8000 mouse anti-EGFP (Clontech) 
in 1% milk in PBS-T at 4°C overnight. This was followed by incubation with 1:3000 HRP-
conjugated goat anti-mouse (Bio-Rad) in 1% milk at room temperature for 1h. Proteins 
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were visualized with Novex ECL Chemluminescent Substrate Reagent Kit (Invitrogen), using 
the ChemiDoc XRS+ System (Bio-Rad). To check for equal loading of proteins, the blot was 
subsequently stripped for 25 minutes in Re-blot Plus Strong stripping solution (Millipore) at 
room temperature, and blocked in 5% milk in PBS-T for 30 minutes at room temperature, 
followed by incubation with 1:1000 mouse anti-beta-actin (Sigma) in 1% milk overnight at 
4°C, and incubation with 1:3000 HRP-conjugated goat anti-mouse (Bio-Rad) in 1% milk at 
room temperature.
Three‑dimensional modeling
The exact three-dimensional structure of human POU3F3 is not known. Therefore, we 
created a homology model based on the crystal structure of the mouse POU3F1 structure 
(PDB file 2XSD)19. The human POU3F3 and mouse POU3F1 sequences show 94% identity 
over 147 residues in the Cterminal domain, containing both the POU-specific and the POU-
homeo domain. We used the YASARA & WHAT IF Twinset modeling algorithm with standard 
parameters for modeling and subsequent analysis20, 21.
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Chromatin remodeling is of crucial importance during brain development. 
Pathogenic alterations of several chromatin remodeling ATPases have been 
implicated in neurodevelopmental disorders. We describe an index case 
with a de novo missense mutation in CHD3, identified during whole genome 
sequencing of a cohort of children with rare speech disorders. To gain a 
comprehensive view of features associated with disruption of this gene, we 
use a genotype-driven approach, collecting and characterizing 35 individuals 
with de novo CHD3 mutations and overlapping phenotypes. Most mutations 
cluster within the ATPase/helicase domain of the encoded protein. Modeling 
their impact on the three-dimensional structure demonstrates disturbance 
of critical binding and interaction motifs. Experimental assays with six of 
the identified mutations show that a subset directly affects ATPase activity, 
and all but one yield alterations in chromatin remodeling. We implicate de 
novo CHD3 mutations in a syndrome characterized by intellectual disability, 





The Chromodomain Helicase DNA-binding (CHD) protein family is a key class of ATP-dependent 
chromatin remodeling proteins, which utilize energy derived from ATP hydrolysis to regulate 
chromatin structure, thereby modulating gene expression1,2. CHD proteins are crucial for 
developmental processes1,3, with various members implicated in major neurodevelopmental 
disorders including CHD2 in epileptic encephalopathy4, CHD7 in CHARGE syndrome5, CHD8 
in autism6,7, and more recently CHD4 and CHD1 in neurodevelopmental syndromes8,9. Three 
CHD proteins (CHD3, CHD4, and CHD5) can exert their chromatin remodeling activity by 
forming the core ATPase subunit of the NuRD complex1,10–12. The NuRD complex is associated 
with various fundamental cellular mechanisms, including genomic integrity and cell cycle 
progression13, and plays important roles in embryonic stem cell differentiation14. A recent 
study reports that the different CHD factors within the NuRD complex (CHD3, CHD4, and 
CHD5) are developmentally regulated in the mouse brain, each having distinct and mostly 
non-redundant functions during cortical development15. In particular, the CHD3 protein has 
been implicated in late neural radial migration and cortical layer specification.
In contrast to most other members of the CHD protein family, a specific syndrome 
associated with mutations in CHD3 (MIM 602120) has not yet been characterized. In this 
study, based on an index case from whole genome sequencing of children with rare speech 
disorders, we assemble a set of 35 probands carrying de novo mutations that disrupt CHD3. 
We characterize the overlapping phenotypic features of probands with CHD3 mutations, 
including intellectual disability (with a wide range of severity), developmental delays, 
macrocephaly, impaired speech and language skills, and characteristic facial features. We 
identify mainly missense mutations that cluster in and around the ATPase/helicase domain 
of the CHD3 protein, and are predicted to disturb function, based on three-dimensional 
modeling. We use functional assays to describe the effects of multiple different CHD3 
mutations on ATPase activity and chromatin remodeling capacities. Taken together, our 
data demonstrate that de novo missense mutations in CHD3 disturb chromatin remodeling 
activities of the encoded protein, thereby causing a neurodevelopmental disorder.
Results
De novo CHD3 mutations cause a neurodevelopmental phenotype. 
During whole genome sequencing of a cohort of 19 unrelated children with a primary 
diagnosis of Childhood Apraxia of Speech (CAS)16, we discovered a de novo missense 
mutation in CHD3, predicted to disrupt the helicase domain of the encoded protein. CAS is 
a rare neurodevelopmental disorder characterized by impairments in learning to produce 
the coordinated sequences of mouth and face movements underlying fluent speech. 
Remarkably, the CHD3 protein is one of the few documented interaction partners of FOXP2 
(see Supplementary Table S1 in ref. 17), a transcription factor that has been implicated in 
monogenic forms of CAS, accompanied by wide-ranging language problems, in multiple 
families and unrelated cases18–20. 
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Discovery of the CHD3 mutation (NM_001005273.2, p.Arg1169Trp) in our index case 
motivated a search for other de novo mutations in this gene. Studies of large numbers of 
simplex families with an autistic proband have documented just two single non-synonymous 
de novo variants in CHD3 in probands21,22, while eight additional non-synonymous variants 
were recently recorded in a study of thousands of children with unexplained developmental 
disorders from the UK23, with limited information on phenotypic profiles of carriers of 
CHD3 variants. Via GeneMatcher24 we assemble a cohort of 35 independently diagnosed 
probands with de novo mutations disrupting CHD3, to systematically assess the phenotypic 
consequences of damage to this gene.
The 35 probands with de novo mutations in CHD3 show overlapping phenotypes, 
summarized in Table 1 and in more detail in Supplementary Data 1. All individuals have 
global developmental delays and/or intellectual disability, with a total IQ varying from 
70–85 (borderline intellectual functioning) to below 35 (severe intellectual disability). Nine 
individuals (29%) show autism or autism-like features, including stereotypic and handflapping 
behavior. Interestingly, the majority of individuals (19 individuals; 58%) have macrocephaly, 
and in cases where neuroimaging has been performed, widening of cerebrospinal fluid 
spaces is noted in 10 out of 30 MRI reports (33%). One individual (individual 5) has 
microcephaly. Hypotonia is reported in 21 individuals (75%). The facial phenotype consists of 
widely spaced eyes, a broad and bossing forehead, periorbital fullness and narrow palpebral 
fissures, laterally sparse eyebrows, low-set and often simple ears with thick helices, and a 
pointed chin (Fig. 1). Joint dislocations and/or hyperlaxity are reported in 12 cases, and 
five individuals have inguinal or umbilical hernias. Five of the 21 male individuals have 
undescended testes. Vision problems are quite common and include hypermetropia (11 
individuals), strabismus (10 individuals), and cerebral visual impairment (three individuals). 
One individual (individual 34) developed epilepsy, two additional individuals had neonatal 
convulsions. In many individuals an abnormal and often unsteady gait is reported, and one 
individual (individual 13) developed symptoms of Parkinsonism at a later age.
Given that our index case was ascertained on the basis of a formal diagnosis of CAS, we pay 
special attention to the association of CHD3 mutations with speech and language deficits. 
The index case was diagnosed with severe speech apraxia at the age of 3 years, and then 
used sign language to communicate effectively. He has severe problems with expressive 
speech, against relatively normal scores on language comprehension tests and a composite 
IQ (KBIT) of 72. In all 33 subjects that were at least 2 years old at the last evaluation, CHD3 
disruptions are associated with delayed milestones in the speech and language domain. The 
average age for first spoken words in this cohort is 2 years and 10 months (range: 1.5–5.5 
years, after excluding six individuals that were non-verbal at the last evaluation). Our data 
suggest that expressive language is more affected than receptive language, and intelligibility 
is often impaired. Speech-related problems identified in our cohort include dysarthria, 
speech apraxia, oromotor problems, and stuttering.
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More extensive clinical information per individual is provided in Supplementary Data 1. As information on the 
different features was not always applicable or known for each patient, the denominator in the “Amount” column 
is different for different clinical characteristics.
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Figure 1: Photographs of affected individuals
Facial photographs showing dysmorphisms in 18 individuals with de novo CHD3 mutations. The majority of 
individuals have macrocephaly with a prominent or bossing forehead, individual 5 has microcephaly. Hypertelorism 
or telecanthus is common, often accompanied by narrow palpebral fissures, deep-set eyes, peri-orbital fullness, 
and/or epicanthal folds. The combination of macrocephaly and deep-set eyes leads to a more prominent supra-
orbital ridge. Some individuals show midface hypoplasia. Many individuals have low-set ears that can be posteriorly 
rotated, and sometimes simple with thick helices. A broad nasal base, prominent nose, a bifid nasal tip, and 
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De novo CHD3 mutations cluster in the helicase domain 
The 35 unrelated probands have 23 different de novo mutations in CHD3 (Fig. 2a, b). None 
of these mutations are present in the GnomAD database (http://gnomad.broadinstitute.
com). Except for four individuals, all individuals have missense mutations. Interestingly, 
within our cohort there are multiple cases of recurrent identical de novo mutations, 
revealing mutational hotspots. The most striking is p.Arg985Trp, found in six children from 
five different families, while two additional individuals have a different substitution affecting 
the same residue (p.Arg985Gln).
The CHD3 protein is characterized by a SNF2-like ATPase/ helicase domain, together with 
two plant homeodomain (PHD) fingers and two chromodomains (Fig. 2b, c)1,11, which 
mediate chromatin interactions and nucleosome remodeling1. The overwhelming majority 
of missense mutations (17/19) cluster within and around the ATPase/helicase motif, a 
functional domain that consists of two subdomains: a Helicase ATP-binding lobe and a 
Helicase-C-terminal lobe. This domain provides energy for nucleosome remodeling through 
its ATPase activity. All missense mutations affect amino acids that are highly conserved, both 
in different species and also in the other CHD proteins that can be part of the NuRD complex 
(Fig. S1), and clearly cluster in and around highly conserved SF2-family helicase motifs 
(Fig. S2). All are predicted to be pathogenic by Polyphen-2 and/or SIFT, and have CADD 
scores above 24 (Supplementary Data 1).
The identified de novo mutations also include one in-frame deletion of one amino acid 
(p.Gly1109del) and two truncating mutations (p.Glu457* and p.Phe1935Glufs*108), 
although the latter causes a frameshift at the very end of the protein, leading to a stop 
codon after 108 amino acids. RNA sequencing of transcripts with and without cycloheximide 
showed that this mutation escapes nonsense-mediated decay (Fig. S2). Finally, one 
case has a splice-site mutation (c.4073-2A>G) which is predicted to yield skipping of 
exon 27, while preserving the reading frame (Fig. 2a). Data from the ExAC database 
(http://exac.broadinstitute.com) indicate that CHD3 is extremely intolerant for loss-of-
function mutations (loss-of-function intolerance score of 1.0) and highly intolerant for 
missense mutations (Z-score of +7.15)25, supporting the pathogenicity of the mutations that 
we found.
All CHD3 mutations were determined to be the most likely causal variant contributing to the 
disorder of the proband. In proband 15 who has a de novo CHD3 p.Asp1120His mutation, 
a de novo truncating mutation in CIC was also identified (NM_015125.3:c.1444G>T; 
p.Glu482*). Since truncating mutations in CIC were recently suggested as a potential cause 
of intellectual disability (ID)26, both mutations might be involved in the phenotype of this 
proband.
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A subset of CHD3 mutations directly affects ATP hydrolysis
The striking clustering of almost all missense mutations in the ATPase/helicase domain of the 
CHD3 protein led us to hypothesize that disturbance of ATPase and/or chromatin remodeling 
activities of CHD3 could be potential pathogenic mechanisms. Three-dimensional modeling 
and mutation analysis of all missense mutations, including analysis of the conserved SF2- 
characteristic helicase motifs, demonstrates clear clustering of mutations and disturbance 
of important binding and interaction domains (Fig. 2d and Supplementary Note 1). Direct 
fluorescence imaging of mCherry-tagged CHD3 mutations in cellular models revealed no 
differences in subcellular localization for the mutated proteins as compared to wild-type 
CHD3 (Fig. S3).
We experimentally assessed ATPase activity of six representative mutations, selected to 
include one mutation in the Helicase ATP-binding lobe and several mutations in the Helicase 
Cterminal lobe. FLAG-tagged full-length wild-type CHD3 protein and each of the six mutant 
proteins were transiently expressed in mammalian HEK293 cells and purified (Fig. S4). 
Radiometric ATPase assays were performed to assess the activity of these mutant proteins 
relative to wild-type, in the presence of dsDNA (Fig. 3), recombinant nucleosomes (Fig. 3), or 
in the absence of DNA substrates as a control (Fig. S5). ATPase activities of p.Arg1121Pro and 
p.Arg1172Gln were significantly lower than wild-type for both substrate conditions. These 
findings are consistent with the modeling data, since p. Arg1121Pro is predicted to disrupt a 
helix integral to motif V, while p.Arg1172Gln is located in helicase motif VI, and both motifs 
are known to be critical in ATP hydrolysis. The activity of p.Asn1159Lys was significantly lower 
only in the presence of dsDNA, although the reason for the different activity depending on 
the substrate is currently unknown. The protein with the p. Leu915Phe mutation, located in 
conserved SNF2-motif III, is significantly hyperactive under both conditions. The p.Arg1187-
Pro and p.Trp1158Arg mutations do not show statistically significant differences from the 
wild-type protein in these ATPase assays. According to the three-dimensional structure, 
the location of p.Arg1187Pro is not close to the ATP-binding or interaction surface. To 
assess whether mutant protein could impact activity of wild-type enzyme, we mixed wild-
type protein with equimolar amounts of several mutant proteins, finding no biochemical 
evidence in this assay for interference (Fig. S6).
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Figure 2: Schematic view of CHD3 transcript and protein with de novo mutations
a Schematic view of CHD3 exons (transcript 1, NM_001005273.2) with the splice site mutation c.4073-2A>G shown 
that most likely leads to skipping of exon 27 (22 amino acids), while preserving the reading frame. Exon 27 is 
part of the beginning of the second DUF domain (DUF 1086). Colors of the domains in a match with colors of 
domains in b and c. Five different types of domains are specified: plant homeodomains (PHD), chromodomains 
(Chromo), a Helicase domain consisting of two parts (Helicase ATP-binding and Helicase C-terminal), domains 
of unknown function (DUF), and a C-terminal 2 domain. b Schematic view of linear CHD3 protein (transcript 1, 
NM_001005273.2) with all mutations, except for the splice site mutation that is shown in a, found in our cohort. 
Almost all missense mutations cluster in or around the Helicase domain of the CHD3 protein. c Overview of one 
of the two CHD3-models used in this study, based on the 3MWY protein structure. This figure shows the different 
domains of the protein in their three-dimensional conformation: chromo domain 1 494–595 (magenta), chromo 
domain 2 631–673 (red), helicase ATP binding domain (yellow), helicase C-terminal domain (green), ATP binding 
residues 761–768 (cyan). ATP is orange, and gray residues do not belong to an indicated domain. Colors of the 
domains in c match with colors of domains in a and b. d The same structure as c, but in this figure the positions 
of the mutated residues are indicated in red, the sidechains of these residues are shown as red balls. The ATP 
molecule is shown in yellow. This figure illustrates the clustering of mutations on specific sites within the Helicase 
ATP-binding domain and Helicase C-terminal domain. A more detailed analysis of the different missense mutations 
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CHD3 mutations disturb chromatin remodeling capacities 
We measured the effects of six mutations on the chromatin remodeling activity of CHD3, 
by assessing restriction enzyme accessibility to nucleosomal DNA27. Consistent with its 
reduced activity in the ATPase assays, the p.Arg1172Gln mutant was partially, but not fully, 
active at chromatin remodeling (Fig. 4). p. Arg1121Pro, which showed severely reduced 
ATPase activity, was highly compromised in the chromatin remodeling assay. Moreover, 
p.Leu915Phe demonstrated hyperactivity in this assay, mirroring its elevated ATPase 
activity. Crucially, chromatin remodeling assays can also detect functional defects beyond 
ATP hydrolysis27. Two of the mutant proteins, p.Trp1158Arg and p. Asn1159Lys, exhibited 
severely compromised ability to remodel chromatin (Fig. 4) against a background of some 
preserved ATPase activity (c.f. Fig. 3). In sum, with the sole exception of p. Arg1187Pro, all 
the mutant versions of CHD3 that we tested differ from wild-type protein in their ability 
to remodel chromatin, with some mutants exhibiting decreased activity while one shows 
increased activity.
Figure 3: ATPase assays
Radiometric ATPase assays were performed to assess the activity of the mutant proteins relative to wild-type, in 
the presence of recombinant nucleosomes (blue), dsDNA (green), or in the absence of DNA substrates as a control 
(Fig. S4). Released phosphate was separated from unhydrolyzed ATP by thin layer chromatography, and detected 
by exposure to a phosphorimager. The experimental values (percentage hydrolyzed ATP) for the different mutant 
conditions were normalized to values for the wild-type condition within the experiment, to derive a normalized 
ATPase activity. The experimental data are presented as means ± standard deviation, individual data points are 
shown as red triangles. Three independent experiments from two individual purifications (wild-type, p.Leu915Phe, 
p.Arg1121Pro, p.Asn1159Lys, p.Arg1172Gln, and p.Arg1187Pro) (N= 6) or one purification (p.Trp1158Arg) (N = 3) 
were performed. Raw values from the individual experiments can be found in Supplementary Data 2. Asterisk (*) 
indicates significant difference for mutant values compared to wild-type values (unpaired t-test, P < 0.05) within 

































In this study, we show that de novo CHD3 mutations cause a neurodevelopmental disorder. 
We demonstrate defining clinical features of this syndrome. The characteristic phenotype 
of individuals with CHD3 mutations overlaps with that reported for de novo mutations in 
CHD4, in which intellectual disability, macrocephaly, ventriculomegaly, undescended testes, 
and similar facial features have been reported. However, comparisons to the CHD4-related 
syndrome are currently limited because so far only five individuals with CHD4 mutations 
have been clinically characterized. Also interesting in this context is the fact that four of 
the six recently described patients with missense mutations in CHD1 have a diagnosis of 
speech apraxia9, a relatively rare condition. Although CHD1 does not function in the same 
protein complex as CHD3 and has different expression patterns9, there might be shared 
pathogenic mechanisms leading to speech problems in patients with mutations in these 
chromatin remodelers.
Based on the molecular and phenotypic data of individuals in our cohort, there is no obvious 
correlation between the precise type or location of the mutation, and the severity of the 
variable features of the resulting syndrome. However, the only individual in our cohort with 
epilepsy is also the only case with a missense mutation in the C-terminal domain of the 
protein. Future identification of more individuals with missense mutations in this region of 
the protein will help resolve whether this reflects a phenotype–genotype correlation.
In addition to defining the phenotype associated with CHD3 mutations, we aimed to 
characterize the effects of CHD3 mutations at a molecular and functional level. ATPase 
assays with six different mutant CHD3 constructs showed a clearly decreased ATPase activity 
for two mutations (p.Arg1121Pro and p.Arg1172Gln) and increased ATPase activity for one 
mutation (p.Leu915Phe). The disturbed ATPase activities are associated with corresponding 
effects on chromatin remodeling capacities for these three mutants, as shown by the 
restriction enzyme accessibility assays. It is currently unclear how deactivating and activating 
mutations can both yield similarly disruptive effects on neurodevelopmental outcomes. 
However, a recent study of cancer-specific mutations in the chromatin remodeling ATPase 
SMARCA4 concluded that mutations in the ATPase core of this enzyme had dominant-
negative impacts on the global chromatin landscape regardless of whether they displayed 
increased or decreased dynamic recovery in fluorescence after photobleaching28. By analogy, 
it seems plausible that perturbed chromatin remodeling activity of CHD3, whether by gain 
or loss of activity relative to wild-type or by affecting its interactions, might likewise alter 
chromatin landscapes, to contribute to a neurodevelopmental phenotype.
Two mutations (p.Trp1158Arg and p.Asn1159Lys) show severely decreased chromatin 
remodeling capacities, despite unaffected ATPase activity in the presence of recombinant 
nucleosomes. In line with these findings, the highly conserved tryptophan residue at a 
position analogous to CHD3 residue 1158 has recently been shown to be critical for chromatin 
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remodeling, but not for ATP hydrolysis, in the context of yeast SNF227. Interestingly, the 
mutation in our cohort affecting this amino acid (p.Trp1158Arg) directly matches the 
position of a previously published mutation in CHD48 (Fig. S1), while the other previously 
published de novo missense mutations in CHD4-related syndrome are also mainly affecting 
the orthologous Helicase domain of CHD4 (Fig. S1)8,29.
To systematically assess whether the distribution of the missense mutations in CHD3 
reflects mutational hotspots in the gene, we performed a formal clustering analysis based 
on mutual distances, as previously described30. This analysis revealed significant clustering 
within the transcript (P = 0.0017), a finding that argues against simple haploinsufficiency 
as an underlying molecular mechanism. The paucity of patients with truncating mutations 
compared to the 31 patients with missense mutations in our cohort also supports this view, 
although the precise mechanistic effects of CHD3 mutations during neurodevelopment are 
a topic for future study.
Taken together, with our research we identify a recognizable neurodevelopmental disorder. 
We define the phenotypic spectrum associated with mutations in CHD3, and show the effects 
of several different mutations on ATPase activity and chromatin remodeling capacities. Our 
findings highlight the importance of chromatin remodeling factors, and specifically the 
CHD3 protein, in human brain development.
Figure 4: Restriction enzyme accessibility assay
a Restriction enzyme accessibility analysis of 
CHD3 wild-type and mutant proteins. 3.125, 6.25, 
or 12.5 nM of CHD3 proteins were incubated with 
347 bp mononucleosomes. Digested fragments 
were analyzed by native polyacrylamide gel. 
b Quantitative analysis of restriction enzyme 
accessibility. Three individual experiments 
from two individual purifications (wild-type, 
p. Leu915Phe, p.Arg1121Pro, p.Asn1159Lys, 
p.Arg1172Gln, and p.Arg1187Pro) (N = 6) or 
one purification (p.Trp1158Arg) (N =3) were 
conducted. The experimental data are presented 



































Individuals and consents 
The authors affirm that (the legal representatives of) all human research participants provided 
informed consent for publication of the images in Fig. 1. Informed consent was also derived 
for the use of biological materials from all individuals or their legal representative. Genetic 
testing and research were performed in accordance with protocols approved by the local 
Institutional Review Boards where the patients were followed. Specifically, research exomes 
were performed after informed consent on protocols approved by the Institutional Review 
Boards of the following institutions: University of British Columbia, Augustana College, CHU 
Dijon, Mass General Hospital for Children, University of Erlangen-Nuremberg, Hamburg 
Chamber of Physicians, Cambridge South—UK Research Ethics Committee, University of 
Wisconsin-Madison Social & Behavioral Sciences.
Annotation of mutations 
All mutations in this report are annotated in GRCh37 (hg19) and CHD3 transcript variant 1 
(NM_001005273.2).
Next-generation sequencing 
For the index case (individual 22), whole genome sequencing was performed using Illumina’s 
HiSeq X Ten technology, the Burrows–Wheeler Aligner (BWA) software version 0.7.8-r45531 
and GATK v.3.432. In other individuals, exome or genome sequencing and data analysis were 
performed as previously described33–44.
Expression and purification of FLAG-CHD3 
CHD3 proteins were prepared as previously described45, with the following modifications. 
FLAG-CHD3 constructs were cloned into expression vectors (kindly provided by Guang Hu) 
using Gateway Cloning technology. Primer sequences are provided in Fig. S1. HEK293-f 
(ThermoFisher, FreeStyle™ 293-F Cells) were grown in suspension culture using FreeStyle™ 
293 Expression Medium (ThermoFisher) in optimum growth flasks (Thomson) using a 
shaking incubator set at 8% CO2, 80% humidity, and 150 rpm shaker rate. The cell count was 
106 cells/ml on the day of transfection. Cells were transfected with 1 mg of expression vector 
using PEI max (Polysciences). Cells were harvested 48 h after transfection by centrifugation 
at 400 × g for 6 min. Cells were washed once with phosphate buffer saline solution prior to 
storage at −80 °C or protein purification.
The cell pellet was resuspended in lysis buffer (20mM HEPES, 1.5mM MgCl2, 10mM KCl, 
1mM DTT, 1mM PMSF, and 1× cOmplete® protease-inhibitor EDTA-free (Roche), pH 
7.6). Cells were incubated on ice for 30 min, vortexed briefly, and nuclei were collected 
by centrifugation (5 min, 3300 × g, 4 °C). The supernatant was discarded and the nuclear 
pellet was resuspended in nuclear extraction buffer (20mM HEPES, 0.5M KCl, 1.5mM 
MgCl2, 0.2mM EDTA, 20% glycerol, 0.2% NP-40, 1mM DTT, 1 mM PMSF, and 1× cOmplete® 
CHD3 helicase domain mutations cause a neurodevelopmental syndrome
93
4
proteaseinhibitor EDTA-free (Roche), pH 7.6). The nuclear pellet was homogenized using a 
Dounce homogenizer, incubated on ice for 30 min, and insoluble material was removed by 
centrifugation (20 min, 110,000 × g, 4 °C). The supernatant (nuclear extract) was incubated 
with α-FLAG M2 affinity gel (Sigma-Aldrich) and rotated overnight at 4 °C. The α-FLAG beads 
were then washed twice with nuclear extraction buffer, followed by 2 additional washes 
with wash buffer (20mM HEPES, 0.1M KCl, 0.2% NP-40, 20% glycerol, and 1mM DTT, pH 
7.6). The FLAG-CHD3 protein was eluted with 0.3 mg/ml 3XFLAG peptide (in 20mM HEPES, 
0.1M KCl, 0.05% NP-40, 20% glycerol, and 1 mM DTT, pH 7.6). Wildtype and mutant protein 
samples were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue (Fig. S4). The 
concentration of the CHD3 proteins was estimated from BSA standards in SDS-PAGE gels 
stained with Coomassie Brilliant Blue.
Radiometric ATPase assay 
Each ATPase reaction (10 μL) contained 20mM Tris–HCl, pH 7.5, 1 mM MgCl2, 0.1 mg/ml BSA, 
1mM DTT, 100 μM ATP, 1 μCi of [γ-32P]ATP as a tracer. 25 nM of each CHD3 purified protein 
was incubated with 70 nM of recombinant nucleosomes or naked dsDNA. Nucleosome was 
reconstituted by the salt gradient dialysis method using recombinant histone octamer and 
201 bp 601 DNA fragment46. The reactions were initiated by the addition of nucleosome or 
DNA substrate and incubated at 37 °C for 40 min. The reaction was quenched by the addition 
of EDTA to a final concentration of 100 mM. Aliquots (2.5 μL) were removed and spotted on 
PEI-cellulose thin-layer chromatography plates and developed in 1M formic acid and 0.5M 
LiCl. ATP hydrolysis was quantified using a Phosphorimager with Image Quant Software. For 
the mixing experiment, all reaction components except for CHD3 protein were incubated 
for 10 min at 37 °C, and the CHD3 protein mixture was added last to start the reaction. This 
experiment was performed 3 times per condition (N = 3) for all conditions, except for the 
conditions “no CHD3”, “WT 12.5 nM” and “WT 25 nM” (N = 2).
For the quantification analysis, we performed 3 individual experiments for each of the 
two biological replicates (total N = 6), except for the p.Trp1158Arg mutant (one biological 
replicate, total N = 3). An unpaired t-test was used to determine whether the activity of the 
mutant proteins differed significantly from wild-type protein activity.
Restriction enzyme accessibility assay 
Remodeling activities were measured with a restriction enzyme accessibility assay as 
previously described27. 12.5 nM nucleosomes (347 bp) were incubated with the indicated 
amounts of CHD3 proteins at 37 °C for 60 min in the remodeling buffer (20mM Tris–HCl pH 
7.5, 1mM DTT, 1mM MgCl2, 1mM ATP, 0.1 mg/ml BSA, and 5 U HhaI). The reactions were 
stopped by adding 2 μL of proteinase K buffer containing 6.7 mg/ml proteinase K, 167mM 
EDTA, and 1.7% SDS. After incubation at 50 °C for 10 min, the DNAs were analyzed by 6% 
native polyacrylamide gel electrophoresis. The separated DNA fragments were visualized 
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with UV light on the ChemiDox XRS system (BIO-RAD). The band intensities were quantified 
by ImageJ.
Cloning constructs for immunofluorescence 
Wild-type CHD3 (NM_001005273.2) was amplified by PCR and cloned into pCR2.1-TOPO 
(Invitrogen) as described47. CHD3 mutation constructs were generated using the QuikChange 
II Site-Directed Mutagenesis Kit (Agilent), primer sequences are provided in Fig. S1. CHD3 
cDNAs were subcloned using BamHI/ NheI restriction sites into a modified pmCherry-C1 
vector (Clontech). All constructs were verified by Sanger sequencing.
Immunofluorescence 
HEK293 cells were obtained from ECACC (Catalogue number 85120602) and grown in 
Dulbecco’s modified Eagle’s medium (Invitrogen), supplemented with 10% fetal bovine serum 
(Invitrogen). Transfection was performed using GeneJuice (Merck-Millipore). The cells were 
seeded onto coverslips coated with poly-L-lysine (Sigma). At 36 h post-transfection, cells 
were fixed using 4% paraformaldehyde solution (Electron Microscopy Sciences) for 10 min 
at room temperature. The mCherry fusion proteins were visualized by direct fluorescence, 
nuclei were visualized with Hoechst 33342 (Invitrogen). Fluorescence images were obtained 
using an Axiovert A-1 fluorescent microscope with ZEN Image Software (Zeiss).
Three‑dimensional modeling 
As no experimentally solved 3D-structure of CHD3 exists, we performed homology modeling 
using the modeling option with standard parameters in the YASARA48 & WHAT IF49 twinset. 
Several models of the ATPase/helicase domain were created. The best scoring model was 
based on template PDB-file 5JXR (sequence identity 41% over the aligned residues). We also 
studied the model based on PDB-file 3MWY (sequence identity 45%), which shows a more 
open conformation and contains an ATP substitute. These two models provided information 
about the relative position of the mutated residues in the different conformation of the 
protein complex.
Clustering analysis of missense mutations 
The locations of observed de novo missense mutations were permutated 1,000,000 times 
over the cDNA of the CHD3 gene (RefSeq transcript: NM_001005273.2). The distances 
between missense mutations were adjusted to take into account the total size of the 
coding region of CHD3 (6003 bp). Then, the geometric mean (the nth root of the product 
of n of all distances separating the mutations) was calculated, giving an index of clustering, 
as previously described30. To circumvent a mean distance of 0 as the result of recurrent 
mutations, pseudocount (adding 1 to all distances and 1 to the gene size) was used. To avoid 
artificial deflation of the clustering P-value, only one of the recurrent mutations present in 
the sibling-pair (individuals 7 and 8) and twin-pair (individuals 20 and 21) were included for 
the analysis.
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Figure S1: Conservation of mutated amino acids and clustering around conserved SNF2-motifs
Alignment of amino acids 724-1243 of the CHD3 protein with the Swiss-Prot sequences of human CHD4 (Q14839), 
CHD3 in drosophila melanogaster (O16102), CHD3 in C. Elegans (Q22516) and SNF2 in yeast (P22082). Missense 
mutations (affected amino acid residues) in our CHD3 cohort are shown in red, while published mutations in CHD4 
are shown in orange1,2. The majority of missense mutations affect highly conserved amino acid residues. The 
missense mutations clearly cluster in or around the known conserved SNF2 motifs (motif I, Ia, II, III, IV, V and VI; 
in figure depicted by boxes with the respective motif number) of the helicase domain. One missense mutation in 
CHD3 (p.W1158R) affects the same residue as a previously published mutation in CHD4: p.W1148L1.
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Figure S2: RNA analysis of the c.5802_5803insGAAC mutation (p.(Phe1935Glufs*108))
To study the effects of the frameshift mutation in the penultimate exon of the CHD3 gene [c.5802_5803insGAAC 
(p.(Phe1935Glufs*108))] in mRNA from individual 35, lymphoblastoid cell lines were generated from peripheral 
blood cells by Epstein-Barr virus transformation following standard procedures. To check for the occurrence of 
nonsense mediated decay, mRNA was isolated from cells that were cultured in the presence (a) and absence (b) of 
cyclohexamide. A negative control was also included (c). CHD3 mRNA was analyzed by the synthesis of cDNA and 
Sanger sequencing according to standard protocols. Sanger analysis shows no difference between the RNA analysis 
from untreated cells and the cells that were treated with cyclohexamide. These data indicate that the alternative 
transcript that is a result of the frameshift mutation is not degraded by nonsense mediated decay. In conclusion, 
in this individual (individual 35) two transcripts are present: the wild-type transcript and the transcript with the 
frameshift, that leads to a stop codon after 108 amino acids.
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Figure S3: localization of wildtype and mutant CHD3
Fluorescence microscopy images of HEK293 cells transfected with wild-type and synthetic CHD3 variants fused 
to mCherry (shown in red). Nuclei were stained with Hoechst 33342 (blue). The localization of CHD3 is nuclear in 
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Figure S4: Purification of wild-type and mutant CHD3
Purified wild-type CHD3 and mutant CHD3. 500 ng of the purified proteins were analyzed by SDS-PAGE and stained 
with Coomassie Brilliant Blue. Proteins were confirmed by mass spectrometry by the NIEHS Mass Spectrometry 
Research and Support Group.
a) Lane 1: protein marker; lane 2: wild-type FLAG-CHD3 (~230 kDa); lane 3: p.Leu915Phe; lane 4: p.Arg1121Pro;  
 lane 5: p.Asn1159Lys; lane 6: p.Arg1172Gln; and lane 7: p.Arg1187Pro.







Figure S5: ATPase activity in the absence of DNA substrate
ATPase activities were measured in the absence of DNA substrates. Released phosphate was separated from 
unhydrolyzed ATP by thin layer chromatography, and detected by exposure to a phosphorimager. The experimental 
values (percentage hydrolyzed ATP) for the different mutant conditions were normalized to values for the wild-
type condition within the experiment, to derive a normalized ATPase activity. Wild-type data points depicted are 
representative, for individual wild-type replicate values for all experiments please see Supplementary Data 2. All 
other raw values for these experiments can also be found in Supplementary Data 2. Three independent experiments 
from two individual purifications (Wild-type, p.Leu915Phe, p.Arg1121Pro, p.Asn1159Lys, p.Arg1172Gln, and 
p.Arg1187Pro) (N=6) or one purification (p.Trp1158Arg) (N=3) were performed. The experimental data are 
presented as means +/- standard deviation, individual data points are shown as red triangles.
Figure S6: Assay with mixing of wildtype and mutant CHD3
Thin layer chromatography was used to detect nucleosome-dependent ATPase activity. Equimolar concentrations 
of wild-type (12.5 nM) and mutant protein (12.5 nM) were incubated with nucleosome for 40 minutes. Error 
bars indicate standard deviations, individual data points are shown as red triangles (N=3 for mixed WT/mutant 
conditions, N=2 for other conditions). Raw values for these experiments can be found in Supplementary Data 2.
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Table S1: Primer sequences
Primers used for cloning of FLAG-CHD3 expression constructs
Fw (5’ to 3’) Rv (5’ to 3’)
gaaaacctgtattttcagggcaaggcggcagacactgtgatcc gggtccctgaaagaggacttcaaggtcgtctatacagatcacctcccc
Primers used to create CHD3 mutant constructs for ATPase and remodeling assays







Primers used to create CHD3 mutant constructs for immunofluorescence







Supplementary Data 1 and 2 are available online via doi:10.1038/s41467-018-06014-6
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Supplementary Note 1: Three-dimensional modeling and mutation analysis 
for de novo CHD3 mutations
Methods





































Mutation numbering corresponds with transcript variant 1, NM_001005273.
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As no experimentally solved 3D-structure of CHD3 exists, we performed homology modeling 
using the modeling option with standard parameters in the YASARA3 & WHAT IF4 twinset. 
Several models of the ATPase/helicase domain were created. The best scoring model was 
based on template PDB-file 5JXR (M. thermophilia MtISWI, sequence identity 41% over 
the aligned residues), which shows a closed conformation of the ATPase/helicase domain. 
We also studied the model based on PDB-file 3MWY (yeast Chd1, sequence identity 45%) 
which shows a more open conformation but contains an ATP substitute. Both templates 
represent an auto-inhibited form, however, it is impossible to say which of these models 
best represents the real biological form of CHD3, since movement of the domains is probably 
important for correct functioning of the protein. Therefore, both models were studied.
Results
Introduction of models and mutations
The complete CHD3 protein (2000 amino acids in isoform 1) is even bigger than the modeled 
domains shown here. Model 1 (closed conformation, based on 5JXR) contains residues 500-
1290, while model 2 (open conformation, based on 3MWY) contains residues 445-1413.
Figure SN1: Overview of the two CHD3- models used in this study. Model 1 on the left represents the opened 
conformation with ATP (orange) bound. The model on the right (model 2) represents a more closed conformation, 
in which the two ATP-domains are interacting.
Domains indicated are: chromo domain 1 (494-595; magenta), chromo domain 2 (631-673; red), helicase ATP 
binding domain (yellow), helicase C-terminal domain (green), ATP binding residues (761-768; cyan). Grey residues 
do not belong to an indicated domain.
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Figure SN2: shows the position of all missense mutations studied here in both conformations. The positions of the 
mutated residues are indicated in red, the sidechains of these residues are shown as red balls. The ATP molecule 
is shown in yellow.
Figure SN1 shows that the position of the domains relative to each other can possibly 
change depending on removal of inhibition and complex formation (with ATP, but probably 
also with other molecules, co-factors and DNA). In the open conformation, a wide gap exists 
between the Helicase ATP-binding domain (yellow) and Helicase C-terminal domain (green), 
while in the closed conformation no gap is seen. The existence of at least two different 
conformations indicates that it is necessary to study the effects of the mutations in these 
two different models.
It is unclear what triggers the conformational change. The authors of the original articles 
that belong to the templates5,6 speculate that the Chromodomains are important for auto-
inhibition and differentiation between naked DNA and DNA with nucleosomes. If that is 
true, both models here represent an autoinhibited state. However, one of them contains 
ATP and the other one shows more interaction within the ATP binding domains.
Also, it might very well be possible that the closed conformation contains ATP while the open 
conformation does not (the opposite of what is shown here). This is one of the limitations 
of modeling; substrates present or missing in the template will also be present or missing 
in the model.
The missense mutations were mapped on the models as is shown in figure SN2.
We performed a detailed analysis of the three-dimensional modeling of the mutations. As 
the CHD3 mutations are found largely clustered in the conserved motifs characteristic of 
the SF2 superfamily of helicases/translocases, we combined the 3D modeling analysis with 
information from the literature on these conserved motifs. A summary of this analysis is 
provided below.
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Table SN1: His886Arg, Leu915Phe, Glu921Lys and Gly961Glu
Model 1 (open state, with ATP) Model 2 (closed confirmation) Conserved motifs?
His886Arg Located on interaction surface 
of Helicase ATP-binding domain. 
Might be responsible for 
correct interactions to facilitate 
ATP-binding. Mutation into an 
Arginine, which is bigger and 
positively charged, might affect 
the function of the protein 
domain.
Residue also located on surface, 
but does not interact with 
other half of Helicase domain. 
However, still in ATP-binding 
domain, and responsible for 
stabilizing interactions, which 
might be lost due to the 
mutation.
His886 is part of the 
Walker B motif in 
motif II. This motif 
coordinates the catalytic 
Mg++ involved in ATP 
hydrolysis.
Leu915Phe Leu915 residue is semiburied, 
and in close contact with His886 
and Glu921. It seems to make 
hydrophobic interactions that 
stabilize ATP-binding domain. A 
bigger residue like Phe will not 
fit and destabilizes the protein.
Leu915 is close to Glu921 and 
Gly961 (in this model His886 is a 
bit further away). Leu915 makes 
still hydrophobic interactions, 
probably important for 
interaction surface with other 
helicase domain. A Phe residue 
will not fit here without causing 
reorganisation of surrounding 
residues.
Leu915 is located in 
conserved motif III.
Glu921Lys This residue is surrounded by 
His886, Gly961 and Leu915. It 
can be found at the surface but 
makes interactions that will be 
lost when mutated into Lys with 
opposite charge.
This residue is semiburied and 
makes hydrogenbonds and 
saltbridges, thereby stabilizing 
the domain. Close to Leu915 
and His886. Mutation into Lys 
will destabilize the area since 
Lys carries an opposite charge 
and has a different shape.
Glu921 is located just 
next to motif III.
Gly961Glu This residue clusters with 
His886, Leu915 and Glu921; 
although these other three are 
closer together. Gly is small and 
flexible, and located close to 
a Proline at the end of a helix. 
Mutation into Glu will introduce 
a much bigger and less flexible 
residue, this will cause a 
structural change that might 
affect the interaction surface 
and protein function.
Gly961 is still close to Leu915. It 
is also more clearly located on 
the surface that interacts with 
the other half of the helicase 
domain. Mutation might affect 
the local structure.
Gly961 is part of conser-
ved motif IV.
Conclusion
These four residues are the only four mutated residues in the Helicase ATP-binding domain. 
In model 1 it is clearly visible that these four residues cluster together and mutation of one 
of them could affect the position of the others. Clustering is not so clear in the closed model 
(model 2), but the residues still appear in the same area. The two Helicase lobes are closer 
together in model 1, and therefore a close interaction with other mutated residues becomes 
visible as well. For example, in this model Asp1120 and Arg1121 are close to Gly961 and 
Leu915. Figure SN3 and SN4 below illustrate this clustering.
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Figure SN3: ATP bound model (model 1) based on 3MWY. In this model, residue H886, E921, L915 and G961 appear 
close together and might be responsible for the correct structure to bind ATP and to interact with the other half 
of the ATP binding domain (shown on the right with a subset of the other mutations shown as red balls) It seems 
possible that mutation of any of these residues would affect the correct conformation of this domain, which might 
affect ATP binding and/or correct interaction with the other half.
Figure SN4: The ATP-free model (model 2) based on 5JXR shows the position of the residues mentioned above. 
Clustering in this model seems less obvious, but the residues are still located in the same domain. In this closed 
conformation, without ATP, it becomes clear how closely the mutations located in the two different helicase lobes 
could be located to each other (see the position of the labeled D1120 and R1121, other mutations in the other 
domain are shown as red balls).
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Table SN2: Arg985Trp, Arg985Gln, Arg1187Pro and Leu1236Pro
Model 1 (open state, with ATP) Model 2 (closed confirmation) Conserved motifs?
Arg985Trp / 
Arg985Gln
Arg985 is located on the surface 
of the Helicase C-terminal 
domain. It is not closely located 
to the ATP-binding or interaction 
surface. It makes a saltbridge 
and could be responsible for 
overall stability of this part of 
the protein. It clusters with 
Arg1187. Mutation of Arg 
into Trp might cause folding 
problems. Mutation into Glu 
would be easier, but stabilizing 
saltbridges would still be lost.
In this model the last C-terminal 
tail has a completely different 
conformation, which might be 
caused by the crystallization 
process. Originally, this model is 
a dimer with the last C-terminal 
tail swapped, and as a result 
Leu1236 is not close to Arg985 
and Arg1187. Also, this model 
does not contain the C-terminal 
bridge (see Leu1326Pro), and 
Arg only seems to add some 
stable interactions to the area, 
contributing to general stable 
protein folding. Mutation into 
either Gln or Trp will affect this 
folding.
This mutation is located 
outside the canonical 
helicase motifs.
Arg1187Pro This residue clusters with 
Arg985 on the surface of the 
protein’s C-terminal helicase 
domain. It might mediate 
interaction with a regulatory 
unit. The residue makes a 
saltbridge, which will be 
lost due to the mutation. 
Mutation into Pro will change 
the backbone conformation. 
Regardless of interactions with 
a regulatory unit, this mutation 
will change local protein 
structure and might affect 
stability and function.
This residue clusters with 
Arg985 on the surface of the 
protein’s C-terminal helicase 
domain. Mutation into Pro 
will change the backbone 
conformation, and will change 
local protein structure and 
might affect stability and 
function.
Arg1187 is part of motif 
VI, a motif that contains 
multiple mutations, 
and contributes to ATP 
binding and hydrolysis.
Leu1236Pro In the ATP bound model, the 
residue is located closely 
to Arg985 and Arg1187 in 
a C-terminal bridge that is 
suggested to be important for 
regulation5.
Leu1236 is found in a helix that 
is used for domain swapping 
in the crystal. The biological 
function of this helix is unclear. 
However, it is known that 
any mutation into Pro will 
affect the local backbone 
structure, because Pro is the 
only amino acid that will force 
the backbone into a rigid turn. 
Regardless of the exact position 
of the residue, this mutation can 
affect the protein’s structure.
This mutation is located 





Residues Arg985, Arg1187 and maybe Leu1236 are found close together. It is unclear what 
the function of the last C-terminal tail is, although it has been suggested to have a regulatory 
effect5. In that case, interactions with the tail are important. If this is not the case, both 
mutations Arg1187Pro and Arg985Trp/Gln are expected to affect the structure and thereby 
maybe affect the function as well.
Figure SN5: Positions of residue R985, R1187 and L1236 in the ATP-bound model. The three residues appear close 
together, although L1236 is officially not part of the helicase C-terminal domain.
Figure SN6: Positions of the residues R985, R1187 and L1236 in the ATP-free model. In this model, we can see that 
the L1236 residue is located in a very different position. This is due to the different position of the last C-terminal 
tail. It is unclear whether this tail has a biologically relevant function.
CHD3 helicase domain mutations cause a neurodevelopmental syndrome
111
4
Table SN3: Asp1120His and Arg1121Pro
Model 1 (open state, with ATP) Model 2 (closed confirmation) Conserved motifs?
Asp1120His Asp1120 is part of a helix in the 
C-terminal helicase domain, 
and clusters with Arg1121. The 
residues are not especially close 
to the ATP, although Asp1120 
seems to be located on the 
possible interaction surface. 
Asp is negatively charged, which 
is needed to make correct 
interactions, mutation into His 
will affect these interactions. 
Mutation might affect 
interaction between domains 
and/or ATP binding.
In this model Asp1120 gets 
close to the other half of the 
helicase domain (Helicase ATP-
binding domain), for example 
close to mutated residue 
Gly961. Asp is negatively 
charged, which is needed to 
make correct interactions, 
mutation into His will affect 
these interactions. Mutation 
might affect interaction 
between domains and/or ATP 
binding..
Asp1120 is part of helix 
integral to conserved 
motif V. Mutations in 
Motif V in the context 
of yeast SNF2 abrogate 
ATP hydrolysis and 
remodeling activity.7,8
Arg1121Pro This residue is located in the 
same helix in the C-terminal 
helicase domain as Asp1120, 
although its sidechain points in 
a different direction. The Arg 
sidechain is positively charged 
and makes hydrogen bonds 
and saltbridges. The Arg 1121 
residue is probably not involved 
in ATP binding or interaction 
with the other domains, but the 
interactions it makes might be 
important for a stable structure. 
Mutation into Pro will surely 
affect the structure because 
interactions will be lost, and 
Pro will change the backbone 
conformation
This residue is located in the 
same helix in the C-terminal 
helicase domain as Asp1120, 
although its sidechain points in 
a different direction. The Arg 
sidechain is positively charged 
and makes hydrogen bonds 
and saltbridges. The Arg 1121 
residue is probably not involved 
in ATP binding or interaction 
with the other domains, but the 
interactions it makes might be 
important for a stable structure. 
Mutation into Pro will surely 
affect the structure because 
interactions will be lost, and 
Pro will change the backbone 
conformation.
Arg1121 is part of helix 
integral to conserved 
motif V. Mutations in 
Motif V in the context 
of yeast SNF2 abrogate 
ATP hydrolysis and 
remodeling activity.7,8
Conclusion
Asp1120 and Arg1121 are part of a helix in the C-terminal helicase domain, integral to 
conserved motif V. The mutations are expected to affect interaction between domains and/
or ATP-binding (Asp1120His), and to affect the stable structure (Arg1121Pro). Mutations in 
Motif V in the context of yeast SNF2 affect ATP hydrolysis and remodeling activity.
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Figure SN7: Positions of R1121 and D1120 in the ATP bound model (model 1). In this model, the residues are not 
located closely to the ATP, but could contribute to the interaction surface.
Figure SN8: ATP-free model (model 2), shows the positions of D1120 and R1121. In this case we can see the close 
proximity of D1120 and G961 (the red residue in the helix right below D1120).
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Table SN4: Thr1136Ile, Trp1158Arg, Asn1159Lys, His1161Arg
Model 1 (open state, with ATP) Model 2 (closed confirmation) Conserved motifs?
Thr1136Ile This residue is located in the 
core of the protein, making 
a hydrogenbond with its –
OH group and hydrophobic 
interactions with the methyl in 
its sidechain. The tight packing 
does not allow a bigger residue 
here. Also, the mutation will 
cause loss of the hydrogenbond 
and thereby destabilize the 
local structure. The surrounding 
residues seem important for 
correct shape of the interaction 
site.
This residue is located in the 
core of the protein, making 
a hydrogenbond with its –
OH group and hydrophobic 
interactions with the methyl in 
its sidechain. The tight packing 
does not allow a bigger residue 
here. Also, the mutation will 
cause loss of the hydrogenbond 
and thereby destabilize the 
local structure. The surrounding 
residues seem important for 
correct shape of the interaction 
site.
This amino acid is located 
within Motif V. Mutations 
in Motif V in the context 
of yeast SNF2 abrogate 
ATP hydrolysis and 
remodeling activity.
Trp1158Arg This residue is clearly important 
for the hydrophobic core of 
the protein. In both models 
it is (semi) buried and makes 
hydrophobic interactions. 
Mutation into anything else 
will affect the stability and the 
structure of this domain.
This residue is clearly important 
for the hydrophobic core of 
the protein. In both models 
it is (semi) buried and makes 
hydrophobic interactions. 
Mutation into anything else 
will affect the stability and the 
structure of this domain.
This Trp residue has 
recently been shown to 
be of critical importance 
in remodeling, by binding 
nucleosomal DNA in the 
minor groove. Mutation 
of this residue impacts 
remodeling, not ATP 
hydrolysis9,10.
Asn1159Lys This residue is located in the 
same helix as some of the 
following mutations (see 
below) and seems to form the 
interaction surface with ATP and 
the other domain. It makes a 
few hydrogenbonds. Mutation 
into something larger and 
positively charged might affect 
interactions.
This residue is located in the 
same helix as some of the 
following mutations(see below). 
This residue is buried and makes 
many interactions, some of 
the interactions are made with 
residues in a N-terminal helix. 
This helix might be important 
for auto-inhibition6. Mutation 
into something larger and 
positively charged might affect 
interactions with surrounding 
residues or with the inhibition 
helix.
This amino acid is 
located adjacent to the 
Trp residue at position 
1158, and might alter 
the environment of this 
critical Trp residue.
His1161Arg This residue follows a similar 
story to the mutations above. 
It is located in the same helix 
as Asn1159 and seems to 
be important for the surface 
interactions. Mutation into 
Arg will change the amino acid 
properties drastically.
This residue follows a similar 
story to the mutations above. 
It is located in the same helix 
as Asn1159 and seems to 
be important for the surface 
interactions. In this model the 
residue makes interactions with 
the putative inhibition helix. 
Mutation into Arg will change 
the amino acid properties 
drastically.
This amino acid is located 
close to the Trp residue at 
position 1158, and might 
alter the environment of 
this critical Trp residue.
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Figure SN9: Overview of the remaining mutations in the core of the protein. Most of these mutations are in the 
ATP-bound open model located on the surface which becomes buried in the closed model. T1136 is located below 
this surface, but is required for correct positioning of the other residues.
Figure SN10: Mutations T1136,W1158, N1159 and H1161. The W1158 is buried and makes many hydrophobic 
interactions. N1159 and H1161 become buried in the closed model and seem to interact with residues in a putative 
inhibition helix (green)6. Recent articles show that W1158 is of critical importance in binding nucleosomal DNA9,10.
Conclusion
Based on recent literature, it is known that the Trp residue at position 1158 is of critical 
importance in remodeling. The Trp binds nucleosomal DNA in the minor groove, and 
mutation of this residue will impact chromatin remodeling. The other two residues (1159 
and 1161) are probably altering the environment of this critical Trp residue.
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Table SN5: Arg1169Trp, His1171Arg and Arg1172Gln
Model 1 (open state, with ATP) Model 2 (closed confirmation) Conserved motifs?
Arg1169Trp This residue is buried in both 
models. The residue might be 
important for correct shaping of 
the interaction surface.
This residue is buried in both 
models. In this model the 
residue is so buried that a 
bigger Trp will never fit.
This mutation is part of 
Motif VI. Arg1169 is an 
Arginine finger that is 
thought to be critical for 
ATP binding and catalysis.
His1171Arg This residue is located close 
to Arg1172 and Arg1169, and 
also responsible for the correct 
interaction surface. Mutation of 
His to Arg introduces a bigger 
residue with positive charge. 
This will change the interaction 
surface.
In this model the residue 
becomes buried (see figure 
11). Mutation of His to Arg 
introduces a bigger residue with 
positive charge. This residue will 
not fit and damages interactions 
made by His. This mutation will 
affect protein structure and 
function.
This mutation is part of 
Motif VI, a critical motif 
for ATP binding and 
catalysis.
Arg1172Gln This mutation might have a 
similar effect as the mutations 
above. It is located on the 
possible interaction surface 
between the two halves of the 
helicase domain. Interactions of 
the Arg will be lost because Gln 
will not have the same size and 
charge.
This mutation becomes 
buried in the closed model. 
Interactions of the Arg will be 
lost because Gln will not have 
the same size and charge.
This mutation is part of 
Motif VI. Arg1172 is an 
Arginine finger that is 
thought to be critical for 
ATP binding and catalysis.
Conclusion
These three mutations are part of Motif VI, a motif that contributes Arginine fingers (Arg1169 
and Arg1172) critical for ATP binding and catalysis. Based on three-dimensional modeling, 
these three mutations are important for correct shaping of the interaction surface.
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Figure SN11: Residues R1169, H1171 and R1172 in the closed model show that these residues are buried and that 
any mutation here can damage the protein structure. See Figure 9 for the modeling of these three mutations in 
the open model (model 1).
Arg1342Gln, Arg1881Leu and Gly1109del
Arg1342Gln
This residue is unfortunately not located in the modeled domain. No information or function 
is known for this residue or this region and therefore it is difficult to predict the effect of the 
mutation. Arg and Gln are both hydrophilic, but Arg is postively charged while Gln is neutral. 
Arg is also is bigger than Gln. Depending on the interactions made by the wild-type, this 
mutation can be damaging.
Arg1881Leu
This residue is not even close to the modeled helicase domains. Again, it is difficult to predict 
an effect without structural knowledge. However, the properties of Arg and Leu amino acids 
are very different. Arg is larger, positively charged and hydrophilic. Leu is smaller, neutral 
and hydrophobic. The differences in properties between these residues can strongly affect 
the protein structure.
Gly1109del
This mutation is the only deletion of 1 residue in patients known so far. It deletes a flexible 
Gly residue in a contact loop. The residue is not located on the interaction surface. Instead, 
it seems to be important for a particular loop structure that interacts with residues in helix 
611-617. Gly itself does not have a sidechain, and therefore is the most flexible residue. The 
fact that residue 1108 is also a Glyc indicates that this loop might need more flexilbiity. The 
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interaction with the 611-617 helix occurs in both models, although the helix seems much 
closer to the residue in the closed model.
The effect of this mutation is difficult to predict without knowing the exact function of the 
loop and the interacting helix. Deletion of 1 residue would result in a shorter loop, but it will 
not affect folding of the remaining protein. Interaction between the helix and the loop might 
be required for regulation, but more information is needed.
Figure SN12: Position of G1109 in the open structure with ATP. G1109 and its surrounding residues interact with 
residues 611-617 in the helix (cyan). The function of this interaction is not known but will be affected by the 
mutation..
Figure SN13: Position of G1109 in the closed model. The loop that contains 1109 is still close to the helix with 
residues 611-617. However, the position of the helix (and the domain that contains this helix) has changed and as 
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WDR5 is a broadly studied, highly conserved protein involved in a wide 
array of biological functions. Among these functions, WDR5 is a part of 
several protein complexes that affect gene regulation via post-translational 
modification of histones. We collected data from ten unrelated individuals 
with six different rare de novo missense variants in WDR5; one identical 
variant was found in four individuals, and another variant in two individuals. 
All ten individuals had neurodevelopmental disorders including speech/
language delays (N=10), intellectual disability (N=8), epilepsy (N=6) and 
autism spectrum disorder (N=4). Additional phenotypic features included 
abnormal growth parameters (N=6), heart anomalies (N=2) and hearing loss 
(N=2). All six missense variants occurred in regions of the WDR5 locus that are 
known to be extremely intolerant for variation. Three-dimensional structures 
indicate that all the residues affected by these variants are located at the 
surface of one side of the WDR5 protein. It is predicted that five out of the 
six amino-acid substitutions disrupt interactions of WDR5 with RbBP5 and/or 
KMT2A/C, as part of the COMPASS family complexes. Thus, we define a new 
neurodevelopmental disorder associated with missense variants in WDR5 
and a broad range of associated features including intellectual disability, 
speech/language impairments, epilepsy and autism spectrum disorders. 
This finding highlights the important role of COMPASS family proteins in 
neurodevelopmental disorders.
Introduction
WDR5 is a small highly conserved protein that is able to interact with a large number of other 
proteins1,2. As a core constituent of many different chromatin-related protein complexes, 
it controls crucial regulatory processes during development3,4. The indispensable function 
of WDR5 is illustrated by its high evolutionary conservation. Even very basic multicellular 
organisms such as Trichoplax adhaerens have a protein with around 90% similarity to the 
334 amino acids of the human orthologue4,5. WDR5 is a member of the WD40 repeat family 
and has seven WD40 domains that each forms a propeller-like wing, resulting in a final 
barrel-shaped protein6. Using two binding sites on opposite sides of the protein, WDR5 can 
act as an adapter to link different proteins and form protein complexes. Since the protein 
is highly multifunctional and ubiquitously expressed7 (data available from https://v19.
proteinatlas.org/ENSG00000196363-WDR5), the unavailability of a well-functioning WDR5 
could potentially impact myriad downstream processes.
Most of the protein complexes that WDR5 participates in affect gene regulation via post-
translational modification of histones. The MLL/SET complexes (also known as COMPASS 
family complexes) catalyse histone 3 lysine 4 (H3K4) di- and trimethylation8,9 and the NSL 
and ATAC complexes are involved in histone acetylation10,11. WDR5 can also be part of an 
embryonic stem cell-specific NuRD complex that combines nucleosome sliding capacities 
with histone deacetylation activity12. In addition to interactions with other proteins, WDR5 
is also able to bind to >1000 different endogenous RNAs (including long non-coding RNAs), 
and binding to certain long non-coding RNAs can be crucial for WDR5 stability and function in 
cells13. A recent study linked WDR5, as part of the COMPASS complex, to a newly discovered 
genetic compensation mechanism: nonsense-induced transcriptional compensation14. 
In short, this mechanism is triggered by a truncating variant in a gene, and leads to the 
expression of related genes, thereby compensating for the effects of a deleterious variant15. 
One of the most well-studied aspects of WDR5 function is its role in embryonic stem cell 
(ESC) self-renewal and maintenance of a pluripotent state16,17. Recently, a direct interaction 
between the p53 protein and WDR5 has been uncovered, in which mouse ESC stem cell 
fate (the differentiation into neuroectoderm or mesoderm) is regulated in a p53-dependent 
manner18. Thus, WDR5 has already been implicated in multiple different molecular pathways 
and mechanisms, and this list is growing steadily.
While the biological functions of the WDR5 protein have been studied from numerous 
angles, there is still little known about the impact of rare germline variants in the gene 
that encodes it. Using data from large-scale sequencing resources, it is clear that WDR5 is 
extremely intolerant for loss-of-function variation: in both the gnomAD database19 (version 
2.1.1; containing sequencing data of 141,456 individuals) and the TOPMED database20 
(containing sequencing data of 62,784 individuals) not a single truncating variant in WDR5 is 
reported. Similarly, WDR5 is also depleted for missense variants. Therefore, the initial finding 
of a de novo missense variant (p.(Thr208Met)) in WDR5 in a child with a developmental 
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speech disorder21, prompted us to investigate the effects and possible pathogenicity of rare 
germline variants in this gene. We collected clinical information on this proband and nine 
additional individuals with rare de novo germline variants in WDR5, collated from several 
clinical exome or genome sequencing studies. We used a range of in silico tools and analyses 
of variants using three-dimensional structures in order to evaluate the likely consequences 
of the different variants found.
Methods
Study participants and consent
Individuals with WDR5 variants were identified via matchmaking using GeneMatcher22, the 
Dutch genetic diagnostic variant classification database (VKGL database)23-25, ClinVar26 and 
denovo-db27. Clinical data and details on variants were collected in a Castor EDC database28. 
Informed consent to share and publish these data was given by all individuals or their legal 
guardian. 
Next generation sequencing and in silico variant analyses 
Details on next generation sequencing methods used to identify the WDR5 variants found 
in all individuals are included in table S1. Variants were analysed using Alamut Visual 2.10. 
Conservation was studied using a Clustal29 alignment of WDR5 amino acid sequences 
extracted from Uniprot (human, mouse and C. elegans)30. To assess the likelihood of 
pathogenicity, the prediction programs SIFT31, PolyPhen-232 and CADD v1.433 were used. 
Three-dimensional (3D) protein modelling 
The effects of the identified variants on the WDR5 protein and its interaction with other 
proteins in the COMPASS family complexes were analyzed using YASARA View34 with FoldX 
v4.0 plugin35. For the WDR5 structure, PDB file 2GNQ was used. PDB files 6KIV and 6KIW36 
were used for the analysis of the core MLL1 and MLL3 complexes, respectively; the 6UH5 
file37 of the yeast COMPASS model was used for the comparison with the human MLL1 
complex. To optimize the position of amino-acid sidechains, all the PDB files that were 
used were corrected by the FoldX repair function using default settings. Different protein 
structures were aligned with SHEBA procedure38, as implemented in YASARA.
Results
Identification and clinical characterization of individuals with de novo WDR5 variants
We collected clinical and molecular data on ten unrelated individuals with a de novo 
missense variant in WDR5. Six different missense variants were reported in these ten 
individuals: p.(Ala169Pro), p.(Arg196Cys), p.(Ala201Val), p.(Thr208Met), p.(Asp213Asn) and 
p.(Lys245Arg). The p.(Thr208Met) variant was found in four unrelated individuals, and the 
p.(Arg196Cys) variant in two unrelated individuals. 
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All individuals had neurodevelopmental disorders with a spectrum of overlapping associated 
features (Figure 1 and table S1). Intellectual disability (ID) was present in eight out of ten 
individuals, with a severity ranging from moderate ID (IQ 35-50, five individuals) to mild ID 
(IQ 50-70, three individuals). Of the two remaining individuals, one individual (individual 6) 
had a borderline level of intellectual functioning (IQ 70-85) and another individual (individual 
4) had no intellectual disability. Interestingly, in all ten individuals speech delays were 
reported. Two individuals (aged 6y and 17y) were non-verbal, and three other individuals 
had a developmental language disorder diagnosis (mixed expressive/receptive language 
disorder in two individuals, and expressive language disorder in one). One of these latter 
three individuals was also reported with verbal dyspraxia. In addition, five individuals were 
reported to have nasal speech, and one individual was reported with persistent stuttering. 
All but one of the individuals with WDR5 variants had motor development delays, with the 
age of first steps ranging from 12-40 months. Hypotonia was reported in six individuals. 
Concerning the behavioural phenotype, four individuals had an autism spectrum disorder 
(ASD) diagnosis, and two individuals were diagnosed with Attention Deficit Hyperactivity 
Disorder (ADHD). 
Six out of the ten individuals were diagnosed with epilepsy, with different forms of 
presentations varying from absence seizures to refractory generalized myoclonic epilepsy. 
In four of these six individuals, the disorder was only present in childhood and medication 
could be discontinued at a later age. A brain MRI scan was performed for seven individuals, 
showing different types of abnormalities in three of these scans: mild ventricular dilatation 
with thinning of the posterior corpus callosum in individual 3, subtle grey matter heterotopias 
in individual 5, and periventricular gliosis in individual 9.
Individuals with WDR5 variants showed divergent growth parameters. One individual had 
macrocephaly (head circumference ≥+2 SD) and another had microcephaly (≤-2 SD). Two 
individuals had tall stature (≥+2 SD). A weight of +2 SD or more (for height) was seen in four 
individuals in total, including all three adult individuals in our study. One individual had a 
low weight (≤-2 SD). No clear correlation between height, weight and head circumference 
was observed (table S1), with the exception of one individual (individual 6) which showed a 
striking pattern of progressive overgrowth (height +3 SD, weight +5 SD, head circumference 
+4 SD at 25 years of age) and one individual (individual 2) with a milder generalized 
overgrowth phenotype (height +3 SD, weight +1.5 SD, head circumference +1.5 SD). 
Different abnormalities of the skeleton and limbs were present in a subset of individuals. 
Bilateral clubfeet were reported in one individual and another individual had hemihypertrophy 
of the left leg. One individual was reported with a hemivertebra of L5 and kyphosis (possibly 
secondary to the hemivertebra), and another individual had scoliosis. Two individuals 
had single palmar creases. In two individuals, heart abnormalities were reported: cardiac 
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arrhythmias and decompensated heart failure requiring surgery in one individual, and left 
ventricular non-compaction cardiomyopathy in another individual. Three individuals were 
reported with frequent infections of the ears and/or airways. One individual had strabismus, 
another individual had amblyopia and hyperopia with astigmatism.
Significant facial dysmorphisms were noted in only a subset of individuals. When comparing 
facial features of seven individuals in our cohort, overlapping facial features included a 
bulbous nasal tip, low-set, posteriorly rotated and/or dysplastic ears, ptosis and thin lip 
vermilion (Figure 2). Two individuals in our cohort, individual 4 and individual 10, had distinct 
facial features compared to the others, with severe micrognathia (requiring tracheostomy in 
one), a small mouth and prominent down-slanting palpebral fissures. These two individuals 
both had conductive hearing loss too, a feature not reported in any of the other individuals. 
Clinical features reported in individuals in our cohort are described in more detail in table S1. 
Figure 1: Clinical features reported in individuals with WDR5 variants
Graphical overview of clinical features reported in ten individuals with WDR5 missense variants. 
Growth parameters are shown as standard deviations to the mean for a certain age. All graphs include 
data for all ten individuals (N=10). ‘EEG abn.’ = EEG abnormalities.
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In silico analysis of variants
The missense variants in our cohort are all located within or flanking the fourth and the fifth 
WD40 domain of WDR5, with each WD40 domain encoding one ‘propeller’ of the three-
dimensional WDR5 structure (Figure 3A and 3B). All missense variants in our study were 
Figure 2: Facial features in individuals with six different WDR5 variants
Facial images of seven individuals with a heterozygous WDR5 variant. Several overlapping facial 
features are seen, such as a bulbous nasal tip (individual 2, 4, 9), low-set, posteriorly rotated and/or 
dysplastic ears (individual 2, 4, 7, 9), ptosis (individual 10) and thin upper lip vermilion (individual 4, 
9, 10). In addition to this, individual 4 and individual 10 have severe micrognathia, a small mouth and 
down-slanting palpebral fissures.
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absent from the gnomAD database19. We used in silico prediction programs to evaluate likely 
pathogenicity for the six different missense variants. The resulting scores are summarised in 
Table 1. All CADD scores were above 22, while SIFT and Polyphen-2 predicted three out of 
the six variants to be pathogenic: p.(Ala169Pro), p.(Arg196Cys) and p.(Thr208Met). 
Three‑dimensional structure analysis
Using three-dimensional structure analysis, we determined that the residues affected 
by all the identified missense variants cluster together on one side of the WDR5 surface, 
suggesting that these variants may disrupt specific interactions with other proteins (Figure 
3B). Different surfaces of WDR5 are known to mediate interactions with different proteins, 
thereby linking them together. In previous co-precipitation experiments with WDR5 and 
short fragments of proteins from complexes in which WDR5 is involved, two distinct 
binding sites were identified: the ‘WDR5-interacting’ (WIN) site39-41 and the ‘WDR5-binding 
motif’ (WBM) site41,42, located on opposite sides (often referred to as ‘top’ and ‘bottom’, 
respectively) of the protein. The variants found in our study are not located in the vicinity of 
these well-studied binding locations. 
However, recently published cryo-electron microscopy 3D structures of the core MLL1 and 
MLL3 complexes revealed a region located between the WIN and WBM binding sites, that 
is involved in the interaction with RbBP5 and/or histone-lysine methylase (KMT) enzymes in 
these complexes36. Five out of the six variants that we identified map within this RbBP5/KMT 
interaction region. Based on the 3D structure analysis of the MLL1 and MLL3 complexes, 
p.(Ala169Pro) and p.(Asp213Asn) are predicted to affect the WDR5 interaction with KMT 
enzymes, and p.(Ala201Val) and p.(Thr208Met) are predicted to affect the interaction 
with the RbBP5 enzymes, while p.(Arg196Cys) most likely influences the interaction with 
both enzymes (Figure 3C-F). The effects of the p.(Lys245Arg) variant cannot be predicted 
using the currently available 3D structures. A detailed description of the predicted effects 
of all variants, from the perspective of the structural modelling analyses, is provided in 
Supplementary Note 1. 
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Figure 3: Overview of variants in linear and threedimensional protein structures
a) Linear structure of WDR5 protein (334 amino acids) with the seven different WD40-domains and 
all identified missense variants shown; in total six different missense variants were found in ten 
individuals, as one variant (p.(Thr208Met)) was found in four unrelated individuals and another 
variant (p.(Arg196Cys)) was found in two unrelated individuals.
b) Three-dimensional visualization of WDR5 (PDB 2GNQ), locations of the amino acids involved in 
missense variants are shown with magenta balls. Colours of the different domains match with the 
colours used in panel A.
c) WDR5 (green) is shown as part of the core MLL1 complex, with RbBP5 (yellow), ASH2L (blue), 
DPY30 (purple) and KMT2A (cyan) (PDB:6KIV). The nucleosome is shown in grey. The locations of 
the amino acids affected in patients identified in this study are shown with balls (magenta). 
d) E) F) WDR5 (green, p.33-332) is shown together with RbBP5 (yellow, p.1-380) and KMT2A (cyan, 
p.3764-3969), as part of the core MLL1 complex (PDB:6KIV). The locations of the amino acids 
affected in patients identified in this study are shown with balls (magenta), from three different 















We identified rare de novo missense variants in WDR5, a gene that encodes a core 
chromatin regulator and is extremely intolerant for variation in the population. We clarify 
the molecular and phenotypic consequences of these rare variants which define a novel 
Mendelian disorder. By using the GeneMatcher database and international collaborations, 
we collected clinical data on a cohort of ten individuals with a de novo variant in WDR5. 
We studied all variants in three-dimensional conformations of WDR5 in interaction with 
COMPASS complex family subunits, and showed that the missense variants are predicted to 
affect important binding sites of WDR5. By combining data from these clinical and in silico 
approaches, we can confidently link WDR5 to a neurodevelopmental disorder with a broad 
spectrum of associated features, further confirming that proteins in the COMPASS complex 
family are important contributors to neurodevelopment.
All individuals in our cohort had a heterozygous de novo missense variant in WDR5: six 
different missense variants were found, affecting amino acids on one surface of the WDR5 
protein. The recurrence of the p.(Thr208Met) and p.(Arg196Cys) variant in four and two 
unrelated individuals, respectively, points to the presence of ‘hotspots’ for recurrent variants 
in WDR5. Three different missense variants in our cohort, p.(Ala169Pro), p.(Arg196Cys) and 
p.(Thr208Met), were found to locate at adjacent amino positions in the three-dimensional 
structure of WDR5. The fact that all identified variants are missense variants, the recurrence 
of specific variants in unrelated individuals and the spatial clustering of the variants on the 
protein surface of WDR5, all suggest that specific pathogenic mechanisms that might be at 
play are not just loss-of-function or haploinsufficiency. 
To the best of our knowledge, truncating variants (e.g. frameshift or nonsense variants) in 
WDR5 have not been identified so far: not in our cohort or any disease cohort in literature, nor 
in healthy individuals (e.g. in the gnomAD or TOPMED database). According to sequencing 
data from the gnomAD database, WDR5 is extremely intolerant for both missense and 
loss-of-function variation. The gene has a LOEUF score of 0.124, which is well within the 
first decile of most highly constrained genes against loss-of-function19. In contrast to the 
absence of truncating variants, heterozygous chromosomal microdeletions encompassing 
the whole WDR5 gene have been reported; the Decipher database lists eleven heterozygous 
deletions that include WDR543. This means that haploinsufficiency for WDR5 is compatible 
with life, but it is unclear how the loss of WDR5 contributes to specific phenotypes found in 
individuals with these deletions, as all deletions are larger than 3 Mb and encompass many 
other genes as well. 
Analysis of the missense variants in a three-dimensional structure of WDR5 in the context of 
the MLL1 or MLL3 complex, revealed that all but one were located at amino-acid positions 
that are important for binding of WDR5 with other proteins of these complexes. Interestingly, 
analysis of the intolerance landscape of the WDR5 gene in the three-dimensional structure of 
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the encoded protein shows that WDR5 is generally intolerant to missense variants, but that 
residues interacting with other proteins are most intolerant for normal variation (Figure S1). 
For five out of six missense variants, we predict that the corresponding amino-acid change 
disrupts the interaction of WDR5 with the MLL1/MLL3 complex subunits RbBP5 and with 
KMT2A/C simultaneously or separately. WDR5 is a crucial core protein within the COMPASS 
complex family; it is essential for complex assembly and activity44,45. Based on 3D analysis 
of the MLL1 and MLL3 complexes, it seems that differently composed COMPASS complexes 
make use of different interaction surfaces of WDR5. Some variants might therefore disrupt 
interactions in only one specific complex. As the core function of the WDR5 protein seems 
to be to act as an ‘adapter’ protein and form links between different molecules, disruption 
of protein-protein interactions within the complex might have important effects on complex 
activity.
However, it is important to take into account that the extensive and detailed three-dimensional 
structures that we used for these analyses are only available for the MLL1/3 complex, 
and not for all other complexes and interactions in which WDR5 is involved. Therefore, it 
remains unclear whether the predicted disruptive effects on WDR5 interactions are specific 
to those with RbBP5/KMT and MLL1/3, or whether interactions with other molecules might 
also be disturbed. For the p.(Lys245Arg) variant, we were not able to predict a possible 
pathogenic mechanism analysing available three-dimensional structures. One hypothesis 
could be that the variant affects a so far uncharacterized interaction site with RbBP5 or 
KMT2A/C, as a comparison of available three-dimensional structures between human MLL1 
and yeast COMPASS complex suggest even more extensive interaction surfaces between 
WDR5 and histone methylases (Figure S2). Another hypothesis is that the p.(Lys245Arg) 
variant affects the interaction with other molecules that are not involved in the MLL1/MLL3 
complex. Lastly, although the de novo occurrence of the p.(Lys245Arg) and the phenotypic 
similarity to the rest of the cohort suggest pathogenicity, the possibility that this is a benign 
variant without any effect on WDR5 function cannot be excluded.
The individuals in our study showed a broad range of clinical features: neurodevelopmental 
phenotypes with several additional abnormalities. All individuals had developmental delays, 
with mild or moderate intellectual disability being present in the majority. Speech and 
language problems were a prominent feature, as was epilepsy. Abnormal height, weight and 
head circumferences were frequently seen, and two individuals had a remarkable distinct 
facial phenotype with severe micrognathia, a small mouth and down-slanted palpebral 
fissures. When comparing the phenotypes corresponding to different variants in our study, 
no clear genotype-phenotype correlation was established. Even in four individuals with the 
exact same p.(Thr208Met) variant a different clinical presentation was seen: e.g. borderline 
vs. moderate intellectual disability, normal growth parameters vs. a generalized overgrowth 
phenotype, and variability in the presence of additional phenotypic features. Altogether, 
WDR5-associated disorder can be characterized as a neurodevelopmental disorder with 
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variable expressivity of associated features. This is in line with other disorders caused by 
variants in genes encoding COMPASS complex family subunits, such as Kabuki syndrome 
(caused by variants in KMT2D or KDM6A)46, Kleefstra syndrome type 2 (caused by variants 
in KMT2C)47 and the neurodevelopmental disorder associated with SETD1A loss-of-function 
variants48-50. In all these COMPASS complex-associated disorders a variable spectrum of 
associated features can be present in varying degrees of severity, including intellectual 
disability, speech and language delays, autism spectrum disorders, epilepsy and abnormal 
growth parameters46-50. 
This study represents the first characterization of a Mendelian disorder associated with 
germline variants in WDR5, and was initiated after the report of a de novo WDR5 variant in a 
child with a speech disorder21. It is worth mentioning that one additional de novo variant in 
WDR5 is reported in the literature: a p.(Lys7Gln) variant, found in a child with a conotruncal 
heart defect with a right aortic arch51. This missense variant is located in the N-terminal tail of 
WDR5, an intrinsically disordered region of the protein (not available for three-dimensional 
protein structure analysis), which is not involved in the beta-propeller structure of WDR5, 
and has been shown to be dispensable for COMPASS complex assembly52. A study in Xenopus 
tropicalis shows that this p.(Lys7Gln) variant might interfere with the ability of WDR5 to 
localize to the bases of left-right organizer cilia, independent from the H3K4-methylation-
related functions of WDR553. As p.(Lys7Gln) is located in a different region of the WDR5 
protein compared to the variants found in our study, and since complete phenotypic details 
are not available for this individual, it is currently unclear whether this reported individual 
has the WDR5-associated neurodevelopmental disorder presented in this study, or whether 
this specific variant gives rise to a different disorder with different pathogenic mechanisms.
All in all, with this study WDR5 can be added to the list of genes robustly associated with 
autosomal dominant neurodevelopmental disorders. All variants found so far are missense 
variants, and although they are not always predicted to be pathogenic by the commonly 
used prediction programs, our three-dimensional protein structure analysis showed that it is 
very likely that five out of the six found missense variants disturb important protein-protein 
interactions. Future studies are needed to confirm that these in silico observations in 3D 
structures indeed affect protein-protein interactions between WDR5 and RbBP5 and KMT 
enzymes, and what the downstream consequences are on H3K4 methyltransferase activity. 
But taken together, with our study we implicate WDR5 variants in an autosomal dominant 
disorder associated with intellectual disability, speech and language delays, epilepsy and 
autism spectrum disorder, thereby highlighting the role of COMPASS complex family protein 
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Figure S1: MetaDome intolerance visualization of WDR5
WDR5 is coloured in line with the MetaDome tolerance scale shown. RbBP5 is shown in yellow and 
KMT2A in cyan (PDB:6KIV). As can be seen in this figure, WDR5 is generally intolerant to missense 




Figure S2: Comparison of the core human MLL1 with the yeast COMPASS complexes
The alignment of human WDR5 in complex with RbBP5 and KMT2A/MLL1 from the core MLL1 complex 
(PDB:6KIV) with homologues of the yeast COMPASS complex (PDB:6UH5) is shown: WDR5 (green, 
p.33-332) with its homologue Swd3 (grey, p.16-326); RbBP5 (yellow, p.1-380) with its homologue 
Swd1 (light blue, p.1-435); KMT2A/MLL1 (cyan, p.3764-3969) with yeast homologue Set1c (dark blue, 
p.819-999). Additionally, yeast Spp1 (purple) is shown. The Spp1 homologue is not present in human 
COMPASS family complexes. The locations of the amino acids that are affect in patients identified in 
this study are shown with balls (magenta). Three different angles are shown: WDR5 faced from the 
WIN site (A), from the WBM site (B), and from the side between WIN and WBM (C).
The human core COMPASS/COMPASS family complexes (eg., MLL1) are highly conserved and have a 
structure similar to the yeast COMPASS complex. Because the yeast COMPASS complex proteins in the 
3D model are more complete, substantially more extensive interaction of the RbBP5 and KMT2A/MLL1 
homologues with WDR5 homologues can be observed (red arrows). Additionally, another interaction 
site of the WDR5 homologue is observed with a Spp1 protein
These 3D modelling data, in addition to the high conservation level and low tolerance to the missense 
and LoF variants in the general population, suggest that also human WDR5 may have significantly more 
extensive interaction surfaces within COMPASS family complexes and other chromatin-remodelling 
complexes.





Wild type residue role Effect of the residue substitution
Ala169 is located in a turn from the third to fourth 
WDR5 beta-propeller. Despite the fact that the Ala169 
is located in close proximity to the KMT2A/MLL1, and 
KMT2C/MLL3 interaction sites, it does not directly 
interact with the KMT enzymes.
Change from the alanine to a larger proline at this 
position is predicted to result in a local backbone 
change, because of the rigid sidechain of the proline. 
This change is predicted to disturb the flexibility 
and local structure of WDR5, which will disrupt the 
binding to the KMT enzymes.
Figure S1: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow), are shown from 
the core MLL1 complex (PDB:6KIV). The mutated aminoacid and nearby aminoacids are shown with 
sticks. The wild type alanine at the position p.169 is colored in magenta and the mutated proline in 
purple.
Supplementary Note 1: Detailed description and visualization of the 




Wild type residue role Effect of the residue substitution
Arg196 is located on the WDR5 lateral surface for 
interaction with RbBP5 and KMT2A enzymes. Arg196 
interacts with Asn3779 in the KMT2A protein and 
Phe332 in the C-term tail of RbBBP5 but has no visible 
interactions with the KMT2C protein.
Cysteine is a much smaller residue and does not 
have a charge. Therefore, a change from the arginine 
to cysteine at this position would result in a loss of 
the hydrogen-bond with Asn3779 in KMT2A, as well 
resulting in an empty pocket between the WDR5, 
KMT2A and RbBBP5 interaction surfaces, which would 
lead to a loss of packing interactions and disruption of 
the interactions between the proteins.
Figure S2: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow), are shown from 
the core MLL1 complex (PDB:6KIV). The mutated aminoacid and nearby aminoacids are shown with 
sticks. The wild type arginine at the position p.196 is colored in magenta and the mutated cysteine in 
purple.





Wild type residue role Effect of the residue substitution
Ala201 is located on the WBM surface of WDR5 and 
interacts with RbBP5. It is located in clear proximity to 
Arg56 and Leu54 in the RbBP5 protein. 
Despite the fact that valine is also small and 
non-polar, it has a bigger sidechain than alanine. 
Therefore, change to a valine at this position could 
affect the interaction with RbBP5 because of the 
change of the interaction surface.
Figure S3: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow), are shown from 
the core MLL1 complex (PDB:6KIV). The mutated aminoacid and nearby aminoacids are shown with 






Wild type residue role Effect of the residue substitution
Thr208 in WDR5 interacts with several RbBP5 C-term 
tail amino acids (Ala331, Pro334). Additionally, it 
makes a hydrogen-bond with a backbone of Ala331 
in RbBBP5. 
Methionine has a substantially bigger size than 
threonine and is not able to form the hydrogen-
bond with RbBP5 Ala331. Therefore, a change to 
methionine at this position is expected to disrupt the 
WDR5 interaction interface with RbBP5.
Figure S4: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow), are shown from the 
core MLL1 complex (PDB:6KIV). The mutated aminoacid and nearby aminoacids are shown with sticks. 
The wild type threonine at the position p.208 is colored in magenta and the mutated methionine in 
purple.





Wild type residue role Effect of the residue substitution
Asp213 is located in a WDR5 hydrophylic loop, which 
is involved in the interaction with the KMT enzymes. 
Although located distantly, it may interact with a 
positively charged KMT2A Lys3878, because the lysine 
has a highly flexible sidechain.
Additionally, Asp213 forms a hydrogen-bond with 
Asn235 in WDR5. 
Change to the aspartate would result in a similar 
amino acid with similar size, although the negative 
charge of the aspartic acid would be lost. The 
hydrogen bond with WDR5 Asn235 would be lost due 
to this change, which may disrupt the stability and 
position of the loop, and, therefore, affect interaction 
with the KMT enzymes. Additionally, it can lose 
interactions with positively charged KMT residues. 
However, the exact effect of the variant is unknown.
Figure S5A: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow) are shown from 
the core MLL1 and MLL3 complexes (PDB:6KIV and 6KIW, respectively). The mutated aminoacid and 
nearby aminoacids are shown with sticks. The wild type aspartic acid at the position p.213 is colored 
in magenta and the mutated aspartate in purple.
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Figure S5B: WDR5 (green) interaction with KMT2C/MLL3 (orange) and RbBP5 (yellow) are shown from 
the core MLL1 and MLL3 complexes (PDB:6KIV and 6KIW, respectively). The mutated aminoacid and 
nearby aminoacids are shown with sticks. The wild type aspartic acid at the position p.213 is colored 
in magenta and the mutated aspartate in purple.
A clustering of missense variants in WDR5 defines a new neurodevelopmental disorder
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Wild type residue role Effect of the residue substitution
Lys245 located in a position that is a significant 
distance from the site of interaction with RbBP5 and 
KMT enzymes and is not known to be involved in a 
protein interaction. 
A change from lysine to arginine at this position, 
would result in a similar amino acid by charge and 
flexibility of the side-chain with minimal effect 
on protein structure or interactions. Even though 
arginine is slightly larger, the effect of this variant is 
not clear.
p.(Lys245Arg)
Figure S6: WDR5 (green) interaction with KMT2A/MLL1 (cyan) and RbBP5 (yellow), are shown from 
the core MLL1 complex (PDB:6KIV). The mutated aminoacid and nearby aminoacids are shown with 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heterozygous variants that disturb the 
transcriptional repressor activity of 
FOXP4 cause a developmental disorder
with speech/language delays and 
multiple congenital abnormalities
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Purpose:
Heterozygous pathogenic variants in various FOXP genes cause specific 
developmental disorders. The phenotype associated with heterozygous 
variants in FOXP4 has not been previously described.
Methods:
We assembled a cohort of eight individuals with heterozygous and mostly de 
novo variants in FOXP4: seven individuals with six different missense variants 
and one individual with a frameshift variant. We collected clinical data to 
delineate the phenotypic spectrum, and used in silico analyses and functional 
cell-based assays to assess pathogenicity of the variants.
Results:
We collected clinical data for six individuals: five individuals with a missense 
variant in the forkhead box DNA-binding domain of FOXP4, and one individual 
with a truncating variant. Overlapping features included speech and language 
delays, growth abnormalities, congenital diaphragmatic hernia, cervical spine 
abnormalities, and ptosis. Luciferase assays showed loss-of-function effects 
for all these variants, and aberrant subcellular localization patterns were seen 
in a subset. The remaining two missense variants were located outside the 
functional domains of FOXP4, and showed transcriptional repressor capacities 
and localization patterns similar to the wild-type protein.
Conclusion:
Collectively, our findings show that heterozygous loss-of-function variants 
in FOXP4 are associated with an autosomal dominant neurodevelopmental 







The FOXP subgroup of transcription factors consists of four different proteins: FOXP1, 
FOXP2, FOXP3, and FOXP4, all with important regulatory functions in developmental 
processes1–3. For three of these FOXP proteins, heterozygous loss-of-function variants have 
been shown to cause Mendelian disorders, encompassing a broad spectrum of associated 
phenotypes. Variants in FOXP1 cause an intellectual disability syndrome with speech delays, 
autism spectrum disorder, dysmorphisms, and congenital abnormalities in some affected 
individuals (MIM 613670)4; variants in FOXP2 give rise to a disorder in which childhood 
apraxia of speech is a prominent feature (MIM 602081)5; while variants in FOXP3 can cause 
X-linked immunodysregulation, polyendocrinopathy, and enteropathy (MIM 304790)6.
In contrast to the other FOXP genes, FOXP4 has not yet been convincingly linked to a Mendelian 
disorder. FOXP4 is expressed in subsets of cells in a variety of tissues throughout the body, 
including in the developing brain, lungs, and gut2,7. The encoded protein has regulatory roles 
in the development and maturation of the central nervous system8,9. It is coexpressed with 
FOXP1 and/or FOXP2 in several different brain regions, such as the cortex, cerebellum, and 
striatum10, where these transcription factors may heterodimerize, to potentially coregulate 
downstream targets. The phenotype associated with heterozygous germline FOXP4 variants 
remains to be defined. A homozygous loss-of-function variant in FOXP4 was previously 
reported in a child with developmental delays, laryngeal hypoplasia, feeding difficulties, and 
a ventricular septal defect, suggesting autosomal recessive inheritance11. However, several 
different heterozygous de novo FOXP4 variants of unknown significance have been identified 
in research cohorts that included individuals with specific disorders (developmental disorders, 
congenital diaphragmatic hernia, or high myopia)12–14 and in clinical diagnostic next-generation 
sequencing laboratories, fitting a possible autosomal dominant disease model.
We aimed to study if heterozygous de novo FOXP4 variants can cause a specific human 
disorder by collecting clinical data of individuals with rare coding FOXP4 variants, 
characterizing the associated phenotype, and investigating the functional impact of variants 
using cell-based assays. A better understanding of pathogenicity of different FOXP4 variants 
and the associated disease models might directly improve clinical care by facilitating 
correct classification of variants found in diagnostic and researchbased sequencing studies 
and providing families with precise recurrent risks. In addition, research on rare FOXP4 
variants and the associated phenotypes expands our knowledge of the key roles that FOXP 
transcription factors play in human disease.




Identification and clinical characterization of individuals with FOXP4 variants 
We used GeneMatcher15 and denovo-db16 to identify individuals with de novo variants in 
the coding region of FOXP4 (including canonical splice sites) and individuals with reported 
FOXP4 variants of unknown significance in diagnostic next-generation sequencing studies. 
De-identified clinical data and variant details were collected using Castor EDC17. Additional 
single-nucleotide variants and copynumber variants considered to be possibly pathogenic 
and/ or to possibly contribute to the phenotype, are listed in Table S1. All variants in this 
paper are annotated with respect to the NM_001012426.1 transcript (FOXP4 isoform 1).
Cell culture and transfection
HEK293T/17 cells (CRL-11268, ATCC) were cultured in DMEM (Gibco) with 10% fetal bovine 
serum (Gibco) and Pen/Strep (Thermo Fisher) at 37°C with 5% CO2. GeneJuice (Merck 
Millipore) was used for transfection, following the manufacturer’s protocol.
DNA constructs and site‑directed mutagenesis
Wild-type FOXP4 (NM_138457.2; FOXP4 isoform 2) was amplified from human fetal brain 
complementary DNA (cDNA) using the primers listed in Table S2. Isoform 2 (NM138457.2; 
667 amino acids) is a slightly shorter isoform than isoform 1 (NM_001012426.1; 680 amino 
acids). For consistency, all variants in this study are annotated using isoform 1. Constructs 
carrying FOXP4 variants were generated using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent). Primer sequences used for site-directed mutagenesis are provided 
in Table S2. FOXP4 wild-type and variant cDNAs were subcloned into pYFP and pRluc vectors 
(Clontech) using BamHI and XbaI restriction sites. All constructs were verified by Sanger 
sequencing. Plasmid sequences are available upon request.
Luciferase assays
For the luciferase assays, we used a pGL4.23 firefly luciferase reporter vector (Promega), in 
which the promoter region of SRPX2 was subcloned as previously described18. HEK293T/17 
cells were transfected with this firefly reporter construct (9.45 ng), a FOXP4-YFP-expression 
construct or empty YFPexpression vector (41.36 ng), and a pGL4.74 (hRluc/TK) Renilla 
reniformis luciferase construct (0.30 ng) 24 hours after seeding in 96-well plates. At 24 
hours post-transfection, cells were lysed and luciferase activities were measured using the 
Dual-Luciferase Reporter Assay System (Promega) and an Infinite M Plex microplate reader 
(Tecan). Firefly luciferase activities (experimental condition) were normalized to Renilla 
luciferase activities (control condition).
Fluorescence imaging of subcellular localization
HEK293T/17 cells were grown on coverslips coated with poly- D-lysine (Merck Millipore) in a 
24-well plate, and transfected 24 hours after seeding, with 125 ng DNA per well. At 24 hours 
post-transfection, the cells were fixed with 4% paraformaldehyde (Electron Microscopy 
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Sciences) in PBS for 15 minutes at room temperature. Hoechst 33342 (Invitrogen) was used 
for nuclear staining, before mounting with Fluorescence Mounting Medium (Dako).
Bioluminescence resonance energy transfer assays
Bioluminescence resonance energy transfer (BRET) assays were performed as previously 
described19. HEK293T/17 cells were plated in white 96-well plates with transparent bottoms 
(Greiner) and transfected with equimolar concentrations of YFP and RLuc plasmids. A 
RLuc-NLS (nuclear localization signal) plasmid was used as a negative control. At 40 hours 
post-transfection, medium was replaced with DMEM without phenol red and 10% fetal 
bovine serum (both Invitrogen), supplemented with 60 μM EnduRen Live Cell Substrate 
(Promega) and incubated for four hours at 37°C. An Infinite F200PRO Microplate reader 
(TECAN) was used for the measurements using the Blue1 and Green1 filter. Corrected 
BRET ratios were calculated using the following formula: 
[Green1(experimental condition)/Blue1(experimental condition)] − [Green1(control condition)/Blue1(control condition)], with 





































CADD score 31 26.8 26.8 27.3 26.3 NA
De novo? + + + + + NK
Gender F M F M M M
Age (years;months) 5;11 8;3 7;10 16 5;0 1;9
Short stature (≤P3) - + * + + - +
Tall stature (≥P97) + - - - - -
Macrocephaly (≥P97) + + - + - -
Delayed motor development + + + - - +
Delayed speech development + + + + + +
Intellectual disability (mild) + - - + - NK
Hypotonia + + + - - +
Congenital diaphragmatic hernia - - - - + +
Cervical spine abnormalities - - - + + -
Ptosis - + + - - -
Strabismus - + + - + -











Individual 1 Individual 2 Individual 4
Individual 4Individual 4Individual 2
A B
C
Figure 1: Clinical features and dysmorphisms
(a) Visual overview of clinical features present in six individuals with a heterozygous FOXP4 variant, more details 
on phenotypes are provided in Table S1. + present, - not present, NA not applicable, NK not known. *Short stature 
in history, after growth hormone treatment now normal height. (b) Facial phenotype of three individuals with a 
FOXP4 variant. Recurrently reported dysmorphisms include tented and/or flared eyebrows, ptosis, small teeth, and 
gingival hyperplasia. (c) Additional abnormalities as noted by physical examination. In individual 2, asymmetric 
scapulae were reported. Individual 4 presented with a very short stature (<P1) and a short and broad neck.




For protein expression experiments, quantified microscopy data, luciferase reporter assays, 
and BRET assays, statistical analysis was done for each type of assay using one-way analysis 
of variance (ANOVA) followed by Bonferroni correction for the number of conditions tested. 
All analyses were performed with GraphPad Prism software.
Ethics statement
All experiments were performed in accordance with relevant guidelines and regulations. All 
study proceedings involving humans were in compliance with the principles set out in the 
Declaration or Helsinki. Next-generation sequencing in this study was either performed in 
a diagnostic setting (with relevant clinical quality accreditations and consent procedures) 
or in a research setting (University of Alabama at Birmingham Institutional Review Board 
[IRB-300000328] and Columbia University Irving Medical Center Institutional Review 
Board [IRB-AAAB2063]). For all individuals in this study, written consent was obtained for 
publication of the data. For the individuals of which photos are published, specific consent 
for publication of photos was obtained.
Results
Identification of FOXP4 variants
Using denovo-db16 and GeneMatcher15, we aimed to collect data on all reported de 
novo variants in the coding region of FOXP4 in research cohorts, as well as all reported 
FOXP4 variants of unknown significance in diagnostic sequencing cohorts. Eight unrelated 
individuals with heterozygous FOXP4 variants were identified, seven of whom had a de novo 
missense variant. One individual carried a truncating FOXP4 variant that was not inherited 
from the mother; the father was unavailable for testing (Fig. 1a; Table S1). Among the seven 
individuals with a de novo missense variant, six different variants were found; two unrelated 
individuals had the same variant (p.Ala514Thr). None of the variants included in our study 
were present in the gnomAD and dbSNP databases.
Phenotypes of individuals with heterozygous FOXP4 variants
We were able to collect further details on phenotypes for six of the eight individuals with 
FOXP4 variants: five individuals with a missense variant in the forkhead box DNA-binding 
domain (four different variants, one recurrent), and the individual with a heterozygous 
truncating variant (p.Gln65Serfs*20). A summary of recurrent clinical features for these 
six individuals can be found in Fig. 1a, with a more detailed overview in Table S1. For the 
two remaining individuals, both of whom had a missense variant outside the forkhead box 
domain, we were not able to collect additional information on phenotypes (all available 
data are included in Table S1).
The six individuals included in our phenotypic comparison comprised four males and two 
females, with an age range of 1 year 9 months to 16 years. Four individuals had a short 
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stature (≤P3), one of these four reached a normal height after treatment with growth 
hormone. One individual had a tall stature. Macrocephaly (head circumference ≥ P97) was 
seen in three out of six individuals. Weights were generally normal for height, although one 
individual (individual 3) had a low weight (≤P3).
Developmental delays were observed in all six individuals. While only four of six individuals 
showed delayed motor development, speech/language development was delayed in all 
of them. All six individuals had received speech therapy and two individuals had a formal 
diagnosis of expressive language disorder. Despite having shown prominent speech delays in 
infancy, for three of six individuals (aged 5–16 years) current speech is described as normal 
with full and complex sentences. Two individuals had a mild intellectual disability, three 
individuals had no intellectual disability, and for one individual this was unknown. Infant 
hypotonia was seen in four of the six individuals.
Different types of congenital abnormalities were present in different individuals. Interestingly, 
congenital diaphragmatic hernia was present in two individuals. Vertebral abnormalities 
were present in two individuals: one individual had abnormalities of the craniocervical 
junction and malformations of several arches of C1, C2, and C3 vertebrae (details in Table S1) 
and in the other individual vertebra C1 was fused to the skull. An additional individual 
had uneven scapulae, but normal spine films (Fig. 1c). Pectus excavatum was reported in 
another individual. Two individuals had ptosis (requiring surgery in one individual), and 
strabismus was reported in three individuals. Cryptorchidism was present in three of four 
males. In addition to congenital abnormalities, overlapping facial features were reported in 
several individuals, which included tented and/or flared eyebrows, small teeth, and gingival 
hyperplasia (Fig. 1b).
In silico variant analysis
We used an array of computational tools to predict the functional effects of all missense 
variants that were found, including the two missense variants for which no additional 
information on phenotypes was available. Four of the six different missense variants 
clustered in the DNA-binding forkhead box domain of the encoded FOXP4 protein, while 
the remaining two were located outside known functional domains (Fig. 2a). The cross-
species conservation of the amino acid sequences in the affected regions is shown in 
Fig. 2b. The mutated amino acid sites are invariant across all the species that we analyzed, 
with the sole exception of the Serine 273 residue, which is less conserved. For all missense 
variants, CADD, PolyPhen, and SIFT scores were derived, all of which predicted pathogenicity 
for the four forkhead box domain variants (Fig. 1a and Table S1).
As no three-dimensional protein structure is available for FOXP4, we used the SWISS-MODEL 
Homology Modeling online tool20 to create a homology model of the forkhead box domain 
structure of FOXP4 (amino acids 456–542) based on a FOXP1 template model. We then 
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visualized the threedimensional location of the four different missense variants mapping 
to this functional domain (Fig. 2c). Three of the four missense variants (p.Ala514Thr, 
p.His517Asn, p.Asn518Ser) are located in the third helix of the DNA-binding domain (the 
recognition helix), and the fourth variant (p.Tyr503Cys) maps to the hinge loop region.
FOXP4 belongs to the large family of FOX transcription factor proteins, defined by the 
presence of the distinctive highly conserved forkhead box domain. For at least 16 FOX 
proteins, missense variants in this characteristic DNA-binding domain have already been 
linked to Mendelian disorders in humans21,22. We therefore assessed whether the potentially 
pathogenic missense variants that we identified in the forkhead box domain of FOXP4 were 
comparable with the known pathogenic missense variants in these other FOX transcription 
factors (Fig. 2d). Indeed missense variants in the FOXP4 DNA-binding domain matched well 
to the known pathogenic missense variants in other FOX transcription factors (Fig. 2d).
We went on to use the MetaDome web tool23 to visualize all six different FOXP4 missense 
variants in the tolerance landscape of the gene (Fig. 2e), which shows regional tolerance 
for genetic variation based on a missense over synonymous variant count ratio using data 
from the gnomAD database24. This showed us that the four missense variants that cluster in 
the FOX domain are located in a region of high intolerance (low missense over synonymous 
variant count ratio), while the two that map elsewhere are located in more tolerant regions 
of the protein (see Table S1). It is interesting to note that the gnomAD Z-score for missense 
variants in FOXP4 as a whole is not particularly high (1.95)24, indicating that the complete 
coding region of the FOXP4 gene is not extremely intolerant for missense variation overall. 
This finding is in line with the results from the MetaDome analysis, which show that only a 
few small regions of FOXP4 show high intolerance for missense variants, including the part 
of the forkhead box domain in which our four different missense variants are located.
Effects of variants on localization and transcriptional repression activity
Functional assays in HEK293T/17 cells were performed for all the seven different FOXP4 
variants that were identified (six missense variants and one variant causing an early 
frameshift). We used overexpression constructs of FOXP4 (isoform 2) with an N-terminal YFP-
tag to assess the subcellular localization of the respective mutant FOXP4 proteins. While all 
experiments were performed with isoform 2 FOXP4 proteins (consisting of 667 amino acids), 
all variants in this study are annotated in isoform 1 for consistency of the interpretation. 
Immunoblotting indicated that the wild-type and mutant proteins were expressed at the 
expected size and at comparable levels (Fig. S1). In assessments of subcellular localization 
using fluorescence imaging, wildtype FOXP4 showed nuclear localization, as did mutant 
proteins with the two missense variants mapping outside the known functional domains 
(p.Ser273Phe and p.Ser429Phe; Fig. 3a). Three of the four different missense variants in 
the forkhead box domain led to aberrant localization of the mutant protein: p.Tyr503Cys 
and p.His517Asn showed cytoplasmic expression with aggregates, and for the p.Asn518Ser 
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variant a nuclear granular pattern was seen. Overexpression of the truncated protein yielded 
by the frameshift variant (p.Gln65Serfs*20) led to diffuse mislocalization in the cytoplasm, 
although the protein was still present in the nucleus.
We used luciferase assays to assess the capacity of FOXP4 to repress an SRPX2-derived 
promoter element. Wild-type FOXP4 showed significant repression of reporter gene 
expression compared with a control construct (Fig. 3b). The four FOXP4 proteins with 
amino acid substitutions in the forkhead box domain (p.Tyr503Cys, p.Ala514Thr, p.His517Asn, 
and p.Asn518Ser) all showed a loss of this transcriptional repressor activity, significantly 
different from wild-type FOXP4. Loss of function was also seen for the truncated FOXP4 
protein (p.Gln65Serfs*20), consistent with the lack of a DNA-binding domain. For proteins 
with the two remaining missense variants (p.Ser273Phe and p.Ser429Phe), both located 
outside known functional domains of FOXP4, repression capacities were no different 
from the wild-type protein. In summary, the localization and luciferase assays pointed to 
pathogenicity for the four missense variants in the forkhead box domain, with a loss-of-
function mechanism, in contrast to the two missense variants located elsewhere in the 
protein, which did not differ from wild-type in these experiments.
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Figure 2: In silico analyses of heterozygous FOXP4 variants 
(a) Linear representation of the FOXP4 protein (Q8IVH2–1) with the identified variants and functional domains 
annotated: FOX forkhead box domain, LZ leucine zipper, ZF zinc finger. (b) Conservation of FOXP4 across different 
species, with the amino acids affected by missense variants indicated. Species include Homo sapiens (UniProt 
sequence Q8IVH2), Pan troglodytes (A0A2J8NZN5), Mus musculus (Q9DBY0), Gallus gallus (A0A3Q2U1E5), Xenopus 
laevis (Q4VYR7), and Danio rerio (B3DJK9). Regions shown span amino acids 269–277, 425–433, and 501–525 
of FOXP4 isoform 1 (Q8IVH2). (c) Visualization of missense variants in the FOX domain in a three-dimensional 
structure. A homology model for the FOX domain of FOXP4 (amino acids 456–542) was built based on template 
structure 2kiu.1.A (FOXP1 monomer), using the SWISS-MODEL Homology Modeling online tool.20 (d) Alignment 
of missense variants in a subset of the FOX domain with pathogenic missense variants in other FOX proteins. An 
alignment was made of the Pfam Forkhead domain (PF00250) using Clustal Omega Multiple Sequence Alignment44 
of all FOX proteins with missense variants present in HGMD database 2019.3. Only missense variants labeled as 
pathogenic were included for this analysis. (e) Tolerance landscape of FOXP4 protein visualized via the MetaDome 
web server.23 A tolerance landscape is computed based on single-nucleotide variants in the gnomAD database, 
and shows per amino acid position the missense over synonymous ratio in a sliding window of 21 residues. Green 
and blue peaks represent regions tolerant to missense variation; red valleys show intolerant regions. The missense 
variants in the FOX domain are located in extremely intolerant regions of FOXP4, while the two remaining missense 
variants are located in extremely tolerant regions.
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Figure 3: Functional assays to assess pathogenicity 
(a) Direct fluorescence imaging of HEK293T/17 cells expressing YFP-FOXP4 fusion proteins (green) with the 
different FOXP4 variants found in our cohort. Nuclei are stained with Hoechst 33342. Scale bar = 10 μm. (b) Results 
of luciferase assays with FOXP4-YFP constructs and the SRPX2-reporter construct. Values are expressed relative to 
the control construct and represent the mean ± SD of four independent experiments, each performed in triplicate. 
P values were calculated using one-way analysis of variance (ANOVA) with Bonferroni correction. (c) Results of 
bioluminescence resonance energy transfer (BRET) assays to measure dimerization capacity of mutant FOXP4 
constructs (donor) with wild-type (WT) FOXP4 (acceptor). Values represent the corrected mean BRET ratio ± SD 
of three independent experiments performed in triplicate. P values were calculated using one-way ANOVA with 
Bonferroni correction.In panel A, B and C, ‘Gln65fs’ is used as a short description for the variant ‘p.Gln65Serfs*20’.
As FOXP4 is known to be able to dimerize with itself and/or other FOXP proteins, mediated by 
a conserved leucine zipper motif25, we also assessed the effects of variants on dimerization 
capacities using BRET assays. In these assays, wild-type and variant versions of FOXP4 with 
an N-terminal Renilla luciferase tag (donor) were coexpressed with wild-type FOXP4 with an 
N-terminal YFP-tag (acceptor). The corrected BRET ratios of all FOXP4 proteins with missense 
variants were no different from those of wild-type FOXP4, indicating intact dimerization 
capacities for all these proteins (Fig. 3c). The truncated version of FOXP4 showed a complete 
loss of dimerization capacity, similar to the negative rLuc-NLS control construct (Fig. 3c).




To characterize the clinical and molecular consequences of heterozygous FOXP4 variants 
identified in several nextgeneration sequencing cohorts, we collected data on individuals 
with rare and possibly pathogenic variants in this gene. We identified seven individuals 
with a de novo missense variant (six different variants, since one was found independently 
in two unrelated cases). Using luciferase assays, we showed that four of the six different 
missense variants had loss-of-function effects on transcription repressor activity of the 
encoded FOXP4 protein. Notably, these four disruptive missense variants were all located 
in the forkhead box DNAbinding domain, a key functional motif of the protein. There was 
also one individual with a frameshift variant of unknown parental origin. The transcript 
with the frameshift variant will most likely undergo nonsense-mediated decay (NMD), 
leading to FOXP4 haploinsufficiency in this individual, and our cell-based experiments 
indicate that any truncated protein resulting from NMD escape would lack repressor 
activity. Based on our findings we conclude that heterozygous FOXP4 variants can cause a 
neurodevelopmental disorder, with prominent speech/language problems, short stature, 
macrocephaly, overlapping dysmorphisms, congenital diaphragmatic hernia, and cervical 
vertebral abnormalities.
Four of the six different missense variants were clustered in the DNA-binding domain of 
the encoded protein, at positions that are highly conserved across species, and also across 
different members of the FOX transcription factor family (Fig. 2b, d). Three of these four 
missense variants (p.Ala514Thr, p.His517Asn, and p.Asn518Ser) map within the third helix 
of the DNA-binding domain (Fig. 2c), also known as the recognition helix since it mediates 
sequence specific interaction with nucleotides in the major groove of the DNA of downstream 
targets26. Many different missense variants in FOX family proteins at similar positions in 
the DNA-binding domain have already been shown to be pathogenic (Fig. 2d). Using direct 
immunofluorescence, we showed that three of the four missense variants located in the 
DNA-binding domain of FOXP4 led to an aberrant subcellular localization of the protein. 
Although the precise mechanism by which these variants affect the localization pattern is 
not known, these results match well with previous observations of aberrant localization 
patterns associated with missense variants in the FOX domain of FOXP127 and FOXP228, and 
in more distantly related forkhead genes such as FOXC129 and FOXC230. We used luciferase 
assays with an SRPX2-derived promoter sequence as a reporter to demonstrate that each 
variant yielded a loss of transcriptional repression activity for the respective FOXP4 protein. 
The fourth DNA-binding domain variant, p.Tyr503Cys, is located in the hinge loop region 
of this motif. Previous studies reported that a variant of the conserved tyrosine residue at 
the equivalent position in FOXP2 (p.Tyr540Phe in FOXP2 isoform 1; NP_055306.1) disrupted 
DNA binding, and also had effects on dimerization capability31. In our assays, the p.Tyr503Cys 
variant of FOXP4 significantly disrupted transcription factor capacities to a similar degree 
to the other DNA-binding domain variants, consistent with loss of function, but no effect 
on dimerization with FOXP4 wildtype protein was observed. All in all, the observations in 
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functional studies for the different forkhead box DNAbinding domain missense variants all 
point to a loss-offunction effect, which is in line with existing literature about other FOX-
associated disorders.
Two missense variants (p.Ser273Phe and p.Ser429Phe) did not show any difference 
compared with wild-type FOXP4 in functional assays. For these variants, the functions of 
the regions and amino acids involved is not known. The p.Ser273Phe variant was found in a 
large exome sequencing study in children with developmental disorders14 but no additional 
information on phenotype could be collected for this individual. The p.Ser429Phe variant 
was found in a small trio exome sequencing cohort, in a young child with high myopia13. 
This individual also carried a hemizygous missense variant in CACNA1F (NP_005174.2: 
p.[Arg1060Trp]), which has already been described as a pathogenic variant causing X-linked 
congenital stationary night blindness (MIM 300071), possibly explaining the phenotype in 
this individual. Taking all data into account, these two missense variants might very well 
be benign variants, although pathogenicity cannot be completely excluded based on our 
assays.
The remaining variant in our study was a frameshift variant, for which the transcript 
will most likely undergo NMD, resulting in haploinsufficiency for FOXP4. If the transcript 
with the variant would still escape NMD, a truncated and dysfunctional version of FOXP4 
would be expressed that has an aberrant subcellular localization pattern, does not show 
transcriptional repressor capacities in SRPX2-reporter luciferase assays, and is unable to 
dimerize. FOXP4 is known to be extremely intolerant of loss-of-function variation, with a 
probability of loss-of-function intolerance (pLI) score of 0.98 based on sequencing data 
from 141,456 individuals, providing independent evidence that FOXP4 haploinsufficiency is 
pathogenic24. The Decipher database contains seven microdeletions encompassing FOXP4, 
but as these are all large deletions (2.41 to 4.57 Mb in size) it is hard to draw conclusions 
about the contribution of FOXP4 haploinsufficiency to the corresponding phenotypes. But 
interestingly, in the literature one individual has been reported with developmental delays, 
laryngeal hypoplasia and a ventricular septal defect, and a homozygous truncating FOXP4 
variant: c.815del; p.(Leu272Profs*95)11. Both parents were shown to be heterozygous for 
this variant, suggesting autosomal recessive inheritance, but no further clinical details were 
reported on the parents or other family relatives. As the individual with the heterozygous 
frameshift variant in our cohort had a phenotype entirely in line with the individuals with 
the likely pathogenic forkhead box domain missense variants: a congenital diaphragmatic 
hernia, short stature, developmental delays, hypotonia, and cryptorchidism, we assume 
that the FOXP4 variant is causative. Although for our missense variants we cannot exclude a 
possible dominant-negative mechanism in addition to the loss-of-function effects, in which 
FOXP4 proteins with these variants would interfere with wild-type FOXP protein functions 
via their intact dimerization capacities, we propose that truncating variants in FOXP4 can be 
pathogenic in a heterozygous state.
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FOXP4 was first characterized by Lu et al.2 and Teufel et al.32 and shown to be expressed in a 
range of tissues, including heart, brain, lung, liver, kidney, and testis. Importantly, FOXP4 is 
not only expressed in adult tissue, but also during different stages of development of, e.g., 
the heart, lungs, gut, and skeleton, where it has been shown to play important functional 
roles2,32–35. This widespread expression pattern, in combination with the large number of 
transcriptional targets and protein–protein interactions known for FOXP transcription 
factors,10,36–38 could potentially yield a large variety of downstream consequences when FOXP4 
functions are compromised. It is thus not surprising that we found a broad range of associated 
phenotypes in individuals with likely pathogenic FOXP4 variants, including growth deficits, 
developmental delays and a spectrum of  associated congenital abnormalities. Although 
caution is warranted given the limited cohort size of our study, variants in FOXP4 seem to 
be associated with certain phenotypic features (e.g., vertebral abnormalities and congenital 
diaphragmatic hernia) that appear distinct from those observed in individuals carrying 
variants in FOXP1 or FOXP2. Congenital anomalies are not a common finding in individuals with 
pathogenic FOXP2 variants39, and in FOXP1-associated disorder different abnormalities are 
recurrently reported, such as congenital heart defects or kidney abnormalities40,41 (Table S3). 
Variants in FOXP3 are not associated with a neurodevelopmental disorder phenotype, and 
were thus not included in this phenotypic comparison. Future studies will establish how 
the distinctive FOXP expression patterns, together with differences in profiles of cofactors 
and downstream targets in the relevant tissues, contribute to the different phenotypes 
associated with haploinsufficency of each transcription factor.
Of note, in FOXP1- and FOXP2-related disorders, expressive speech problems are a 
prominent feature40, and the contributions of these regulatory factors to the development 
and function of relevant neural circuits are extensively studied10,42. A recent study linking 
FoxP1/2/4 functions to vocal learning in songbirds suggested that FOXP4 should also be 
considered as a candidate for involvement in vocal disorders43. Indeed, all individuals with 
likely pathogenic FOXP4 variants in our study had delayed speech/language development, 
with expressive problems prominently present. As FOXP1, FOXP2, and FOXP4 show 
partially overlapping coexpression in various different regions of the developing brain10, 
further research is needed to delineate if loss-offunction of FOXP4 directly impairs speech/
language development, or whether secondary disruption of FOXP1 and/or FOXP2 function 
via heterodimerization with dysfunctional FOXP4 could play a role as well.
In conclusion, through clinical characterization and functional assays, we implicate 
heterozygous FOXP4 variants in a neurodevelopmental disorder with mild developmental 
delays, most prominently in the speech/language domain. The disorder shows variable 
expressivity: a broad spectrum of associated features is present in a subset of individuals 
and includes short stature, macrocephaly, congenital diaphragmatic hernia, vertebral 
abnormalities, ptosis, and cryptorchidism. As several congenital abnormalities are 
recurrently observed in our patients with likely pathogenic variants, and developmental 
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delays can be mild, the possibility of FOXP4 involvement should not only be considered 
in individuals with neurodevelopmental disorders but also in cohorts of individuals with 
multiple congenital abnormalities, in particular, congenital diaphragmatic hernia and/or 
vertebral abnormalities.
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Table S2: Primer sequences
Primer Sequence (5’-3’)
FOXP4 cloning with BamHI restriction site (forward) aggatcctggtggaatctgcctcggagac
FOXP4 cloning with XbaI restriction site (reverse) ctctagattaggacagttcttctcccggca
Site-directed mutagenesis Y503C (forward) caccaggatgttcgcctgtttccgcagaaacactg
Site-directed mutagenesis Y503C (reverse) cagtgtttctgcggaaacaggcgaacatcctggtg
Site-directed mutagenesis N518S (forward) acgccgtgcgccacagcctcagcc
Site-directed mutagenesis N518S (reverse) ggctgaggctgtggcgcacggcgt
Site-directed mutagenesis S429F (forward) ccctggcctgggctttgcctccctg
Site-directed mutagenesis S429F (reverse) cagggaggcaaagcccaggccaggg
Site-directed mutagenesis Q65Sfs*20 (forward) gagcctgttgctgctgaagtgcagcagctc
Site-directed mutagenesis Q65Sfs*20 (reverse) gagctgctgcacttcagcagcaacaggctc
Site-directed mutagenesis S273F (forward) gtctcaccccccctcttccaccataccctgc
Site-directed mutagenesis S273F (reverse) gcagggtatggtggaagagggggggtgagac
Site-directed mutagenesis A514T (forward) gccacctggaagaacaccgtgcgccac
Site-directed mutagenesis A514T (reverse) gtggcgcacggtgttcttccaggtggc
Site-directed mutagenesis H517N (forward) gaacgccgtgcgcaacaacctcagcct
Site-directed mutagenesis H517N (reverse) aggctgaggttgttgcgcacggcgttc














Delayed motor development 















Congenital diaphragmatic hernia 



































The phenotypic features of individuals with FOXP4 variants in our study, in comparison with phenotypes reported 
in individuals with pathogenic FOXP1 or FOXP2 variants. For the analysis of common FOXP1- and FOXP2-associated 
features, the following cohort studies were used: Bekheirnia et al.20172, Le Fevre et al. 20133, Reuter et al. 20174, 
Siper et al. 20175, Sollis et al. 20166 and Sollis et al. 20177. For FOXP1 and FOXP2, a ‘+’ was scored if this feature was 
reported in two unrelated individuals in the studies mentioned. As a result, some phenotypes annotated with a ‘+’ 
are only present in a small subset of individuals with FOXP1- or FOXP2-associated disorder.
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Figure S1: Immunoblot analysis of overexpression constructs 
Western Blot of HEK293T/17 cells in which FOXP4-YFP constructs used for functional assays were overexpressed. 
UT = untransfected, WT= wild-type. Expected molecular weight of wild-type FOXP4-YFP and FOXP4-YFP with 
missense variants: ~102 kDa. Expected molecular weight of Q65Sfs*20 variant: ~38kDa. All different expressed 
YFP-fusion proteins are present at the expected molecular weights. The immunoblot was stripped and re-probed 
with beta-actin as a loading control.
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SATB2-associated syndrome (SAS) is a neurodevelopmental disorder caused 
by heterozygous pathogenic variants in the SATB2 gene, and is typically 
characterized by intellectual disability and severely impaired communication 
skills. The goal of this study was to contribute to the understanding of speech 
and language impairments in SAS, in the context of general developmental 
skills and cognitive and adaptive functioning. We performed detailed oral 
motor, speech and language profiling in combination with neuropsychological 
assessments in 23 individuals with a molecularly confirmed SAS diagnosis: 
11 primarily verbal individuals and 12 primarily nonverbal individuals, 
independent of their ages. All individuals had severe receptive language 
delays. For all verbal individuals, we were able to define underlying speech 
conditions. While childhood apraxia of speech was most prevalent, oral motor 
problems appeared frequent as well and were more present in the nonverbal 
group than in the verbal group. For seven individuals, age-appropriate 
Wechsler indices could be derived, showing that the level of intellectual 
functioning of these individuals varied from moderate-mild ID to mild ID-
borderline intellectual functioning. Assessments of adaptive functioning 
with the Vineland Screener showed relatively high scores on the domain 
‘daily functioning’ and relatively low scores on the domain ‘communication’ 
in most individuals. Altogether, this study provides a detailed delineation of 
oral motor, speech and language skills and neuropsychological functioning in 
individuals with SAS, and can provide families and caregivers with information 






The introduction of new DNA sequencing technologies (next generation sequencing) has 
rapidly improved the identification of genes of which high-penetrance disruptive variants 
can cause neurodevelopmental disorders. Amongst the most commonly affected genes in 
neurodevelopmental disorders is SATB21. The neurodevelopmental disorder associated with 
pathogenic variants in this gene is known as SATB2-associated syndrome (SAS).
SAS presents with marked craniofacial dysmorphisms, intellectual disability (ID), 
developmental delay, as well as generally restricted or absent speech and severely impaired 
communicative skills2. Patients with SAS often use communication methods other than (or 
in addition to) spoken language, such as gestures, sign language and/or augmentative and 
alternative communication (AAC) devices.  In addition to speech problems, other features 
related to oral motor skills or oral abnormalities are common, including cleft palate, teeth 
anomalies, drooling, and feeding problems2. 
SAS is caused by heterozygous disruptions of the SATB2 gene. These are mostly variants with 
a clear loss-of-function effect (frameshift and nonsense variants), but missense variants, 
variants predicted to affect splicing and copy number variants are reported as well3. The 
SATB2 protein is a transcription factor with important roles in cortical development4. 
One could hypothesize that loss-of-function of SATB2 might disproportionately affect the 
development of higher cognitive functions, such as attention, memory, and executive 
functioning. While speech problems are prominent in SAS, there is limited information 
about mechanisms underlying the oral motor, speech and language impairments observed 
in affected individuals, other than one recent study on the assessment of speech and 
language phenotypes in a SAS cohort5. That study found that individuals with SAS generally 
show prominent language impairments, childhood apraxia of speech, and various oral motor 
problems, including hypernasal resonance, pharyngeal phase dysphagia and drooling5.
The current study aimed to contribute to the understanding of speech and language 
abnormalities in SAS in the context of general developmental capacities and cognitive and 
adaptive functioning. The study design included a detailed characterization of oral motor, 
speech and language profiles combined with neuropsychological testing in 23 individuals 
with a molecularly confirmed diagnosis of SAS. 




General study design and data collection
Study design 
This study has an observational and cross-sectional study design and was approved by 
the medical research and ethics committee Arnhem-Nijmegen (CMO Arnhem-Nijmegen; 
study number NL64562.091.18). All study procedures were in line with the principles of the 
Declaration of Helsinki. Recruitment and inclusion for the study took place between April 
and November 2019. After inclusion and the informed consent procedure, individuals were 
invited for two testing visits within the Radboud University Medical Center in Nijmegen, the 
Netherlands: one visit with one of the two speech language therapists (SLTs), and one visit 
with a healthcare psychologist. During one of these two visits, a clinical geneticist in training 
collected details on medical history and growth parameters. In addition to this, parents and/
or caregivers were asked to fill in standardized questionnaires about the patient with SAS. 
Data collection finished in March 2020.
Individuals
Individuals with SAS from the Netherlands and Belgium were recruited via the Dutch SAS 
family support group or via the Clinical Genetics department where their SAS diagnosis 
was established. In order to be eligible to participate in the study, individuals had to meet 
all of the following three criteria: (1) established molecular diagnosis of SATB2-associated 
syndrome, (2) age of at least two years old at time of testing, and (3) raised in a Dutch-
speaking family with Dutch as first language. There was one exclusion criterion: Individuals 
with SAS who also had another molecular diagnosis that likely contributed to their 
developmental phenotype were excluded from participation. In total, 23 individuals were 
included for participation in the study. 
General data collection
Data on developmental and medical history were collected via medical file notes and a 
standardized medical history during one of the visits. Growth parameters were measured 
during the visit or, if this was not possible, derived from recent measurements in another 
context. All official molecular test reports with the SATB2 diagnosis were collected, and 
variant details were converted into standardized  nomenclature using hg19 as a reference 
genome, and NM_001172509.1 (SATB2 isoform 1) as the standard transcript. All data were 
de-identified and stored in a secure and study-specific Castor EDC database6.
Speech and language profiling
Communication measures
Contingent upon use of words and dominant communication mode, individuals were 
categorized as primarily nonverbal (an expressive vocabulary of no more than 10 words, 
communicating nonverbal more than verbal) or verbal (an expressive vocabulary of more 
than 10 words with speaking as the primary mode of communication).
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The Communication Function Classification System (CFCS)7 was used to rate overall 
communication abilities. The CFCS is a validated discriminative tool that allows clinicians 
and parents to categorize children’s communication skills into five mutually exclusive levels 
(CFCS I-V) of everyday communicative function with sending and receiving messages via any 
modality (e.g., spoken language, sign language, speech-generating electronic devices) with 
familiar and unfamiliar communication partners.
Utilised forms of augmentative and alternative communication (AAC) were recorded and 
categorized in (a) unaided – no-tech (gestures, manual signs, facial expressions, vocalizations, 
verbalizations, body language), (b) aided – low-/light-tech (pictures, objects, photographs, 
writing, communication boards/books), and (c) aided – high-tech (speech generating devices 
(SGD), single-message devices and recordable/digitized devices, AAC software that enables 
dynamic symbol/language representation and that is used with some form of technology 
hardware such as computer, tablet, or smartphone)8.
Language measures
Receptive vocabulary was assessed in most individuals with the Dutch version of the 
Peabody Picture Vocabulary test-III9, yielding a vocabulary quotient. The Schlichting tests 
for Language Comprehension and Language Production10,11 were used to measure receptive 
and expressive language skills. These norm-based standard scores or Q scores have a mean 
score of 100 (SD 15), with a score of 85-115 representing average range performance.
When administration of the Schlichting tests was not possible due limited language and/
or understanding, the Dutch Nonspeech Test (NNST)12 was used. This test comprises a 
receptive scale and an expressive scale. Scores on both scales were expressed in percentile 
scores, with a mean score of 50.
Subtests of the Dutch version of the Clinical Evaluation of Language Fundamentals (CELF)13 
were used instead of the Schlichting tests when individuals had a sufficient level of 
language. The subtests ‘concepts and following directions’, ‘expressive vocabulary’, ‘recalling 
sentences’, and ‘formulating sentences’ were administered.
The Q scores and percentile scores of all the language assessments were interpreted as mild 
(1-1.5 SD below mean), moderate (1.5-2 SD below mean) and severe (>2 SD below mean).
Speech measures
Where children had sufficient speech, a conversational sample was obtained. The observed 
speech symptoms provided a basis to form a clinical impression of characteristics of different 
speech disorders, including a phonological delay or disorder, childhood apraxia of speech 
(CAS), dysarthria or an articulation deficit. Speech characteristics were analysed using 
Dodd’s Model for Differential Diagnosis14 and protocols for the classification of dysarthria15.
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The intelligibility of speech was measured in primarily verbal individuals using the Dutch 
version of the Intelligibility in Context Scale (ICS)16. This seven-item questionnaire rates the 
degree to which the patient’s speech is understood by different communication partners 
(parents/life partners, immediate family, extended family, friends, acquaintances, teachers/
colleagues, strangers) on a five point scale (1=never, 2=rarely, 3=sometimes, 4=usually, 
5=always).
Feeding and oral motor evaluation
A specifically designed questionnaire for problems with swallowing related to different 
consistencies of food was used in all individuals. It also included questions regarding 
drooling and dental problems. This semi-structured questionnaire is used in earlier studies 
where it has demonstrated its usefulness and importance to differentiate dysphagia 
characteristics17,18. Problems with only chewing (refers to problems in the oral phase) and 
chewing and choking (refers to problems in the oropharyngeal phase) were scored with a 
five-point scale and recoded into two categories (-) no problems or (+) problems to a certain 
extent (2 = less than once a day, 3= once every day, 4= several times a day, 5= food is not 
offered). 
Structural or functional impairments of the oral region were assessed with the self-
composed Oral-facial Motor Assessment for Children (OMAC). This assessment tool 
examines oral motor function (e.g., face, lips, tongue, velum, jaw), oral-facial structural 
integrity (e.g., symmetry, lip seal), strength (e.g., eye closure, lip closure, tongue, jaw) and 
the saliva swallow (e.g., slurping, swallowing on demand) by observation. Problems with 
the performance or imitation of the items were scored and recoded in the category (-) no 
problems and (+) problems to a certain extent.
Neuropsychological assessment
Intellectual and cognitive functioning
For the reliable and valid assessment of intellectual functioning, three Dutch-language variants 
of the Wechsler intelligence scales were used, depending on the age of the individual. The 
Wechsler Preschool and Primary Scale of Intelligence Third Edition (WPPSI-III-NL19) was used 
for individuals aged between 2;6 and 7;11 years, the Wechsler Intelligence Scale for Children 
Fifth Edition (WISC-V-NL20) for individuals with chronological ages between 8 and 17;11 
years, and the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV-NL21) for individuals 
of 18 years and older. The WPPSI-III-NL, WISC-V-NL, and WAIS-IV-NL provide a full scale 
IQ (FSIQ, M= 100, SD=15), based on the performance on four (age group 2;6-3;11), seven 
(age group 4-7;11) and 10 subtests, respectively (WISC-V-NL age range 6-16;11, WAIS-IV-NL 
age range 16-84;11). Raw scores are converted to Wechsler standard scores (range 1-19) 
which are used to calculate IQ and index scores. In addition to Full Scale IQ, the WPPSI-III-NL 
provides a Verbal IQ (VIQ), a Performance IQ (PIQ) and a Processing Speed Quotient (PSQ; 
only for the age group 4-7;11). The WISC-V-NL provides a Verbal Comprehension Index (VCI), 
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Visual Spatial Index (VSI), and indices for Fluid Reasoning (FRI), working memory (WMI) and 
processing speed (PSI). The WAIS-IV-NL provides indices for Verbal Comprehension (VCI), 
Perceptual Reasoning (PRI), Working Memory (WMI) and Processing Speed (PSI). When 
age appropriate testing was not possible due to limited language and/or understanding, 
the WPPSI-III-NL was administered. Raw scores were converted into developmental age 
equivalents ranging from ‘below 2;7’ to ‘above 7;10’. Although test administration was 
performed according to standard procedures, slight alterations were made to compensate 
for language problems of the individuals. For instance individuals were allowed to respond 
using Dutch Sign Language and/or using AAC when verbal responses were required, and 
extra verbal cues and explanation were given to engage individuals further when non-
compliant (i.e. ‘testing of limits’). 
Adaptive functioning
Adaptive behaviour has been described as the combination of conceptual, social, and 
practical skills acquired to function adequately in daily life22. The level of adaptive 
functioning was measured using the Vineland Screener 0-6 years23, filled out by parents. 
This questionnaire is a Dutch screener version of the golden standard Vineland Adaptive 
Behavior Scales24 and consists of 72 questions, providing a total score and four domain 
scores: communication, social functioning, daily functioning, and motor skills. Raw scores 
were converted to developmental age scores (in months), reflecting the level of adaptive 
functioning23. 
Behavioural problems
The presence of behavioural problems was measured by parent-based reports, using age-
specific versions of the Achenbach System of Empirically Based Assessment25: the Dutch 
versions of the Child Behavior Checklist (CBCL/1,5-526 and CBCL/6-1827) and the proxy 
version of the Adult Behavior Checklist (ABCL/18-59)28. These parent-based questionnaires 
consist of 100, 113 and 134 items, respectively, and provide a total score for observed 
behavioural problems, scales for internalizing (i.e., anxiety, depression and withdrawal) 
and externalizing (i.e., agressive behaviour, conflict with others/social mores) problems, 
and several syndrome subscales. In this study, only the syndrome scales were included that 
were present in all three versions: somatic, anxious, withdrawn, attention and aggression 
problems. Raw scores were converted to standardized T-scores. For the the total score and 
internalizing and externalizing scales, a score of 64 and higher is considered to be in the 
clinical range (i.e. consideration of professional help is warranted), for the syndrome scale 
the cut-off for a score in the clinical range is a T score of 7026-28. 
Results
Individuals and characteristics
In total, 32 individuals were examined for eligibility to participate in the study. Nine were not 
included, because the parents/caregivers decided not to participate after being informed 
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about study details (n=6), because the child was not raised with Dutch as first language (n=2) 
or because the SATB2 disruption was part of a large microdeletion with many other genes 
possibly affecting neurodevelopment (n=1). A total of 23 individuals started participation 
in the study, all of whom completed it; 70% of these individuals were male. The age of 
individuals at inclusion varied from 2;10 years to 40 years old (median age 11;7). Growth 
parameters and other baseline characteristics are included in table 1. 
Details on the SATB2 variants in the individuals are included in Table S1. In short, the 
majority of individuals (21/23; 91%) had a heterozygous single nucleotide variant (SNV) 
affecting SATB2; two individuals (9%) had a de novo 2q33.1 microdeletion (table 1). Almost 
all variants (21/23; 91%) were confirmed to be de novo, hence not present in blood-derived 
DNA of either of the two parents of the individuals. Two individuals were siblings and carried 
the same de novo variant, suggesting germline mosaicism in one of the parents. Constitutive 
mosaicism was not detectable by Sanger sequencing of parental blood samples. In one 
individual, the SATB2 variant was found to be a mosaic variant, and present in 32 of 143 
exome sequencing reads (~22%). The age at which the molecular diagnosis of SATB2 was 
established in each individual varied between 0;5 years and 44;1 years, with a median of 
10;10 years (table 1).
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Table 1: Patient characteristics
Nonverbal (n=12) Verbal (n=11) Total (n=23)
General
Gender (% male/% female) 67%/33% 73%27% 70%/30%
Median age at inclusion in y;m (range) 11;6 (2;11-39;4) 11;7 (5;6-40;9) 11;7 (2;11-40;9)
Genetic diagnosis
- SNV (%) 92% 91% 91%
- nonsense (%) 50% 18% 35%
- frameshift (%) 25% 36% 30%
- missense (%) 8% 27% 17%
- splice (%) 8% 9% 9%
- CNV (%) 8% 9% 9%
Confirmed de novo (%) 83% 100% 91%
Mosaic variant in individual (%) 0% 9% 4%
Median age of molecular diagnosis 8;1 (0;5-44;1) 10;10 (4;0-37;7) 10;10 (0;5-44;1)
Growth parameters
Mean birth weight (SD) 3570g (446) 3485g (626) 3531g (524)
Mean height corrected for age (SD) -0.3 SD (1.5) 0.8 SD (1.3) +0.3 SD (1.4)
Mean weight corrected for age (SD) -0.3 SD (1.3) -0.5 SD (1.4) -0.4 SD (1.4)
Mean head circumference corrected for age (SD) 0.0 SD (0.7) 0.2 SD (0.8) 0.0 SD (0.8)
Neuro/development
Median age of walking in months (range) 23 (18-42) 23.5 (17-36) 23 (17-36)
Gross motor delays (%) 100% 82% 91%
Fine motor delays 100% 100% 100%
Epilepsy (confirmed) 17% 9% 13%
Other
Cleft palate (%) 50% 18% 35%
Dental problems (%) 83% 91% 87%
Vision problems (%) 50% 36% 43%
Hearing loss (%) 0% 0% 0%




A summary of results per individual is included in table 2. Verbal communication was 
primarily used by 11 individuals (47.8%), whereas 12 individuals were nonverbal (52.2%). 
As a group, individuals with primarily verbal communication and nonverbal individuals were 
comparable in terms of chronological age: median age of the verbal group was 11;7 years 
(range 5;6-40;9 years) and that of the nonverbal group was 11;6 years (range 2;11-39;4).
AAC was used by most individuals (n = 20/23; 87.0%). The most commonly used form of 
AAC was signs (n = 14/23; 60.87%). Signs were used alone or in combination with other 
forms of unaided or aided AAC, e.g., vocalizations, gestures, objects, pictures/photographs, 
communication books, AAC software, and speech generating devices.
On the CFCS, all individuals exhibited problems with reliable communication with unfamiliar 
partners (CFCS level III, IV, or V). Three individuals (13%) were rated level V (seldom effective 
sender and receiver even with familiar partners), 15 individuals (65%) level IV (sometimes 
effective sender and receiver with familiar partners), and 5 individuals (22%) level III 
(effective sender and receiver with familiar partners). In the verbal group, all individuals 
were rated with level III or IV, and in the nonverbal group all individuals had level IV or V 
(Figure 1A). 
Language
Receptive language abilities were measured in 21 individuals. Two individuals were not 
assessed because test procedures were not developmentally appropriate or individuals 
were not able to be tested. All the tested individuals showed severe receptive language 
deficits when compared to age-related peers, except for one (individual 5) with a mild 
deficit. Expressive language could be measured in nine verbal individuals. Eight of them had 
a severe expressive language deficit, and one had a moderate to severe deficit (individual 
10) when compared to age-related peers. 
Speech
All individuals, except one, showed difficulties with speech production. For the ten remaining 
verbal individuals a speech diagnosis could be established. The 12 nonverbal individuals 
did not produce enough verbal utterances to be able to differentiate between speech 
diagnoses although speech symptoms could be described. Six of these 12 individuals had no 
verbal utterances. The other six had an expressive vocabulary of less than 10 words; three 
of those individuals showed symptoms of phonological delay, and one had symptoms of 
dysarthria. In the verbal group, the most common speech diagnosis was Childhood Apraxia 
of Speech (CAS) (n=8). Two of these individuals showed symptoms of CAS only, while the 
other six showed symptoms of CAS combined with additional speech diagnoses; CAS and 
phonological delay (n=2/6), CAS and dysarthria (n=1/6), CAS and phonological delay and 
dysarthria (n=3/6). The described symptoms of CAS were: words are pronounced sound by 
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sound, fluency difficulties, problems with ‘automation’ of words, difficulties with speaking 
on demand, difficulties with maximum repetition rate or diadochokineses. Dysarthria was 
characterised by slow speech, low pitch, hypernasality, and difficulties with respiratory and 
voice coordination. One verbal individual showed symptoms of dysarthria only and another 
verbal individual showed symptoms of a phonological delay (i.e., delayed and atypical 
phonological speech-sound processes) in combination with an articulation deficit (phonetic 
distortion). A single verbal individual had no characteristics of any speech disorder. For eight 
verbal individuals the ICS questionnaire was completed. The mean intelligibility score was 
3.41 (range: 2.1 – 5). These findings indicate that the primarily verbal individuals in our 
study population are ‘sometimes’ to ‘usually’ understood. 
Feeding and oral motor evaluation
Feeding and swallowing problems were common in the total group of individuals with 
87% affected (n=20), while in the remaining three individuals no feeding problems were 
mentioned. In the nonverbal group, all individuals had feeding problems. In the verbal 
group, 80% exhibited feeding problems. For the feeding problems in the nonverbal 
group, 25% involved swallowing problems in the oral phase (e.g. chewing problems and 
overstuffing) and 75% involved the oropharyngeal phase (e.g. choking, aspiration). This is 
in contrast to the swallowing problems in the verbal group where 87.5% suffered from oral 
phase problems and only 12.5% showed oropharyngeal phase problems.
Almost half (48%, n=11) of all 23 individuals showed problems with saliva control (drooling). 
In the nonverbal group (n=12) there were more individuals suffering from drooling (67%, 
n=8) compared with the verbal group (30%, n=3). It was difficult for the individuals to collect 
saliva consciously and swallow it on request, only three individuals of the total group (all 
part of the verbal group) were able to slurp saliva and swallow it on demand.
Although data collection was not complete due to limited developmental capacities and 
cooperation of the individuals, oral motor functioning (movements of the face, lips, tongue, 
velum, jaw) was problematic for almost all individuals in the total group, except for two 
individuals in the verbal group. Oral facial structural integrity was normal in only three 
individuals in the non-verbal group, in contrast to five individuals in the verbal group. Only 
two individuals in the verbal group were able to generate strength when executing orofacial 
movements. 
Neuropsychological functioning
Observation of behaviour during testing procedures showed clear differences with regard 
to task understanding and concentration, both of which likely mediated task compliance 
that was further hampered in case of increased restlessness. We classified the results of 
formal neuropsychological testing using Wechsler scales in three groups (Figure 1B): a 
group in which age appropriate adminstration of Wechsler subtasks was possible (twelve 
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individuals), a group with results of non age appropriate administration of WPPSI-III-NL with 
individuals eight years and older (eight individuals), and a group in which no formal testing 
was possible (three individuals). 
The first group of individuals consisted of twelve individuals (52%) in which standardized 
Wechsler scores were derived. In four of these individuals, a complete profile could be 
established, with notable differences in indices. In three individuals, a single Wechsler 
Index score based on only non-verbal tasks could be calculated. Based upon the different 
indices, the level of intellectual functioning in these seven individuals could be classified as 
moderate to mild ID (n=1), mild ID (n=5) and mild ID to below average (n=1) respectively. In 
the remaining five individuals, the administered single subtasks were not sufficient to extract 
indices. Looking at the group of twelve individuals with standardized Wechsler scores, six 
individuals were classified as verbal, and six were classified as nonverbal.
In the second group, consisting of eight individuals (35%), non-age matched Wechsler 
administration of several subtasks of the WPPSI-II-NL were derived. These eight individuals 
had a chronological age of 9;3 to 40;9, and age equivalents calculated based on Wechsler 
subtask scores ranged from <2.7 years to <7.1 years. Of these eight individuals, five were 
classified as verbal and three as nonverbal (Figure 1B; Table 1).
The last group consists of three individuals (13%), who were non-eligible for testing in 
either form, due to lack of understanding and cooperation. These three individuals were all 
classified as non verbal.  
As measured by the Vineland Total score (n=19), a distinction between chronological and 
developmental age ranges was found: 35-489 months versus 12-68 months, respectively 
(Figure 1E). One individual (individual 20, 24 years old) obtained the maximum score of 
68 months on the Vineland Screener (i.e. representing a ceiling effect), resulting in scores 
which do not reflect the actual (higher) level of adaptive functioning. When excluding 
this single case, the highest adaptive functioning score is 59 months. Inspection of the 
normalized age equivalents for the total group of individuals showed distinct differences 
in the domain profile, where the level of daily functioning appeared to be relatively high 
and the level of communication skills relatively low compared to the total score (Figure 
1D). When distinguishing between verbal and nonverbal individuals, identical patterns were 
seen across subdomains (Figure 1D). The overall levels of adaptive functioning seem to be 
higher in the verbal group compared to the nonverbal group (Figure 1C).
When comparing the results of receptive language tests (converted to age equivalents) with 
the age equivalents matching the Vineland adaptive functioning total score, the results of 
these language tests seem to align with the estimated level of adaptive functioning (Figure 1F). 
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Receptive language test scores
Figure 1: Visual summary of test results 
a) Distribution of CFCS test scores in nonverbal and verbal individuals
b) Wechsler tests and subtests performed in nonverbal and verbal individuals.
c) Distribution of age equivalents of Vineland total scores in nonverbal and verbal individuals.
d) Distribution of normalized Vineland scores for each of the four Vineland domains. Individual Vineland scores 
(age equivalents) per domain were normalized by dividing each score by the total Vineland score (age 
equivalent) of the same individual: a score of 1.0 indicates that the age equivalent of the domain score is 
similar to the age equivalent of the total score of this individual.
e) Age equivalents of Vineland total scores (months) obtained in nonverbal and verbal individuals versus 
chronological age (months). 
f) Age equivalents of test scores of three different receptive language (sub)tests, compared to Vineland total 
score age equivalents. The grey triangle indicates a ceiling effect for the Vineland test score, as the maximum 
score of 68 months was obtained for this test.
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By reviewing clinical histories with parents and caregivers, sleep disturbances were mentioned 
in 13 individuals, varying from trouble falling asleep and difficulty staying asleep to increased 
mobility and/or anxiety. When asked about possible sensory processing problems, these 
were mentioned in 15 individuals (e.g. high pain threshold, easily overstimulated). Present 
challenging behaviors were mentioned for five individuals, whereas in a sixth individual 
these problems had occurred earlier. Regarding psychiatric comorbidity, in three individuals 
concentration problems were mentioned, and in four individuals autistic traits were 
mentioned, without meeting formal criteria for a classification of autism spectrum disorder. 
Based on CBCL/ABCL total (t-)scores (n=18), behavioural problems within the clinical range 
were reported in six individuals (33%) of which four are classified as non-verbal and two 
as verbal. In three individuals (16%, all non-verbal) both internalizing and externalizing 
problems were reported. In two individuals (11%, one verbal, one non-verbal) only 
externalizing problems were reported and in one individual (5%, verbal) only internalizing 
problems. Three individuals (22%, all non-verbal) scored within the clinical range for both 
attention and aggression problems, of which one (5%) scored within the clinical range on 
somatic problems, and one on withdrawn behaviour (5%). One individual (5%, non-verbal) 
scored within the clinical range for attention problems and one  (5%, verbal) for aggression 
problems.
Genotype‑phenotype comparison
In terms of genotype-phenotype relations, we looked more specifically to the different types 
of genetic variants disrupting SATB2 that were present in our cohort and the associated 
general developmental and speech-language phenotype. Fourteen individuals had a 
nonsense or frameshift variant likely causing haploinsufficiency via nonsense-mediated 
mRNA decay. Two individuals had a variant affecting a canonical splice site and predicted to 
disrupt correct splicing of the SATB2 transcript, also likely leading to SATB2 haploinsufficiency. 
We thus consider the variants in these 16 individuals to be clear loss-of-function variants. 
In addition, four individuals had a missense variant in SATB2, two individuals had a 2q33.1 
microdeletion, and one individual had a mosaic frameshift variant. 
Within the group of individuals with a missense variant (n=4), three individuals were 
classified as primarily verbal (75%) and one individual was primarily nonverbal (25%). In the 
group of individuals with a loss-of-function single nucleotide variant (n=16), six individuals 
were classified as primarily verbal (37.5%), and 10 individuals as primarily nonverbal (62.5%). 
In the group of individuals with a missense variant, the age equivalents of Vineland adaptive 
functioning total scores ranged from 36 to 59 months (median 39.5), while in the group of 




With this study we aimed to delineate oral motor, speech, language profiles in the context 
of cognitive and adaptive functioning in 23 individuals with SATB2-associated syndrome, 
a neurodevelopmental disorder generally characterized by intellectual disability and 
prominent speech and language problems. We used standardized observations and 
questionnaires and validated tests to characterize speech/language and oral motor 
functioning and neuropsychological capacities of primarily verbal (n=11, 47%) and primarily 
nonverbal (n=12, 52%) individuals with SAS. 
Regarding oral motor functioning, almost all individuals (87%) were reported to have 
feeding problems in addition to speech problems. In the nonverbal group, oropharyngeal 
problems (chewing with choking) were common (75%), and in the verbal group mainly 
oral phase problems with chewing and/or overstuffing were seen (87.5%). This finding is 
in contrast to a recently published study on speech, language and feeding phenotypes in 
SAS, which reported pharyngeal phase problems in the majority of assessed individuals 5, 
both non-verbal and verbal. About half of the children in our cohort (48%) suffer from 
drooling, a problem more present in the nonverbal group. All in all, oral motor problems 
seem to be a significant problem in the nonverbal group, suggesting that personalized 
approaches are needed to evaluate and treat oral motor and feeding difficulties. 
Using standardized language tests, expressive and receptive language deficits were found 
in all individuals that could be assessed for such abilities. Almost all had severe receptive 
language delays, but further discrimination of the individual levels was hampered by floor 
effects reached using these tests. Age equivalents of receptive language scores correspond 
to age equivalents of total Vineland scores, suggesting that the Vineland screener is a 
useful instrument to give an indication of receptive language in clinical practice, with 
further studies needed to gain insight in the underlying (shared) theoretical constructs. In 
10/11 verbal individuals, differentiation of speech symptoms led to diagnoses of speech-
related disorders. While childhood apraxia of speech was most common, other diagnoses 
included phonological delays, dysarthria, and articulation impairment. For SATB2-associated 
disorder, a previous study reported a diagnosis of childhood apraxia of speech in all 40 
individuals with enough verbal ability in their SAS cohort 5. While one might hypothesize that 
individuals with the same genetic disorder have similar speech and language phenotypes, 
the results of our detailed diagnostic speech profiling show that even with the same genetic 
syndrome, divergent speech problems may occur. Subgroups with childhood apraxia of 
speech, phonological delay, dysarthria and articulation impairment are thought to represent 
different underlying deficits 29, although such problems might sometimes co-occur. These 
underlying deficits can be described in terms of problems with phonological encoding, 
speech motor planning, speech motor programming and speech motor execution30. The 
results of the current study show the need for detailed personalized speech and language 
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assessments in each individual with SAS, since distinct speech problems will benefit from 
different approaches to intervention. 
It is currently unclear which processes underly the absence of speech as a primary mode 
of communication in the nonverbal group. Based on the results of cognitive, language and 
oral motor assessments, we would expect these individuals to be able to develop a certain 
level of speech. As a result, the absence of speech is possibly the result of neurobiological 
mechanisms involved in the speech process, or behavioural characteristics, but is not 
simply secondary to cognition, language or oral motor impairments. It is hard to generate 
hypotheses regarding the specific speech process involved, as we identified several different 
processes in the verbal group that contributed to impaired speech development. Possibly, 
the verbal versus nonverbal distinction in SAS is mainly caused by severity of impairments in 
one or more of the speech processes. It is interesting to note in this context that observation 
of individuals during assessments showed limited levels of initiation of communication, in 
addition to lower levels of frustration than would be expected based on the severely limited 
communication in most individuals.
Generally it is difficult to assess the IQ levels in individuals with ID by using conventional 
methods that are based on the normal population. Therefore we converted the Wechsler 
based test scores in corresponding developmental age equivalents, in order to derive useful 
scores for all or several indices for a subset of individuals. Nonetheless, for the vast majority 
of the cohort we were able to obtain scores on adaptive functioning. Previous studies 
using Vineland Adaptive Behaviour Scales have shown that different genetic disorders can 
give rise to distinctive profiles of adaptive functioning, which might also be partly age-
dependent 31-33. The relative weakness of communication in the adaptive functioning profile 
observed in the Vineland scores within our study is in line with the findings from direct 
speech and language assessments, as well as the literature on SAS so far (e.g.34). Variations 
in adaptive functioning domains with relatively strong daily-living skills based on Vineland 
questionnaires are commonly reported in other neurodevelopmental disorders 33,35,36. As 
already shown for other genetic syndromes, the assumption that cognitive functioning is 
strictly related to all adaptive functioning domains does also not apply to SAS 37. Classifying 
an accurate level of ID based on the required equal weighting of intellectual functioning (i.e. 
IQ) and level of adaptive functioning 38 is therefore a challenge and more in-depth analysis 
of intellectual functioning and adaptive functioning is required.
In the literature on SAS, behavioural issues have been reported in the majority of individuals, 
with different forms of challenging behaviour being present, including autistic traits, 
hyperactivity and aggression 34,39. In our study, autistic traits were mentioned by parents or 
caregivers in only four individuals (none meeting requirements for a formal ASD diagnosis), 
and two individuals (9%) received methylphenidate because of attention problems. Broader 
behavioural issues in our study cohort were evaluated using CBCL/ABCL questionnaires, and 
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we found one third of assessed individuals to have scores within the clinical range, which 
seems to be in line with the level of ID and/or verbal proficiency. Clinical range scores did 
not reflect the level of test cooperation. Growing literature on genetic syndromes from a 
multidisciplinary perspective (i.e., neuropsychology, psychiatry and clinical genetics) shows 
that particular behaviours should be interpreted in a wider context in order to understand 
if, and in what way, they should be regarded as specific to the phenotype 40,41. Research in 
KBG syndrome, for instance, showed that social difficulties reported in patients might well 
be related to (the level of) ID instead of reflecting a specific ASD trait 42. A longitudinal meta-
analysis by Chow et al. 43 shows that receptive language skills in particular have a strong 
predictive property when it comes to challenging behaviour, and that improving (receptive) 
language skills can have a mitigating effect on the development of behavioural problems. 
Although our results do not directly support this link between problems in language and 
behaviour, it is possible that the relatively low levels of frustration observed in individuals 
in our study and a related lack of initiation contribute to the severe speech phenotype. 
Findings like these warrant a broad and strong dimensional approach to clinical assessment 
using gold standard instruments and a careful consideration of contextual factors to correctly 
interpret a particular behaviour as part of the SAS phenotype profile 40,41. Research has also 
shown that it is necessary to interpret challenging behaviour in ID in relation to contextual 
variables, in order to establish an effective intervention plan 44. 
Different types of heterozygous SATB2 disruptions were found in the individuals included in 
our study. While there is some evidence that missense variants of SATB2 might be associated 
with milder phenotypes 3, functional characterization of effects of variants in this gene has 
so far been limited. It is therefore unclear whether missense variants have different effects 
from the loss-of-function that is assumed for most other variants 3,45. As SATB2 encodes a 
transcription factor that can have pleiotropic effects on multiple different pathways and 
developmental processes in the brain, it is important to realize that many different factors 
(e.g. stochastic developmental factors) might ultimately contribute to the phenotypic 
presentation, even between individuals with identical pathogenic variants. 
In addition to individuals with single nucleotide variants affecting SATB2, our cohort included 
two individuals (individual 4 and 20) in which a de novo 2q33.1 microdeletion including the 
SATB2 gene was reported. Re-evaluation of the original array-CGH report of individual 20 
however could not confirm the involvement of the SATB2 gene with certainty. We therefore 
performed a CytoScan XON array analysis, which showed that the deletion was located just 
six kilobases downstream of SATB2. Although the breakpoints of the deletion were located 
outside the coding region of SATB2, and thus a loss-of-function effect via haploinsufficiency 
is unlikely for this individual, positional effects of this deletion on SATB2 gene expression 
cannot be excluded. 
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Our study has some limitations that should be taken into account. First, due to the low 
prevalence of SATB2 variants in the population, it is not  possible to study a large cohort of 
affected individuals with the same native language in the same age range. The consequent 
differences in chronological ages in our cohort, as well as the varying levels of cognitive 
functioning, made systematic testing using comparable tests more difficult and in some 
cases impossible, leading to suboptimal data collection. It is also unclear if the chronological 
age of individuals in this study might have affected the results, as current possibilities on 
diagnostics, speech therapy and education are very different compared to the situation 
decades ago. On the other hand, while these limitations are applicable for the study data on 
a group level, they do not apply for the usability of the data on an individual level, e.g. for 
intra-individual comparisons in a longitudinal study setting.
Nonetheless, our research can serve as a base for future studies on speech, language, oral 
motor and cognitive functioning in SAS. Ideally, longitudinal studies should be executed 
in which children with a SAS diagnosis at a young age are included for early diagnostics 
on a speech, language and cognitive level, and for subsequent targeted interventions. In 
addition, for future studies we recommend the inclusion of nonverbal test batteries aimed 
at specific cognitive domains (i.e. attention, processing speed, executive functioning) as well 
as general level of intellectual functioning, combined with gold standard proxy instruments, 
to be able to better define cognitive performance in individuals with SAS of all levels. 
In summary, with this study we provide a delineation of speech, language and oral 
motor skills in indviduals with SAS, combined with emerging data on neuropsychological 
functioning. While overlapping and highly recurrent features were seen for both the speech 
and language domain and the adaptive functioning profile, there was also a high variability 
observed, mainly in severity of features. This study can provide families, speech therapists, 
psychologists and other caregivers with the necessary information to guide diagnostic and 
treatment approaches in order to obtain the best functional outcomes in individuals with 
SATB2 associated syndrome.
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The GENTOS study: Rationale and 
design of a prospective cohort study 
to investigate genetic causes of 
developmental language disorders
Lot Snijders Blok, Karen van Hulst, Leenke van Haaften, 
Tjitske Kleefstra, Simon E. Fisher, Han G. Brunner
Rationale: 
The genetic architecture underlying developmental language disorders (DLD) 
is poorly understood. It has been established that genetic factors play an 
important role in the aetiology of DLD, but we still know little about the genes 
involved, and the proportion of children with DLD that carry a monogenic 
causal variant (e.g. a rare de novo mutation). Different studies in the literature 
and observations in a clinical genetics outpatient clinic setting point to a 
model in which there is a role for de novo single nucleotide DNA variants. 
However, so far no trio-based (i.e. screening of proband and both parents) 
next-generation sequencing studies of a systematically ascertained DLD 
cohort have been performed. 
Objectives:
We determine the diagnostic yield of whole genome sequencing (WGS) in 
DLD. In addition to determining this diagnostic yield, we aim to gain insights 
into the types of variants and genetic loci that are involved. 
Study design:
The study is designed as a prospective cohort study of fifty children with 
DLD, in whom WGS will be performed in each proband and both parents. 
The study population consists of children (4-18 years) with a severe form of 
DLD (in Dutch TOS; taalontwikkelingsstoornis), and a negative family history. 
WGS data will be analysed on an individual level to identify (possible) disease-
causing variants in the probands. Data will subsequently be analysed on a 
group level, to determine the diagnostic yield and secondary parameters of 
the study. Inclusion for this study started in March 2020. 
Main study parameters and endpoints:
The primary objective of this study is to define the diagnostic yield of WGS 
in children with a severe DLD and a negative family history. In addition to 
this, we aim to identify the genes in which variants are found to (possibly) 
cause DLD, the corresponding molecular pathways, and the type of genetic 
variation involved. We also aim to identify possible patient subgroups with a 







A developmental language disorder (DLD) is a neurodevelopmental disorder that is 
characterized by unexpected problems with language production, comprehension and 
communication, despite adequate linguistic input in the absence of a clear primary cause 
like deafness or brain traumas. A DLD can have a major impact on communication skills and 
development in children, and often persists later in life1,2. The prevalence of developmental 
language disorders amongst children is not exactly known, but a study of pre-schoolers 
(around 5 years of age) in the USA identified impairments in ~7% of the sample3. Among 
children diagnosed with developmental language disorders, the severity and impact on 
daily life is extremely variable. Some children only need minor support and cope adequately 
in regular schools4. However, those with more severe forms of disorder typically require 
intensive treatment and special education, and they may experience problems with 
participation and functioning in society throughout life5. 
The terminology and criteria used to describe DLD represent an ongoing topic of debate 
in international diagnostic and research settings6. Several different names have been used 
in this field, including SLI (Specific Language Impairment), and SLCN (Speech, Language 
and Communication Needs), with results of a recent Delphi survey recommending 
adoption of the consensus English term DLD. In the Netherlands, since 2014 the label 
TOS (taalontwikkelingsstoornis) has been widely used by the various care and education 
organizations4. In this chapter, we use the English term DLD to refer to the condition that 
meets the accepted Dutch diagnostic criteria for the disorder, as defined by Gerrits & van 
Niel in 20127, and as used in the “Dutch guidelines for speech/language therapy in TOS” 
published in 20178.
Genetics of DLD
The genetic architecture underlying DLD is poorly understood, even though it is well 
established that genetic factors contribute significantly9,10.  In children with most major 
neurodevelopmental disorders (e.g. intellectual disability or autism), genetic testing has 
become an accepted part of the diagnostic procedure11. In the past years, the introduction 
of next generation DNA sequencing techniques as a genetic diagnostic tool for intellectual 
disability and autism has dramatically improved the diagnostic yield, and thus also 
increased our knowledge of the molecular pathology involved. Enhanced testing has also 
highlighted the prevalence of causative de novo mutations (i.e. absent from parents, newly 
arising in the proband) in these neurodevelopmental disorders12. The finding of a de novo 
mutation disrupting a gene is very often the start of a research project characterizing a new 
neurodevelopmental disorder, and over the last years this has led to the identification of a 
growing number of genes involved in intellectual disability and autism, with more and more 
families knowing why their child develops in a way that is different from her/his peers.
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But what about DLD? The large genetic cohort studies on intellectual disability and autism 
stand in stark contrast to the much more limited molecular genetic research so far on 
speech and language disorders, despite the fact that the latter are also prevalent and 
crucial for modern society. It has been established from familial clustering and twin studies 
that inherited factors play an important role in the aetiology of DLD13, but we still know 
little about the specific genes involved and how they go awry. So far, FOXP2 is one of the 
few well-characterized genes that have been robustly implicated in a specific speech and 
language disorder14,15. We also do not yet know what proportion of children with a DLD 
have a monogenic cause (e.g. a rare de novo mutation), and in what proportion of families 
the inheritance pattern is multifactorial instead of monogenic. A whole exome sequencing 
(WES) study in 43 unrelated probands with DLD reported rare variants in known genes 
associated with developmental disorders and in new candidate genes, but did not use a 
trio design to facilitate filtering for de novo variants16. In a whole genome sequencing (WGS) 
study of a small cohort of children with a specific speech disorder (childhood apraxia of 
speech), causative de novo mutations were found in three of the nine probands in which 
trio-sequencing was performed17, suggesting that monogenic causes are quite common for 
this severe form of speech disorder. Another exome and genome sequencing study reported 
pathogenic or likely pathogenic variants in 11 of 34 probands with childhood apraxia of 
speech18.  Another recent study using high-resolution microarrays in 58 Swedish probands 
with severe DLD shows an enrichment of rare clinically significant (and in some cases de 
novo) deletions and duplications, again supporting the involvement of monogenic causes19. 
In addition to these findings from the published literature, over the last couple of years 
several children with severe forms of DLD have been referred to the Human Genetics 
department at the Radboudumc for genetic testing. In some of these children for whom 
trio-based exome sequencing was performed in a diagnostic setting, rare de novo mutations 
were found in genes that are known to be implicated in intellectual disability and/or autism. 
These anecdotal observations point to a model in which there is a role for de novo single 
nucleotide DNA variants in the aetiology of DLD. Crucially, so far this possibility has not 
been investigated through formal trio-based next-generation sequencing of a systematically 
ascertained DLD cohort, and the relative contribution of such de novo variants remains 
unknown.
Aims and relevance of this study
The main goal of this study is to gain more knowledge on the use of diagnostic genetic 
testing by NGS in children with severe forms of DLD. It is very important to know if a child 
has an isolated DLD, or whether the difficulties are part of a more complex syndrome, in 
order to give the best support. In clinical practice, we frequently see that initially, only the 
speech/language problem gets attention, and it is realized (much) later that the problems 
are more complex. It is currently unclear in a clinical setting if and when genetic testing is 
indicated in children with DLD, and what the odds are of finding a genetic cause. Currently, 
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some children are referred to clinical genetics centers already with this indication, but many 
other children are not, and no clear policy or guidelines exist. Possible improvements include 
more knowledge on the topic, more structure and clarity in referrals, and additionally clear 
guidelines for requesting genetic diagnostic tests. A prerequisite for such policy changes lies 
with systematic research, like this GENTOS study. 
A second aim of this study is to gain insight into the type of genetic variants and genes 
involved in the pathogenesis of DLD. Many examples already exist of children with a DLD in 
whom a causative variant in the DNA is found in a gene already associated with autism or 
intellectual disability. In some cases even an identical variant is found. The degree of overlap 
between DLD and other developmental disorders on a molecular level is not yet known, 
and it is unclear if and what specific (groups of) genes are more specifically involved in 
the development of these speech/language disorders. More knowledge on the underlying 
genetic causes can have impact on how children with DLD are classified and treated. At this 
moment DLD is considered a separate entity, which does not facilitate the recognition of 
children with underlying genetic causes, or with additional medical problems. 
While not the main goal of the GENTOS study,  this research project might in the longer 
term contribute to our understanding of the molecular and neurobiological mechanisms 
underlying normal and abnormal speech/language development. 
Materials and methods
Study design
The GENTOS study is a single-centre prospective cohort study of fifty subjects with a severe 
form of DLD. WGS will be performed in cases as well as both their parents. The study 
protocol is approved by the medical research and ethics committee Arnhem-Nijmegen 
(NL67516.091.19). Figure 1 shows the flowchart of the main study design.
Each trio (proband and parents) is included via an individual intake in the outpatient clinic of 
the Amalia’s Children Hospital at the Radboudumc Nijmegen. Medical and historical data will 
be collected and stored in a study-specific research database. A summary of the data will be 
added to EPIC (electronical record system of hospital) as a research note. Blood is collected 
from the affected child and the unaffected parents. Data from WGS will be analysed per 
proband-parent trio in order to determine the origin of the identified variants in the child 
(paternal, maternal or de novo). For each patient, an individual research report is made that 
records variants of interest (“causative” or “possible causative” variants) for that patient, 
according to guidelines of the American College of Medical Genetics (ACMG) guidelines 20. 
The variants of interest will be linked to the individual patient characteristics in the study 
database. The WGS data will also be analysed for all 50 probands combined. By this cohort 
analysis, recurrent mutations or recurrently involved genes can be found. Also, a group-wide 
analysis of diagnostic yield will be performed, including a description of the type and nature 
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of variants found in this cohort, and an analysis to define possible subgroups with higher or 
lower diagnostic yields.
Participants
Individuals are eligible for participation if they have a severe TOS requiring special education 
or ambulatory support in a ‘Cluster 2 setting’ (i.e. specifically aimed at children with hearing 
or speech/language impairments), are between 4-18 years at the time of inclusion, have 
speech problems and a nonverbal IQ of at least 70. The parents and siblings of the probands 
should not have any speech or language disorders, learning difficulties requiring special 
education or autism spectrum disorders. Detailed inclusion and exclusion criteria are listed 
in Table 1. 
whole genome sequencing (WGS)
data analysis for individual case
Trio (child with TOS + parents)
Study overview
N=50
data analysis on group level




WGS data on cohort:
- What is diagnostic yield?
- Which genes / pathways / types 
of variants involved?
- Subgroups with higher/lower 
yield?




Families can show their interest in participating in the study, by submitting their e-mail address 
to our study website (www.radboudumc.nl/gentos). This website contains information on 
the study in line with the study protocol. If parents show their interest, they receive more 
information on the study (including patient information letter and consent forms) via post 
and a telephone call with the researcher is planned, in which the study details are discussed 
(study procedure, consent procedure, inclusion criteria, etc.). An intake appointment in the 
clinic is planned with the family once signed informed consent has been obtained. 
Study intake in clinic
The proband and both parents visit the hospital for an intake appointment, which takes place 
in the Radboudumc Amalia’s Children Hospital. During this intake, the medical history of the 
child and a short history on the family is taken by the clinical researcher under supervision 
of a clinical geneticist. In addition to the clinical history, a short physical examination of the 
child is performed, to measure growth parameters and screen for any possible dysmorphic 
features. Immediately after the clinical intake, a blood withdrawal takes place at the same 
clinic. A certified nurse of the children’s clinic from the Amalia Children’s Hospital performs 
a venipuncture in the child and parents.
Sample collection and WGS
Blood is collected in two EDTA tubes (6,0ml per tube) and one heparin tube (5.0ml). Genomic 
DNA is isolated from EDTA blood from child and parents separately using the standard 
conditions of the Genome Diagnostics facility of the Radboudumc. Each sample will be given 
a DNA-number that will be linked to the study-specific identification number of the proband 
Table 1: Inclusion and exclusion criteria
Inclusion criteria
1. Diagnosis TOS (taalontwikkelingsstoornis) given in the Netherlands
2. Age at inclusion: 4-18y
3. IQ > 70 on non-verbal test
4. Indication for education at Cluster 2 school or ambulatory Cluster 2 support
5. Speech must be affected*
6. A negative first-degree family history for speech and language disorders, speech therapy, autism spectrum 
disorders and special education.
Exclusion criteria
1. An autism spectrum disorder diagnosis made by a child psychiatrist or GZ psychologist
2. Next generation sequencing (including WES) has already been performed, or is being performed at the 
time of inclusion.
3. One biological parent is not available for genetic testing (or both biological parents are not available)
*This will be determined by one of the speech/language therapists of the study team, based on the subdomain 
‘speech’ in the diagnostic test report from the Audiology Center that is required for a Cluster 2 indication. 
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and parents. The isolated DNA and remaining blood samples will be stored under standard 
conditions in the Tissue Culture facility of the Human Genetics Department. A fraction of the 
isolated DNA of the trio (proband and parents) will be sent (using the Radboudumc Clinical 
Utility Studies pipeline) for WGS.
Sample size 
The primary outcome of this study is the diagnostic yield of WGS in children with a severe 
DLD. This yield will be calculated as a proportion (with corresponding confidence interval). 
Because of this study design, a formal power calculation is not applicable. To determine the 
sample size needed for our study, in order to give an informative and reliable estimation 
of diagnostic yield, several different factors were taken into consideration: 1) the expected 
diagnostic yield (~30%) based on studies in developmental speech disorders and other 
neurodevelopmental disorder, 2) the selection of a subgroup of children of TOS for our study 
that is likely enriched for monogenic causes and 3) the expected genetic heterogeneity of 
DLD. 
All in all, we determined that the study sample size should be 50 trios. This sample size is 
most likely large enough to answer our primary research question: “What is the diagnostic 
yield of WGS in children with severe DLD and a negative family history?”, with a proportion 
that is representative and reliable. In addition to determining the diagnostic yield, we will 
describe the type of variants and genes found to be (possibly) causative for DLD. Comparable 
study designs, sequencing strategies and sample sizes have already proven successful in 
multiple other cohort studies performed in the Radboudumc Human Genetics Department 
(see references21 and22 as an example), and in sequencing studies performed worldwide in 
paediatric patients (reviewed in reference23). 
Primary outcomes
The primary outcome of this study is the diagnostic yield of WGS in a cohort of children 
with a severe DLD and a negative family history. This diagnostic yield will be determined 
by categorizing individual sequencing results into three categories according to ACMG 
guidelines20, as further discussed in the ‘Data analysis’ paragraph.
Secondary outcomes 
This study has three secondary parameters/endpoints: A) the types of variants found to 
(possibly) cause DLD (CNV versus SNV, inherited versus de novo, etc.); B) the types of genes 
in which variants are found to (possibly) cause DLD (genes already known to be involved in 
neurodevelopmental disorders versus genes not yet associated with neurodevelopmental 
disorders); and C) possible subgroups in the cohort that might have a significantly different 




The interpretation of genetic data will be carried out based on the clinical information in 
the individual data summary from the Castor EDC database. To aid WGS data interpretation, 
a predefined gene-list (referred to as gene panel), will be used consisting of genes known 
to play a role in the etiology of neurodevelopmental disorders. This gene list is available 
on the website of the Genome Diagnostics department of the Radboudumc: “Intellectual 
disability gene panel DG 2.14” (1158 genes). If no possible pathogenic variants are found 
in genes listed in this gene panel, the data (including genes not associated with disease 
so far) is further analyzed (‘open genome analysis’) using pre-defined filters used in the 
standard clinical exome analysis pipeline as well, including but not limited to: inheritance 
of variant (maternal, paternal, de novo), allele frequency, presence in control databases 
(e.g. gnomAD24), presence in disease databases (e.g. HGMD25, ClinVar26), predicted effect 
on RNA/protein level (using various in silico prediction programs). Using this standardized 
data analysis pipeline, each patient will be classified into one of the following diagnostic 
classes: 1) No obvious pathogenic variant(s) in a known disease-causing gene are observed 
in the proband; no definitive genetic diagnosis is obtained 2) A possible pathogenic disease-
gene variant is observed (or multiple possible pathogenic variants are observed); a possible 
genetic diagnosis is obtained and 3) a pathogenic disease-gene variant is observed and 
validated, which explains the DLD in the child; a definitive genetic diagnosis is obtained.
The diagnostic yield will be defined and described on a group level, using the data from 
individual WGS results. For the total group, a descriptive report will be made on the overall 
outcomes of the WGS analysis in all subjects, in which the variant types will be described, 
the inheritance patterns, characteristics of the genes involved and possible subgroups with 
a different (higher or lower) diagnostic yield. Figure S1 shows a simplified visual overview of 
data analysis procedures.
Clinical data from speech and language tests will be independently assessed by two speech 
therapists  separately before being added to the database. Clinical data analysis will be 
descriptive. High quality speech and language test data from Audiology Centers, of tests 
that have been performed less than five years ago at the time of inclusion, will be used as 
reference for the clinical speech and language characterization. 
Incidental findings
A concern for exome or genome wide screening technologies is the small, but non-trivial, 
potential for identification of incidental findings. In this light, it is noteworthy that WES has 
been implemented clinically in the Netherlands as a first-tier genetic test for a wide range 
of neurodevelopemnatl disorders since September 2012. Most, if not all, ethical, legal and 
societal aspects associated with the diagnostic test in this study are thus identical to those 
faced when WES is used in clinical practice. The risk for incidental findings with our current 
WGS set-up would normally be comparable with the risk in diagnostic WES studies. However, 
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before analyzing the WGS data we will remove all possible variants found in 59 medically 
actionable genes, as defined by the American College of Medical Genetics and Genomics 
(ACMG)27, to minimize the identification of incidental findings in this study. 
The final odds of an incidental finding with the current analysis and filtering set-up is low. 
A study on clinical findings using WES from the Radboudumc reported a chance of 0.9% for 
a set of 56 ‘medically actionable genes’28 that was screened29. In our in-house experience 
of approximately 1,500 diagnostic exomes using trio-based WES an incidental finding was 
identified in 1.4% of individuals30. In both studies, incidental findings included variants found 
in medically actionable genes. By removing all variants in these medical actionable genes 
from the filtering and analysis process, the actual risk for incidental findings in our study will 
be very low, much less than 1%. If despite all measures to reduce the chance, an incidental 
finding is still discovered in our study, the standard clinical procedure for incidental findings 
of the Radboudumc will be used. This means that an external committee, consisting of at 
least an ethicist, lawyer, clinical geneticist, a clinical molecular laboratory specialist and a 
medical expert in the disease for which the variant was identified, will review the finding, and 
will make a decision by balancing the possible medical benefits with the ethical principles of 
doing no harm and the right to (not) be informed.
Data management
Each participant receives a unique study specific identification number, which can only be 
traced back to personal data via an identification code list that will be kept separately from 
the study data. This code list is accessible only to assigned members of the study team. 
De-identified clinical data is stored in a electronic case report files (eCRF) in a study-specific 
Castor EDC database. The specific data added to the eCRF per proband is specified in table S2. 
A de-identified proband-specific summary will be exported from Castor and provided to the 
researchers that perform the WGS data analysis, and is used for the individual interpretation 
of WGS variants. Results of previously performed tests and reports on medical history of 
patients are received as electronic files or on paper. All files are digitized in password-
protected digital folders. Informed consent forms are digitized but original consent forms 
are stored as well. All other paperwork is destroyed once the files are safely digitally stored. 
WGS data will be stored in FASTQ format, labelled with study-specific identification numbers. 
BAM files (alignment data), SNV/CNV variant annotation files (VCF-files, hcdiff-files) and 
variant analysis files in (Microsoft Excel) will be stored in password-protected folders. 
A schematic overview of clinical data analysis and data management procedures is provided 
in Figure S1. All data and material will be stored for a period of 15 years. The handling of 
personal data complies with the Dutch Personal Data Protection Act (de Wet Bescherming 
Persoonsgegevens; Wbp). A qualified monitor is assigned to monitor the study, including 




With this study we aim to better understand the contribution of Mendelian genetic causes 
of DLD. We designed this prospective study of a selected cohort of individuals diagnosed 
with a severe DLD in the Netherlands to systematically assess the role of rare pathogenic 
variants in the development of this disorder. With this, we aim to define the total diagnostic 
yield and the contribution of different types of variants and inheritance patterns to this 
yield, to find out which genes are involved and whether there are any differences observed 
in diagnostic yield between different subgroups.
For this study we chose to include 50 children that meet all inclusion criteria and their 
parents. Probands are drawn from the population of children that are living in the 
Netherlands, and are diagnosed with DLD. The exact prevalence of this disorder in the 
Netherlands is not known4, but is likely comparable with the prevalence of 7% that is 
reported in a USA-based study among five-year-olds3. Not all children with DLD will meet 
the criteria for inclusion in our study. In particular, the need for didactic ‘Cluster 2 support’ 
on the one hand, and requirement of a negative family history on the other, will limit the 
number of children that are eligible to participate in our study. There are no recent reports 
available on how many Dutch children with DLD need Cluster 2 support. A report from the 
Dutch Inspectorate for Education from 2009 states that 9,088 children attended a Cluster 
2 school in 2008 (this includes children with speech and language disorders, but also those 
with hearing impairments) and that 3,807 children with speech and language difficulties 
received ambulatory Cluster 2 support31, which means these children go to regular schools 
but receive extra support from ‘Cluster 2 trained’ teachers and therapists. Based on the 
total number of children that receive Cluster 2 support, our own experiences with the target 
group, and close consultation with several leading experts working in the DLD field, we 
expect it will be feasible to recruit the planned number of 50 patients for our study. 
For this study, a sample size of 50 trios (affected individuals and their unaffected parents) 
is defined. Formal sample size calculations are not possible for this type of study design, 
and no reliable data are available on the expected diagnostic yield in DLD. More data are 
available for other neurodevelopmental disorders. In a recent study in which trio-based 
WGS was performed in 309 trios with intellectual disability and/or developmental delays, 
a diagnostic yield of 29% was reported32. When WGS is used in patients with severe forms 
of intellectual disability, a yield as high as 62% is obtained33. Although diagnostic yield is 
largely dependent on the coverage of the sequencing platform, and on the specific inclusion 
criteria of cohort studies, the diagnostic yield for epilepsy is reported to be 24-36% 34, and 
20-25.8% for autism spectrum disorders 35,36. If DLD has a similar genetic architecture to 
other neurodevelopmental disorders such as intellectual disability, autism and epilepsy, we 
anticipate a diagnostic yield in the same range.
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We chose to include a specifically selected group of children with DLD, which may not be 
representative for the population of children with a DLD as a whole. Because the size of our 
study is restricted by the costs of WGS, we have chosen to enrich our cohort for children 
that most likely have rare monogenic causes, by including those with a severe form of DLD 
and a negative family history. If this strategy leads to a substantial diagnostic yield, screening 
can be extended to cohorts with milder forms of DLD in future studies. Alternatively, if the 
diagnostic yield for rare monogenic causes turns out to be low, this kind of diagnostic testing 
might not be useful for broader populations of children with DLD.
In conclusion, our study can serve as a first study to determine the diagnostic yield of trio-
based WGS in a selected cohort of children with a severe DLD in the Netherlands. Knowledge 
of frequencies and types of underlying monogenic causes will lead to a better understanding 
of the genetic architecture and pathogenic mechanisms. Moreover, such knowledge is 
crucial to guide referral strategies and diagnostic decisions, and to work towards better and 
more personalized healthcare for individuals with DLD, in the Netherlands and abroad.
Study status
Inclusion for this study started in March 2020 and is still ongoing at the time of writing.
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EPIC: research note in patient 
record of subject (child with TOS) 
Castor: de-identified clinical 
data with restricted access
Medical history
Clinic l data ov view
De-identified data summary for 
interpretation of WGS variants
Data analysis on group level
Individual WGS result
Family history Physical examination
De-identified publication of 
group data for publication
Figure S1: Schematic overview of clinical data analysis and data management procedures 
Table S1: Subgroups with a possible different diagnostic yield
Category Subgroup 1 Subgroup 2
Cluster 2 support Attends cluster 2 school Ambulatory support
Non-verbal IQ (last test) < 90 ≥90
Speech sound disorder reported Yes No
Receptive language problems Yes No
Receptive Language (RL) versus Expressive Language (EL) RL>EL RL = EL
Pragmatic language problems reported Yes No
Age of DLD diagnosis < 4 years ≥ 4 years
Congenital abnormalities Yes No
Epilepsy/seizures in history Yes No
Gender Male Female
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Birth weight / head circumference
Congenital abnormalities
Neonatal problems
Details of DLD Age of diagnosis
Details of speech problems
Details of language problems 
Feeding history, saliva control, oral sensory issues
History of therapeutic intervention
Results of previously performed tests
(Neuro)development Gross motor development/milestones
Fine motor development










Family history (1st and 2nd degree family members)
DLD DLD or speech/language difficulties?
Development Developmental delays?
Cognitive impairments?
Other Other important medical issues?
Physical examination
Growth parameters Height 
Weight
Head circumference
Dysmorphic features Description of features (in Human Phenotype Ontology (HPO) terms)
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Summary of results 
The goal of this thesis was to study biological etiology and clinical aspects of disorders that 
disrupt speech and language developmental, taking advantage of the new opportunities of 
the next generation sequencing era. By using exome and genome sequencing data of children 
with major developmental speech and language disorders, we were able to identify five new 
genes in which pathogenic variants appeared causative: MED13, POU3F3, CHD3, WDR5 and 
FOXP4. We characterized the full clinical spectrum of the disorders associated with disruptive 
mutations of these genes. Apart from speech and language deficits we found a wide range 
of phenotypic features. Therefore, we consider these to be Mendelian neurodevelopmental 
syndromes. Using both in silico and in vitro cell-based approaches, we were able to confirm 
pathogenicity for the identified variants. In addition to these genome-first Mendelian 
disorder discovery studies, we performed extensive speech/language phenotyping and 
neuropsychological profiling in 23 individuals with SATB2-associated syndrome, a known 
neurodevelopmental disorder involving severe impairments in communication. Lastly, we 
designed a novel study to systematically assess de novo variants in a selected cohort of 
children with a severe developmental language disorder. 
This research demonstrated how trio-based next generation sequencing studies can be used 
to delineate genetic pathways underlying developmental speech and language problems, 
and how de novo variants in Mendelian disease genes can disrupt skills in these domains. We 
found that different underlying mechanisms and pathways can lead to similar disturbances 
in speech and language. Conversely, similar molecular disruptions can give rise to different 
phenotypes in different probands. A combination of complementary methods were used 
including 1) trio-based next generation sequencing in children with primary developmental 
speech and language disorders, 2) in vitro studies for assessing pathogenicity and 3) 
systematic phenotyping. Studying developmental speech and language disorders from this 
multidisciplinary perspective, including the integration of knowledge from clinical genetics, 
molecular biology, speech and language pathology and neuropsychology, contributes to a 
more complete understanding of this important class of disorders, and may be adapted in 
future studies.
Novel contributions to the field 
We studied children with a developmental speech and/or language disorder as a starting 
point for characterizing new genes in which de novo mutations lead to developmental 
phenotypes. With this genotype-driven approach, we were able to associate five genes 
to a novel Mendelian developmental disorder. The disorders caused by heterozygous 
variants in three of these five genes are now listed in the OMIM database as Mendelian 
neurodevelopmental disorders: MED13 variants cause ‘intellectual developmental disorder 
61’ (MIM #618009), CHD3 variants cause ‘Snijders Blok-Campeau syndrome’ (MIM #618205) 
and the disorder associated with variants in POU3F3 has been listed as ‘Snijders Blok-Fisher 
syndrome’ (MIM #618604). For the disorders associated with heterozygous variants in the 




For the genes CHD3 and WDR5, our starting point was a small published cohort study (n=19) 
by Eising et al.1 on children with childhood apraxia of speech, in which a de novo variant 
of unknown significance was reported in CHD3 in one affected individual, and in WDR5 
in another individual1. Clinical and molecular studies on CHD3 and WDR5 confirmed the 
pathogenicity of these variants, and established new Mendelian disorders associated with 
severe speech and language deficits and various additional features (Chapter 4 and 5). 
The study of Eising et al.1, as well as a subsequent cohort study (n=34) by Hildebrand et 
al.2, provided the first evidence to suggest a high diagnostic yield of rare de novo variants 
in children with a developmental speech disorder. To more systematically assess the 
contributions of pathogenic de novo variants to developmental language disorders, we 
designed a new prospective cohort study: the GENTOS study (Chapter 8).  
In addition to gene discovery, we performed in-depth phenotypic characterization of 
individuals with heterozygous pathogenic SATB2 variants from a speech, language, oral 
motor and neuropsychological perspective. Studies that combine phenotyping on a speech/
language level and on a neuropsychological level are scarce. While a previous study reported 
childhood apraxia of speech to be present in all studied individuals with SATB2-associated 
syndrome3 (n=61), we showed that in addition, several other speech diagnoses were found 
to contribute to the severe problems observed. We also described a characteristic profile 
in adaptive functioning assessed by Vineland screener tests for individuals with pathogenic 
SATB2 variants, with relatively high scores on the ‘Daily Functioning’ domain and relatively 
low scores on the ‘Communication’ domain. The results can guide a personalized approach 
for parents and therapists. 
Clinical relevance and implications of genetic studies in developmental 
speech and language disorders 
Using trio-based next generation sequencing data to identify de novo variants 
Research on the genetics of developmental speech and language disorders has often 
tended to focus on multifactorial inheritance4. Our research is distinctive in focusing 
largely on Mendelian causes of speech and language problems. In Chapter 2-6, we used 
next generation sequencing data to specifically search for Mendelian disorders involving 
prominent speech and language impairments. Over the last decade, many studies have 
already shown that next generation sequencing in parent-child trios provides a powerful 
tool to identify underlying molecular defects for a plethora of different types of disorders5-7. 
We applied such an approach here, with family-based sequencing data and follow-up of 
interesting de novo variants. This strategy is effective, because it does not depend on the 
availability of large systematically phenotyped speech and language disorder cohorts.  
While our studies illustrate the possibility and relevance of finding a clinically relevant de 
novo pathogenic variant, they do not tell us which fraction of individuals with speech and 
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language disorders carries  high-penetrance variants of this nature. For developmental 
disorders in general, it is estimated that around 40% of individuals have a pathogenic de 
novo variant in the coding sequence8. We designed the GENTOS study (Chapter 8) to give an 
insight into the diagnostic yield for rare pathogenic variants in a selected group of children 
with a developmental language disorder. Preliminary literature on this topic suggests a 
diagnostic yield of around 30% for individuals with a developmental speech disorder such 
as childhood apraxia of speech1,2. This estimate is expected to increase, as sequencing 
conditions (e.g. sequencing coverage and quality of sequencing data) and knowledge on 
pathogenic variants improve. 
Confirming pathogenicity of variants
In Chapters 2-6, we used a combination of publicly available data, in silico tools and in vitro 
functional assays in cell systems, in order to reliably interpret the likely effects of variants of 
interest. In Chapter 2, 3 and 5 we used three-dimensional modeling to derive hypotheses 
on pathogenic mechanisms, taking advantage of prior knowledge on protein structures. 
Modeling has been shown to be effective in differentiating neutral versus pathogenic 
missense variants in different types of genetic disorders, and is becoming increasingly 
available for large-scale analyses of missense variants9,10. 
In addition to in silico tools, functional studies can provide empirical support for etiological 
relevance of identified variants. In Chapter 3, 4 and 6 different in vitro assays were used to 
demonstrate pathogenicity. We showed that most of the de novo CHD3 gene variants that we 
studied disrupted chromatin remodeling capacities of the CHD3 protein, and that variants 
in POU3F3 and FOXP4 interfered with transcriptional activities of the encoded transcription 
factors. Although proving pathogenicity can be a challenge and is often time-consuming, 
assigning functional evidence to variants of unknown significance is of crucial importance 
to their correct classification11,12. Functional evidence, from in vitro assays as well as in vivo 
studies, can elucidate molecular mechanisms and pathways involved in neurodevelopmental 
(disease) processes. Saturation mutagenesis approaches in combination with protein-
dependent functional read-outs may enable more high-throughput tests of variants13. Also, 
models more relevant for three-dimensional organization in early brain development, such 
as brain organoids14, are increasingly used for functional validation and further follow-up of 
variants of interest.
Follow-up of candidate genes: identification of variable phenotype expressivity
In Chapter 2-6, after the identification of a possible pathogenic candidate gene, we collected 
additional individuals with potential pathogenic variants in the same gene. Strategies 
included searches through public databases such as DECIPHER15, ClinVar16, HGMD17 and 
denovo-db18, using ‘gene matchmaking’ platforms such as GeneMatcher19, querying large 
clinical and research sequencing datasets (from academic and commercial sequencing 




Using this approach, we were able to capture a phenotypic spectrum associated with these 
rare variants, that typically appeared broader than the initial disorder of interest; both in 
terms of neurodevelopmental phenotypes and in terms of additional clinical features such 
as dysmorphisms or congenital abnormalities.
Mendelian disorders often present with more than just the neurodevelopmental 
phenotype. In our studies this is illustrated by the presence of gene-specific associated 
features in subsets of individuals with the disorders described in Chapter 2-6: e.g. optic 
nerve abnormalities and Duane anomaly in some individuals with a MED13 variant (Chapter 
2), characteristic prominent and cupped ears in all individuals with a loss-of-function variant 
in POU3F3 (Chapter 3), macrocephaly and a distinctive facial gestalt in individuals with 
a pathogenic variant in CHD3 (Chapter 4), and a congenital diaphragmatic hernia and/or 
vertebral abnormalities in a subset of individuals with FOXP4 variants (Chapter 6). While 
Figure 1: Frequency of neurodevelopmental phenotypes observed in five different Mendelian 
disorders
Frequencies of different neurodevelopmental disorder phenotypes are shown for the Mendelian 
disorders associated with FOXP4, WDR5, MED13, CHD3 and POU3F3, as clinically characterized in 
Chapter 2-6 of this thesis. The size of each circle represents the associated frequency per phenotype. 
For the intellectual disability phenotype, the frequency of different degrees of severity is visualized 
using pie charts. ASD = Autism Spectrum Disorder, AD(H)D = Attention Deficit (Hyperactivity) Disorder.
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in clinical genetics the terms ‘syndromic’ and ‘nonsyndromic’ are often used to classify 
individuals with and without co-morbidities in addition to their primary phenotype (e.g. 
syndromic versus nonsyndromic intellectual disability)20, our results once more highlight the 
unclear boundaries between these two categories, because of clinical variability. Also, some 
of these additional features are subtle and may initially escape recognition. Objectively 
assessing dysmorphisms is challenging and not always within the competencies of the 
attending physician.
For the results of the clinical characterization in Chapter 2-6, some skew is likely towards the 
more severe end of the phenotypic spectrum. NGS studies with a trio approach are known 
to be biased towards more severe phenotypes21, and diagnostic testing using NGS might also 
be performed less frequently in individuals with phenotypes without developmental delays, 
compared to those with neurodevelopmental disorders. The rarity of the causative gene 
variants often precludes statistically significant conclusions on presence and prevalence of 
phenotypic features. Chapter 6 represents an example of a small discovery cohort, as de novo 
variants in FOXP4 seem to be very rare. Although no doubt exists about the pathogenicity 
of the variants affecting the transcriptional repressor activity of FOXP4 as presented in this 
study, novel associated features remain to be identified, once more individuals with the 
associated disorder are studied. On the other hand, our study on CHD3 variants in Chapter 
4 involved 35 individuals with a de novo variant in this gene. This is a relatively large group 
for such a gene discovery cohort, and allowed a robust first characterization of the CHD3-
associated phenotype. Indeed, our data on phenotypic features in this disorder have recently 
been confirmed in a clinical follow-up study using an independent cohort of individuals with 
pathogenic CHD3 variants22. 
“Speech/language disorder-specific” genes?
The search for “speech/language disorder-specific” genes
We studied de novo pathogenic variants in children with developmental speech and language 
disorders to identify five new neurodevelopmental disorders, caused by disruption of genes 
that had not previously been linked to any Mendelian disorder (Chapter 2-6). As discussed 
in the previous paragraphs, as cohorts were investigated beyond the initial probands, 
the associated phenotypes were not restricted to speech and language. Although such 
problems turned out to be a prominent feature in all five newly characterized disorders, 
other neurodevelopmental issues such as intellectual disability, autism spectrum disorders, 
ADHD and epilepsy phenotypes were commonly found, and to variable degrees (Figure 1). 
As an example, in Chapter 5 we show how a single p.(Thr208Met) missense variant in WDR5 
gives rise to a severe mixed language disorder and borderline intellectual disability in one 
individual, and to a phenotype with moderate ID, autism spectrum disorder and absent 
speech in another individual. 
Based on our results and those of previous cohort studies1,2, the genetic causes of speech 




spectrum disorders. In addition, speech/language delays diagnosed at a young age can be 
the first presentation of broader neurodevelopmental impairments at a later age23. We 
cannot currently explain differences in neurodevelopmental phenotypes among individuals 
with similar molecular defects. Such clinical variability may reflect local regulatory genetic 
variants24, other effects of genetic background25, and modulation by environmental and/
or social factors. A recent publication on 22q11.2 deletion syndrome shows how polygenic 
scores based on common genetic variation might be used in future for better prediction of 
expected phenotypes in individuals with rare genetic variants26. It has further been posited 
that stochastic events or small inter-individual differences in important pathways during 
development might lead to large downstream differences with a major impact on the 
phenotype27. 
Genes associated with significant speech/language disorder phenotypes
For the newly characterized Mendelian disorders in Chapter 2-6, the speech and language 
problems form a prominent and important part of a broader clinical spectrum. For instance, 
in our CHD3-associated disorder cohort the overwhelming majority of individuals (25 of 27 
for whom information was available) with a pathogenic variant in this gene was receiving (or 
had received) speech therapy (Chapter 4). The most frequent phenotypes that we observed 
in individuals with pathogenic variants in CHD3 included childhood apraxia of speech, 
impaired intelligibility, fluency problems, and mixed or expressive language disorders. 
Speech and language delays or disorders were reported in all individuals with pathogenic 
MED13 variants (Chapter 2), with an emphasis on expressive speech problems rather than 
receptive language problems. In FOXP4-associated disorder (Chapter 6), all six individuals 
with confirmed pathogenic variants in the study had speech and language delays, with 
a formal expressive language disorder diagnosis in two individuals. In individuals with 
pathogenic variants in POU3F3 (Chapter 3) or WDR5 (Chapter 5) severe speech and language 
problems are a commonly reported phenotypic feature too. And as is shown in Chapter 7, 
even when observed in the context of more substantial intellectual disability, as observed in 
SATB2-associated syndrome, impaired speech and language can still have a large disruptive 
effect on daily functioning. 
All in all, pathogenic variants in a subset of neurodevelopmental disorder genes, including 
the genes characterized in this thesis, give rise to neurodevelopmental disorders with 
prominent speech and language dysfunction (Figure 2A). This means that speech and 
language problems and disorders are more frequently and more severely present in 
individuals with variants in these genes, compared to individuals with variants in other 
genes associated with neurodevelopmental disorders. Thus, clinical practice is better 
suited to a model which acknowledges the diversity of features associated with variants 




Do “speech and language-disorder specific” genes exist?
Current data do not exclude that “speech/language disorder specific” genes may exist after 
all, although considerations of the complexity of biological mappings between DNA and 
behaviour/cognition suggest that this degree of specificity is unlikely28,29. We and others have 
been unable to find genes for which Mendelian pathogenic variants specifically cause speech 
and language disorders, without any other associated neurodevelopmental phenotypes. In 
this regard, FOXP2 remains the most striking example of genotype-phenotype associations 
that clearly involve a developmental speech disorder. The majority of individuals with a 
pathogenic FOXP2 variant have severe speech problems (childhood apraxia of speech), but 
Figure 2: Recommendations for classification of genes and disorders 
a) The question is whether “speech/langue-disorder specific” genes exist after all. Based on the current 
literature and the results of the research in this thesis, a model in which separate sets of genes are 
associated with different phenotypes (e.g. intellectual disability, speech/language disorders or ASD) 
is not likely. We propose a model in which a subset of the genes in which pathogenic variants cause 
neurodevelopmental disorders is associated with more prominent and/or more frequent speech/
language disorder phenotypes.
b) A clinical classification strategy for individuals with speech and language disorders in which 
the clinical diagnosis depends on whether a causative molecular defect has been identified is not 
recommended. We recommend to use clinical and molecular labels or diagnoses separately and 
independently.
Not likely: More likely:
A) “Speech/language-disorder specific” genes?
Genes associated with
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even here, the neurodevelopmental phenotypes observed in these individuals are often not 
limited to speech problems30. Our findings on speech and language are in line with recent 
work on monogenic causes of autism spectrum disorders, which concluded that there was 
presently no evidence for “autism-specific” genes 31. 
To more robustly rule out the existence of “speech/language disorder-specific” genes, 
prospective highly selected cohort studies are needed. The GENTOS study (Chapter 8) is 
designed to potentially identify these genes, especially if de novo variants are involved. 
Definitive conclusions on the (non)existence of such genes, taking into account the possibility 
of inherited variants in combination with reduced penetrance and variable expressivity, will 
require much larger studies based on comprehensive data sets. An example of such a large 
dataset could be the UK Biobank, a long-term study in the United Kingdom which investigates 
the contribution of genetic and environmental factors to the development of disease 32. 
This database contains clinical data and genetic data on 500,000 participants and recently 
released exome sequencing data on 200,000 individuals. However, this resource is mainly 
aimed at complex disease of middle and older ages. Currently, no suitable parameters are 
available in UK Biobank with respect to developmental speech and language deficits of the 
participants, limiting its usage for shedding light on etiology of this major class of disorders.
Consequences for classification: should speech and language disorders be considered a 
separate entity?
Given the overlapping genetics demonstrated here and elsewhere, one might wonder 
whether developmental speech and language disorders should be considered as an 
etiologically distinct entity, separate from other neurodevelopmental disorders. We think 
it is important to keep a clear distinction between a clinical and a molecular diagnosis. 
While different children might have an identical genetic diagnosis (even carrying the same 
pathogenic variant), the phenotype might still differ from one case to the next. If a child 
has a clinically defined developmental language disorder, and then a molecular cause is 
found that is predominantly associated with autism spectrum disorder or intellectual 
disability, the child should still receive treatment that is matched to the clinical needs (i.e. 
language disorder). A molecular diagnosis is important as it accounts for the developmental 
problems in the child, and establishes the origin of the disorder and the inheritance pattern. 
Sometimes, a molecular diagnosis can also be helpful for informing parents about a likely 
prognosis. Yet, molecular classification should not subsume clinical classification. It is not 
possible to classify children with clinical diagnoses based on molecular data alone. Although 
progress has been made in better understanding and predicting clinical outcomes in 
Mendelian disorders (e.g. as has recently been shown in 22q11 deletion syndrome26), for 
the foreseeable future, a pathogenic variant will not predict the exact clinical outcome for 
these types of disorders. 
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In clinical linguistics, a molecular diagnosis is sometimes used as an exclusion criterion for 
the label ‘developmental language disorder’ (in abbreviated form, DLD), for instance in 
the recommendations of the CATALISE consortium33. The authors argue that the term DLD 
should be used exclusively when there is no underlying biomedical condition present, such 
as e.g. Down syndrome34. Based on the findings of this thesis, with the current knowledge 
of the likely genetic underpinnings of developmental speech and language disorders, as 
well as the impossibility to clinically separate Mendelian from non-Mendelian disorders, 
we would argue strongly against making this distinction based on the presence/absence 
of an underlying molecular diagnosis (Figure 2B). As also illustrated by chapter 7, a genetic 
diagnosis can give guidance and clarity for all families involved, but the clinical diagnosis 
remains the cornerstone of care. 
Results in the context of the neurobiology of speech and language
Networks of genes and proteins involved in shaping a “language-ready” brain
It was once believed, that the brain had highly specific regions important for language 
functioning, e.g. the Broca and Wernicke regions35,36. The current picture though is more 
complex than this classical neurobiological view36,37. While many parts of the multifaceted 
human-specific capacity to acquire and use complex language remain to be discovered, it 
is known that multiple different cortical and subcortical regions are involved, as well as the 
basal ganglia and cerebellum, together forming distributed circuits. Moreover,both frontal 
and temporal regions are involved in expressive and receptive language processes, and the 
initial simplistic views regarding lateralization of the crucial circuits are being replaced by a 
more nuanced perspective36,38,39. 
This neurobiological complexity fits with the genetic heterogeneity of speech and language 
deficits demonstrated here and elsewhere in the literature. A highly intricate interplay of 
different genes and their encoded proteins, differently expressed in time during development 
and in diverse brain regions, is needed to shape the developing brain in such a way that it 
is able process and produce speech and language - the basis of the so-called “language-
ready” brain38,40. As a result, disruptions of an array of different types of genes and encoded 
proteins could potentially impact on speech and language capacities. Studying the genes 
and pathways involved in abnormal speech and language development might shed light on 
the crucial neurobiological mechanisms.
Characteristics of genes involved in Mendelian causes of speech/language disorders
Although the molecular underpinnings of developmental speech and language disorders 
reflect extreme genetic heterogeneity, as discussed previously, a subset of genes linked to 
Mendelian neurodevelopmental disorders seems to be associated with a more common and/
or more prominent speech and language phenotype. Knowledge about the characteristics 




play a role, might lead us to molecular pathways involved in normal and abnormal speech 
and language development. 
Nonetheless, considerable uncertainty remains with regard to the nature of these molecular 
pathways. Two published studies provide evidence that a set of genes co-expressed in early 
human brain development and involved in regulatory pathways shows enrichment in NGS 
screening of childhood apraxia of speech1,2, but further studies are needed to replicate and 
confirm these findings. 
If we look at the five genes characterized in Chapter 2-6 of this thesis, we can note that 
all are highly expressed during early brain development, and that the encoded proteins 
are known to have important functions in gene regulation processes. FOXP4 and POU3F3 
are transcription factors that regulate the expression of a large variety of target genes41,42, 
MED13 is involved in transcriptional regulation and transcription initiation as part of the 
Mediator complex43, CHD3 is involved in chromatin remodeling44, and WDR5 is a crucial 
part of different well-known protein complexes involved in chromatin-related regulatory 
functions45. 
So far, a large part of the literature on the molecular biology of speech and language 
development is focused on functions of FOXP2 and its orthologs in brain development, animal 
vocalizations and human speech46. Several of the genes and proteins that we identified 
have direct links to FOXP2. Strikingly, FOXP4, is not only a paralog of FOXP2 with partially 
overlapping expression patterns in several brain regions, but is also known to dimerize with 
itself or with FOXP2 in order to exert its transcriptional regulation functions47. As mentioned 
in Chapter 4, the protein CHD3 has been found to be an interactor of FOXP2 in a yeast two-
hybrid assay48. In addition to these protein-protein interactions, we have demonstrated in 
Chapter 3 that an intronic element in the FOXP2 gene can serve as a functional binding site 
for POU3F3. Previous work has shown that phenotypic networks often reflect underlying 
biological networks defined by regulation or protein-protein interactions49,50.
While it is tempting to speculate that dysfunctions in developmental speech and language 
disorders might be the result of converging molecular pathways and networks, further 
research is needed to study this and further define the essential processes and relevant 
neural circuits. Although the advances and developments in genetics and molecular biology 
are promising, there is still a significant gap between gene/protein function and cellular 
networks on one side, and human brain functioning and phenotypes on the other side.
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Proposal for diagnostic genetic testing using NGS in developmental speech 
and language disorders 
Based on the results of this thesis and published literature we propose genetic testing using 
NGS for the following individuals:
• Individuals with a severe developmental speech disorder (with exception of individuals 
with developmental speech disorders only affecting fluency of speech, e.g. stuttering)
• Individuals with a severe developmental language disorder and additional abnormalities 
(e.g. dysmorphisms, growth parameters, congenital abnormalities, etc.)
• Severe developmental language disorder with a negative first-degree family history 
It does not seem helpful to only focus on genes that have been associated with speech and 
language disorders in prior literature, due to the variable expressivity of many Mendelian 
neurodevelopmental disorders in combination with possibly incomplete phenotypic reports. 
We would therefore advocate a targeted NGS analysis of all developmental disorder genes 
in individuals with developmental speech and language disorders.
In view of the relevance of finding de novo variants, a negative family history should not 
be used as an exclusion criterion for genetic testing. In fact, the likelihood of finding a 
Mendelian cause in a child with a severe speech and/or language disorder and a completely 
negative family history may well exceed that of a child with a strongly positive family history. 
In individuals with familial aggregation of speech and language disorders, multifactorial 
inheritance is probably the most likely explanation, although some families with rare high-
penetrance variants have also been reported (e.g. the KE family with a pathogenic variant 
in FOXP251). There is currently no molecular test that can demonstrate multifactorial genetic 
predisposition. 
Lastly, the presence of co-morbidities might point more strongly to an underlying Mendelian 
cause, but the absence of additional features should not be used to exclude this possibility.
Future perspectives
Clinical value of NGS in developmental speech and language disorders
We suggest not to be reluctant to use NGS in individuals who present mainly or solely with 
developmental speech and language disorders. This will benefit children/probands and their 
families, as a molecular diagnosis can provide clarity about the cause of the disorder, about 
the recurrence risk for family members, and can also be informative regarding presence 
of co-morbidities and relevant recommendations. As shown in Chapter 7, a molecular 
diagnosis can also guide more personalized diagnostic and treatment options for speech 
and language therapists. Although a small number of studies suggest otherwise52, so far, 
there is no clear evidence for molecularly guided drug treatment to ameliorate language 
dysfunction in developmental speech and language disorders. As these disorders are the 




available in the future to solve all problems. However, one might speculate that for specific 
molecular defects, certain drugs will ultimately be found to lead to improvement on specific 
cognitive or speech/language related functions.
Systematic and consistent phenotyping in developmental speech and language disorders
One of the main challenges in genetics research in the speech and language field is the lack 
of consistency in phenotypic classification. On a clinical level, different types of classifications 
and labeling are used, which hamper proper comparisons. Clinical geneticists often rely on 
data from diverse international sources, so that when an individual from one country is 
reported with a developmental speech disorder, another individual from a different country 
with verbal dyspraxia, and a third individual has reported speech delays, these divergent 
terms might still indicate the same phenotype. The field of genetics of developmental speech 
and language disorders would benefit from comparable and systematic classification and 
labeling. For other Mendelian disorders, standardized phenotyping is increasingly performed 
using Human Phenotype Ontology (HPO) terms53. For developmental speech and language 
disorders, only a few standard terms are available in HPO, e.g. ‘delayed speech and language 
development’,  ‘absent speech’, ‘expressive language delay’, ‘receptive speech delay’ and 
‘childhood apraxia of speech’. Though these can be used in a rough stratification, they do 
not completely match with the proposed and commonly used diagnostic classifications, and 
also are insufficiently detailed to allow good distinctions between different types of speech 
and language disorders.
In NGS research studies in neurodevelopmental disorders, speech/language-oriented 
phenotype data are often incomplete or absent. While presence or absence of intellectual 
disability and specific somatic features are commonly reported, reliable phenotype data 
on behaviour as well as speech and language development and/or speech- and language-
related diagnoses are often lacking. This might lead to a bias in published literature on 
such phenotypes of Mendelian neurodevelopmental disorders. Research studies with 
systematically collected speech and language data would advance the field. A number of 
initiatives are currently aimed at overcoming these difficulties. As an example, the GenLang 
consortium (http://genlang.org) brings together genetic data and researchers on normal 
and abnormal speech and language function from multiple different laboratories around 
the world, in order to set up large-scale cohort meta-analyses with enough power to detect 
important genetic variants. Another example of an initiative that can be used for improving 
systematic phenotyping in Mendelian disorders is the Dutch Computer Articulation 
Instrument, which is designed to systematically and automatically assess speech capacities, 
and has already been shown to be useful in diagnosing specific speech problems in 
individuals with Koolen-de Vries syndrome54. 
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Consortia, data sharing and patient empowerment
There is increasing interaction of scientists studying basic biological or genetic concepts with 
clinicians or therapists. Such a multidisciplinary approach is crucial to bring this research 
field forward. For example, as developmental speech and language disorders often co-
occur with (symptoms of) other neurodevelopmental disorders, it is challenging to correctly 
diagnose and differentiate on a phenotype level between cognitive problems, behavioural 
problems and speech/language problems. A multidisciplinary approach, involving speech 
therapists and neuropsychologists with experience with this complex group of phenotypes, 
would allow the selection of appropriate instruments and test settings. Therefore the 
establishment of expert centres with multidisciplinary teams and international embedding 
in EU reference networks is crucial for connecting expert clinical knowledge to fundamental 
research.
Data sharing efforts such as GeneMatcher19 have greatly enhanced the identification of new 
Mendelian disorders, similar to other genomic collaborative efforts such as the gnomAD 
database55. Especially in the context of rare variants and rare disorders, data sharing and 
open science practices are of paramount importance for the progress in this research field.
Last but not least, collaboration with parents and families involved is highly recommended. 
Families have more experience with a disorder than most researchers will ever have, and can 
provide researchers and clinicians with useful suggestions and insights. Due to social media, 
parents from individuals with rare diseases all around the world can easily get in contact 
with each other and share and collect information. In addition to collecting interesting 
phenotype details via families (and clinicians) involved, we have collaborated with parents 
in our research projects to optimize study designs before execution (SATB2). For the FOXP4 
study, it was the parents contacting us about an interesting FOXP4 variant found in their 
child, which initiated this research project. Altogether, empowering patients and families 
in research designs and execution will benefit all parties in performing meaningful research 
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While most children acquire speech and language capacities relatively effortlessly, 
some children have speech or language problems. If these problems persist, a child 
might have a developmental speech or language disorder. Developmental speech and 
language disorders are neurobiological disorders, and children with these disorders 
might have problems with different aspects of speech and/or language and with different 
levels of severity. Developmental speech and language disorders often co-occur with 
other neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder 
(ADHD), delayed motor development and developmental dyslexia. The presence of other 
neurodevelopmental disorders might complicate diagnosis and therapeutic interventions. 
In Chapter 1 we provide an overview of the current literature on developmental speech and 
language disorders. We discuss the clinical presentation, the commonly used terminology 
and diagnostic categorization, and the current knowledge on the genetics of these disorders. 
It is clear from family and twin studies that developmental speech and language disorders 
are strongly influenced by genetics. While the underlying genetic architecture might be 
complex and multifactorial, the exact contribution of Mendelian causes to developmental 
speech and language disorders is currently unclear. 
The aim of this thesis was to investigate Mendelian causes of developmental speech and 
language disorders, in order to better understand the molecular underpinnings of these 
disorders and ultimately improve clinical care. We studied the impact of rare de novo 
variants from a clinical and molecular perspective, using a wide range of methods including 
next generation sequencing, systematic phenotyping and functional assessments with cell-
based assays. Using this approach, we identified and characterized five new Mendelian 
disorders with speech and language impairments as a core phenotypic feature (Chapter 
2-6), and performed detailed speech, language and neuropsychological profiling in SATB2-
associated syndrome, a known disorder associated with severe speech problems (Chapter 7). 
We also designed a prospective cohort study (Chapter 8) to systematically investigate the 
role of de novo variants in the emergence of severe developmental language disorder (DLD).
Chapter 2 describes our research on pathogenic variants in MED13, a gene encoding a 
component of the CDK8-kinase module that can reversibly bind with the Mediator complex. 
We collected clinical data and variant details on 13 individuals with pathogenic variants 
in this gene and defined a new neurodevelopmental disorder characterized by intellectual 
disability (or general developmental delays) and speech/language delays or disorders. 
Additional features reported in a subset of individuals were autism spectrum disorder (ASD), 
Attention Deficit Hyperactivity Disorder (ADHD), hypotonia, optic nerve abnormalities, 
Duane anomaly and mild congenital heart defects. In addition to six truncating variants, 
we reported a clustering of non-truncating variants (missense variants and an in-frame 
deletion of one amino acid) in two regions of the encoded MED13 protein: an N-terminal 
237
English summary
and C-terminal region. The four N-terminal clustering mutations affect two adjacent amino 
acids that are known to be involved in MED13 ubiquitination and degradation, p.Thr326 and 
p.Pro327. All in all, our findings add MED13 to the group of CDK8-kinase module-associated 
disease genes.
In Chapter 3 we present the results of our study on POU3F3 (also known as Brain-1), a gene 
encoding a transcription factor that is highly important in gene regulation during early stages 
of brain development. We compiled a cohort of 19 individuals with heterozygous truncating 
or missense variants in this gene, and found that all individuals had developmental delays 
and/or intellectual disability, with impairments in speech and language skills. The majority 
of individuals had remarkable ear abnormalities: low-set,  prominent and often cupped ears. 
Using luciferase assays, we showed that two missense variants reduced the transactivation 
capacity of the encoded transcription factor, while one variant displayed a gain-of-
function effect. In bioluminescence resonance energy transfer (BRET) interaction assays, 
all the truncated POU3F3 versions showed significantly impaired dimerization capacities, 
whereas all missense variants had unaffected dimerization with wild-type POU3F3. All in 
all, we implicate disruptions of POU3F3 in a characteristic and potentially recognizable 
neurodevelopmental disorder.
The identification of pathogenic variants in CHD3 as a cause of a developmental disorder 
with macrocephaly and prominent speech impairment is described in Chapter 4. As part of a 
large international collaboration we collected phenotype and variant data on 35 individuals 
with de novo variants in CHD3, a gene encoding a protein involved in chromatin remodeling 
via nucleosome sliding. Individuals with pathogenic CHD3 variants showed developmental 
delays or intellectual disability with varying degrees of severity, and often macrocephaly 
and prominent speech problems. A remarkable facial phenotype was also observed in the 
majority of affected individuals. Most individuals had missense variants clustering within 
the ATPase/helicase domain of CHD3. We performed experimental assays measuring ATPase 
enzyme activity and nucleosome sliding capacities in order to determine pathogenicity and 
better understand the molecular mechanisms underlying this disorder.
Chapter 5 shows the results of our research on WDR5, a highly conserved protein 
involved in a wide array of biological functions, mostly as part of protein complexes (e.g. 
the COMPASS complex) affecting gene regulation via post-translational modification of 
histones. We collected clinical data on ten unrelated individuals with six different de novo 
variants in WDR5. We described the phenotypic spectrum of the newly identified WDR5-
associated neurodevelopmental disorder, which includes speech and language delays, 
intellectual disability, epilepsy, autism spectrum disorder, abnormal growth parameters, 
heart abnormalities and hearing loss. Three-dimensional protein structures indicated that 
all residues affected by missense variants are located at the surface of one side of the WDR5 
protein, and we predicted that five out of the six found variants might disrupt interactions 
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with RbBP5 and/or KMT2A/C. Our research on WDR5 highlights the important role of 
COMPASS family proteins in neurodevelopmental disorders.
While heterozygous variants in various FOXP genes cause developmental disorders, the 
phenotype associated with pathogenic variants in FOXP4 has not been previously described. 
In Chapter 6 we studied FOXP4 by assembling a cohort of eight individuals with heterozygous 
and mostly de novo variants in this gene. We collected clinical data for six individuals: five 
individuals with a missense variant in the forkhead box domain of FOXP4 and one individual 
with a truncating variant. Overlapping features included speech and language delays, growth 
abnormalities, congenital diaphragmatic hernia, cervical spine abnormalities and ptosis. 
Luciferase assays showed loss-of-function effects for all missense variants in the forkhead 
box domain, while BRET assays showed intact dimerization capacities. In short, our findings 
show that, in addition to FOXP1 and FOXP2, loss-of-function of FOXP4 is associated with an 
autosomal dominant developmental disorder with speech and language delays. 
Besides the identification and characterization of new Mendelian disorders, in Chapter 7 
we investigated speech and language impairments and neuropsychological functioning in 
a known neurodevelopmental disorder: SATB2-associated syndrome (SAS). We performed 
detailed oral motor, speech and language profiling in combination with neuropsychological 
assessments in 23 individuals with a molecularly confirmed SAS diagnosis. We identified 
severe language delays in all individuals, defined underlying speech conditions for all verbal 
individuals and a common profile of adaptive functioning in this disorder. In addition to 
overlapping and recurrent phenotypes, we also observed a high variability, mainly in severity 
of features. This study gives more insight in speech, language and neuropsychological 
functioning in individuals with SAS, and provides families, therapists and other caregivers 
with information to guide diagnostic and treatment approaches.
While Chapter 2-7 shows that there is no doubt that rare pathogenic variants can cause 
severe speech and language impairments (including DLD), we still know little about the 
proportion of children with a DLD that carry a monogenic causal variant. In Chapter 8 we 
describe the design of a prospective cohort study, the GENTOS study, to systematically 
assess the diagnostic yield of whole genome sequencing in DLD. With this study we also aim 
to identify additional genes in which variants can cause DLD, the corresponding molecular 
pathways and the type of genetic variation involved. Knowledge of frequencies and types of 
underlying molecular causes will lead to a better understanding of the genetic architecture in 
DLD, but is also crucial to better guide referral strategies and diagnostic decisions. Inclusion 
for the GENTOS study started in March 2020 and is still ongoing at the time of writing.
In Chapter 9 we summarize the results of our research and describe the clinical relevance and 
implications. We discuss how we studied de novo variants in children with developmental 
speech and language disorders, to identify five new neurodevelopmental disorders with 
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associated phenotypes not restricted to speech and language disorders. In addition to 
similar molecular disruptions giving rise to different phenotypes in different probands, we 
showed how different underlying mechanisms and pathways can lead to similar disturbances 
in speech and language. We did not find any evidence for the existence of “speech and 
language-disorder specific” genes, but we observed that pathogenic variants in a subset of 
the total group of neurodevelopmental disorder genes, including the genes characterized in 
this thesis, give rise to neurodevelopmental disorders with prominent speech and language 
dysfunction. For the classification of genetic disorders of speech and language, we think that 
clinical practice is better suited to a model which acknowledges the diversity of features 
associated with variants in a given gene, rather than a model in which variants in any single 
gene lead to a highly specific neurodevelopmental phenotype. 
For the future, we suggest not to be reluctant to use next generation sequencing in 
individuals who present mainly or solely with developmental speech and language disorder. 
A molecular diagnosis can benefit affected individuals and their families, as it can provide 
clarity about the cause of the disorder, recurrence risk and the incidence of possible 
relevant co-morbidities. To improve genetics research in the speech and language field, 
systematic and consistent phenotyping is of paramount importance and remains one of the 
big challenges. Furthermore, research consortia, data sharing and patient empowerment 
are highly recommended and will benefit all parties in performing meaningful research with 




De meeste kinderen verwerven zonder al te veel moeite spraak- en taalvaardigheden, maar 
voor sommige kinderen geldt dit niet: zij hebben problemen met de spraak- en taalontwikkeling. 
Als deze problemen aanhouden, kan een kind een spraak- of taalontwikkelingsstoornis hebben. 
Spraak- en taalontwikkelingsstoornissen zijn neurobiologische ontwikkelingsstoornissen. 
Kinderen met deze aandoeningen kunnen problemen hebben met verschillende aspecten 
van de spraak- en taalontwikkeling, en ook de ernst van de problemen kan zeer variabel zijn. 
Spraak- en taalontwikkelingsstoornissen komen vaak samen voor met andere ontwikkelingss-
toornissen zoals bijvoorbeeld ADHD, een vertraagde motorische ontwikkeling en dyslexie. De 
aanwezigheid van andere ontwikkelingsstoornissen kan het stellen van een juiste diagnose of 
het toepassen van de juiste behandeling soms bemoeilijken.
In Hoofdstuk 1 geven we een overzicht van de huidige literatuur over spraak- en taalontwik-
kelingsstoornissen. We beschrijven de klinische presentatie, de veelgebruikte terminologie 
en diagnostische categorisatie, en de huidige kennis over de genetische achtergrond van 
deze aandoeningen. Vanuit familiestudies en tweelingstudies is al bekend dat het ontstaan 
van spraak- en taalontwikkelingsstoornissen sterk wordt beïnvloed door genetische 
factoren. De onderliggende genetische basis is echter vaak complex en multifactorieel, en 
de precieze bijdrage van Mendeliaans overervende DNA-varianten aan het ontstaan van 
spraak- en taalontwikkelingsstoornissen is tot op heden onbekend.
Het doel van dit proefschrift was om Mendeliaans overervende oorzaken van spraak- en 
taalontwikkelingsstoornissen te bestuderen, om de moleculaire achtergrond van deze 
aandoeningen beter te begrijpen om zo uiteindelijk de zorg te kunnen verbeteren. We 
bestudeerden hiervoor de impact van zeldzame de novo varianten vanuit een klinisch en 
moleculair perspectief, en maakten hierbij gebruik van veel verschillende methoden zoals next 
generation sequencing, systematisch fenotyperen en functionele laboratoriumexperimenten. 
Door deze aanpak hebben we vijf nieuwe Mendeliaans overervende aandoeningen ontdekt en 
gekarakteriseerd waarbij spraak- en taalproblemen een belangrijk symptoom zijn (Hoofdstuk 
2-6), en hebben we het spraak-, taal en neuropsychologisch profiel van SATB2-geassocieerd 
syndroom (een bekende aandoening waarbij ernstige spraakproblemen op de voorgrond 
staan) uitgebreid in kaart gebracht (Hoofdstuk 7). We hebben ook een prospectieve cohort 
studie opgezet (Hoofdstuk 8) waarmee op een systematische manier de bijdrage van de novo 
varianten aan het ontstaan van taalontwikkelingsstoornissen (TOS) kan worden onderzocht.
Hoofdstuk 2 beschrijft ons onderzoek naar pathogene varianten in MED13, een gen dat 
codeert voor een component van de CDK8-kinase module, dat reversibel kan binden met het 
zogenoemde Mediator complex. We hebben klinische gegevens en gegevens over de gevonden 
varianten verzameld van 13 individuen met pathogene varianten in dit gen, en zo hebben we een 
nieuwe ontwikkelingsstoornis beschreven, die wordt gekarakteriseerd door een verstandelijke 
beperking (of algehele ontwikkelingsachterstand) en spraak- en taalstoornissen. Bijkomende 
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kenmerken die werden gezien in een deel van de personen met varianten in MED13 waren 
autismespectrumstoornis, ADHD, hypotonie, afwijkingen aan de oogzenuw, Duane anomalie 
en milde aangeboren hartafwijkingen. Naast zes truncerende varianten vonden we ook een 
clustering van niet-truncerende varianten (missense varianten en een in-frame deletie van 
één aminozuur) in twee verschillende regio’s van het MED13 eiwit: een N-terminale en een 
C-terminale regio. De vier mutaties in de N-terminale regio beïnvloeden twee naast elkaar 
gelegen aminozuren waarvan bekend is dat zij een rol spelen bij de ubiquitinatie en degradatie 
van MED13; p.Thr326 en p.Pro327. Al met al kan door ons onderzoek MED13 worden toegevoegd 
aan de groep van ‘CDK8-kinase module-associated disease genes’.
In Hoofdstuk 3 presenteren we de resultaten van onze studie over POU3F3 (ook bekend 
als Brain-1), een gen dat codeert voor een transcriptiefactor die essentieel is voor een 
goede genregulatie tijdens de vroege hersenontwikkeling. We vonden 19 personen met 
heterozygote truncerende varianten of missense varianten in dit gen, en stelden vast dat 
al deze personen een ontwikkelingsachterstand en/of verstandelijke beperking hadden 
met hierbij ook problemen met de spraak- en taalvaardigheden. De meerderheid van 
deze personen had opvallende oorafwijkingen: laagstaande, prominente oren en vaak 
zogenoemde cupped ears. Met luciferase experimenten konden we aantonen dat twee 
missense varianten de transactivatie capaciteit van de transcriptiefactor verlaagden, terwijl 
een andere variant juist een toegenomen functie liet zien. Met bioluminescence resonance 
energie transfer (BRET) interactie experimenten zagen we dat alle getrunceerde versies 
van POU3F3 een significant verminderde dimerisatie lieten zien, terwijl alle missense 
varianten wel een normale dimerisatie met POU3F3 vertoonden. Alles bijeengenomen 
toonden wij aan dat mutaties in POU3F3 een karakteristieke en mogelijk ook herkenbare 
ontwikkelingsstoornis kunnen veroorzaken.
De identificatie van pathogene varianten in CHD3 als oorzaak voor een ontwikkelingsstoornis 
met macrocefalie en opvallende spraakproblemen is beschreven in Hoofdstuk 4. Als 
onderdeel van een grote internationale samenwerking verzamelden we gegevens over 
fenotypes en varianten van personen met een de novo variant in CHD3. CHD3 is een gen dat 
codeert voor een eiwit dat betrokken is bij chromatin remodeling via nucleosome sliding. 
Personen met een pathogene variant in CHD3 hadden een ontwikkelingsachterstand of 
verstandelijke beperking met verschillende gradaties van ernst, en vaak ook macrocefalie en 
duidelijke spraakproblemen. Bij de meerderheid werden ook opvallende uiterlijke kenmerken 
gezien. De meeste personen in onze studie hadden missense varianten, clusterend in het 
ATPase/helicase domein van CHD3. Met functionele experimenten hebben wij de de ATPase 
enzymactiviteit en de nucleosome sliding capaciteit van verschillende varianten bepaald om 
zo de pathogeniciteit te kunnen beoordelen, en zo de moleculaire mechanismen van deze 
aandoening beter te kunnen begrijpen.
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Hoofdstuk 5 laat de resultaten zien van ons onderzoek naar WDR5, een sterk geconserveerd 
eiwit betrokken bij zeer veel verschillende biologische processen, meestal als onderdeel 
van een eiwitcomplex (bijvoorbeeld het COMPASS complex) dat genregulatie beïnvloedt 
via prosttranslationele modificatie van histonen. We verzamelden klinische gegevens van 
tien personen met zes verschillende de novo varianten in WDR5. We beschreven het spec-
trum van fenotypes geassocieerd met deze nieuwe ontwikkelingsstoornis veroorzaakt door 
WDR5-varianten, waarbij o.a. een achterlopende spraak- en taalontwikkeling, verstandelijke 
beperking, epilepsie, autismespectrumstoornissen, abnormale groeiparameters, hartafwi-
jkingen en gehoorverlies werden gezien. Door de varianten te visualiseren in driedimensio-
nale eiwitstructuren zagen we dat alle betrokken aminozuren (aminozuren beïnvloed door 
missense varianten) aan het oppervlak van één kant van het WDR5 eiwit lagen, en voor-
spelden we dat vijf van de zes gevonden varianten de interactie met RbBP5 en/of KMT2A/C 
verstoren. Ons onderzoek over WDR5 onderstreept de belangrijke rol van eiwitten uit de 
‘COMPASS complex’-familie in ontwikkelingsstoornissen.
Hoewel heterozygote varianten in verschillende FOXP genen ontwikkelingsstoornissen 
kunnen veroorzaken, was het fenotype veroorzaakt door pathogene varianten in FOXP4 tot 
nu toe nog niet beschreven. In Hoofdstuk 6 bestudeerden we FOXP4 door een cohort van 
acht personen met een heterozygote en meestal de novo variant in dit gen samen te stellen. 
We verzamelden klinische gegevens over zes personen: vijf personen met een missense 
variant in het forkhead box domein van FOXP4 en een persoon met een truncerende variant. 
Overlappende kenmerken waren spraak- en taalproblemen, afwijkende groeiparameters, 
een aangeboren breuk in het middenrif (hernia diafragmatica), afwijkende nekwervels en 
een hangend ooglid (ptosis). Luciferase experimenten lieten een loss-of-function effect zien 
voor alle missense varianten in het forkhead box domein, terwijl BRET experimenten voor 
deze varianten een normale dimerisatie capaciteit liet zien. Al met al toonden wij aan dat 
dat, naast FOXP1 en FOXP2, een verlies van functie van FOXP4 ook geassocieerd is met een 
autosomaal dominante ontwikkelingsstoornis met taal- en spraakproblemen.
Naast het identificeren en karakteriseren van nieuwe Mendeliaans overervende aandoeningen, 
onderzochten we in Hoofdstuk 7 de spraak- en taalstoornissen en het neuropsychologisch 
functioneren in een bekende ontwikkelingsstoornis: SATB2-geassocieerd syndroom (SAS). We 
hebben hiervoor gedetailleerd logopedisch onderzoek verricht van zowel de mondmotoriek, 
spraak- en taalvaardigheden, in combinatie met neuropsychologische testen in 23 personen 
met een moleculair bevestigde diagnose SAS. We stelden vast dat alle personen ernstige 
taalachterstanden hadden, konden onderliggende spraakproblemen definiëren voor alle 
verbale personen, en zagen een overeenkomend profiel voor het adaptief functioneren bij 
deze aandoening. In aanvulling op de overlappende en terugkerende fenotypes was er ook 
een sterke variabiliteit, met name in ernst, van de kenmerken van deze aandoening. Deze 
studie geeft meer inzicht in het functioneren op spraak-, taal en neurologisch gebied in 
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personen met SAS en geeft families, behandelaars en andere zorgverleners informatie die 
van belang kan zijn voor goede diagnostiek, behandeling en begeleiding.
Hoewel Hoofdstuk 2-7 laten zien dat er geen twijfel is dat zeldzame pathogene varianten 
ernstige spraak- en taalstoornissen (inclusief TOS) kunnen veroorzaken, is het nog niet duidelijk 
hoeveel kinderen met TOS zo’n monogene oorzakelijke DNA-variant hebben. In Hoofdstuk 8 
beschrijven wij de opzet van een prospectieve cohort studie, de GENTOS studie, om systematisch 
de ‘diagnostische opbrengst’ van genoomsequencing bij TOS te onderzoeken. Met deze studie 
hopen we nog meer genen te vinden waarin varianten TOS kunnen veroorzaken, evenals de 
bijbehorende moleculaire pathways en het type varianten dat hierbij betrokken is. Meer kennis 
over frequentie van genetische aandoeningen en de soorten genetische varianten is belangrijk 
om de genetische achtergrond van TOS te begrijpen, maar is ook cruciaal voor het bepalen van 
de juiste verwijsstrategieën en diagnostische beslissingen. Inclusie voor de GENTOS studie is 
gestart in maart 2020 en is nog steeds bezig op het moment van schrijven.
In Hoofdstuk 9 vatten we de resultaten van ons onderzoek samen en beschrijven we de klinische 
relevantie en implicaties. We beschrijven hoe we de novo varianten in kinderen met spraak- 
en taalontwikkelingsstoornissen bestudeerden, en zo vijf nieuwe ontwikkelingsstoornissen 
hebben geïdentificeerd waarbij het geassocieerde fenotype breder was dan alleen spraak- 
en taalstoornissen. We lieten zien hoe vergelijkbare moleculaire defecten verschillende 
fenotypes kunnen geven bij verschillende personen, en hoe verschillende onderliggende 
moleculaire mechanismen vergelijkbare stoornissen in de spraak- en taalontwikkeling kunnen 
veroorzaken. We hebben geen bewijs gevonden voor het bestaan van ‘spraak- en taalstoornis-
specifieke genen’, maar we zagen wel dat pathogene varianten in een deel van de totale groep 
van genen geassocieerd met ontwikkelingsstoornissen, inclusief de genen gekarakteriseerd 
in dit proefschrift, ontwikkelingsstoornissen kunnen veroorzaken met prominente 
spraak- en taalproblemen. Voor de classificatie van genetische stoornissen met spraak- en 
taalproblematiek, denken wij dat een model dat de diversiteit van kenmerken geassocieerd 
met varianten in een specifiek gen erkent beter aansluit bij de klinische praktijk dan een model 
waarbij varianten in een specifiek gen altijd leiden tot een heel specifiek fenotype.
Voor de toekomst is het wat ons betreft belangrijk om niet terughoudend te zijn met het gebruik 
van next generation sequencing in personen waarbij een spraak- of taalontwikkelingsstoornis 
op de voorgrond staat. Een genetische diagnose kan voor aangedane personen en hun 
familieleden belangrijk zijn, omdat het duidelijkheid kan geven over de oorzaak van de 
problemen, de herhalingskans en over het optreden van mogelijk relevante co-morbiditeit. 
Om wetenschappelijk onderzoek over genetica van spraak- en taalstoornissen te verbeteren, 
is systematisch en consistente fenotypering cruciaal, dit blijft één van de grootste uitdagingen. 
Daarnaast zijn research consortia, het delen van data en patient empowerment belangrijk, en 
kan dit alle partijen ten goede komen bij het verrichten van betekenisvolle studies met grote 




Daar is het moment dan eindelijk, mijn boekje is af! En dit boekje was absoluut nooit tot 
stand gekomen zonder de steun en bijdragen van heel veel verschillende mensen op heel 
veel verschillende momenten. Ik voel me vereerd met zoveel mooie, leuke en getalenteerde 
mensen te hebben gewerkt (of nog steeds te werken), maar ook om buiten het werk zoveel 
fijne mensen om mij heen te hebben…dus bij deze alvast voor iedereen die daar ook maar 
op enige wijze aan heeft bijgedragen: mijn dank is groot!
Allereerst natuurlijk heel veel dank voor mijn promotieteam: Han, Simon en Tjitske. Han, 
wat heb ik veel van jou geleerd, en wat was het fijn om jou als promotor te hebben. Als ik 
iets moeilijk vond, gefrustreerd was over een samenwerking of situatie, of even niet wist 
hoe verder kon ik altijd bij jou terecht en nam je me altijd serieus. Jouw brede kennis over de 
genetica-geschiedenis maar ook visie op de toekomst van ons vakgebied is een fantastische 
bron van inspiratie voor elke geneticus-in-spé. Je nuchtere e-mails met toepasselijke 
citaten of slechte grappen waren een zeer welkome verademing in de soms rare wereld 
van wetenschappelijke tijdschriften, ethische commissies en bureaucratische procedures. 
Ik vergeet nooit meer hoe ik onderweg naar de ESHG in Göteborg een mail kreeg van jou, 
als reactie op de mededeling dat onze studie-opzet wéér niet was goedgekeurd door de 
ethische commissie, met daarin: ‘als ik je zie krijg je een ijsje’. Precies wat ik nodig had 😊 
(niet dat ijsje, wel die e-mail). 
Simon, it was an honour to be able to work in your lab and to be a member of the very famous 
Protein Group. You, as well as all the other Language & Genetics people, have created a great 
atmosphere and a very safe space for me to develop my wetlab skills and research skills in 
general. I admire your knowledge on a wide range of genetics-related topics, varying from 
basic molecular biology, cell-based assays and animal studies to complex trait analyses and 
evolutionary genetics, in combination with the fact that you are always open for questions 
and discussions. Over the last four-and-a-half years, you have patiently corrected all my 
English mistakes and every time I am writing an English text now, I think about your text 
balloons with comments like: “the word data is plural”. I also want to specifically thank you 
and Han for the endless support and trust in me in the most difficult months of my PhD in 
May and June 2017.
Tjitske, al sinds ik als co-assistent bij de Genetica rondliep werken we samen aan 
onderzoeksprojecten. Jij hebt mij, altijd geduldig, de eerste kneepjes van onderzoek doen 
geleerd, terwijl ik zelf soms nog geen idee had waar ik eigenlijk mee bezig was. Nadat het 
DDX3X project een beetje uit de hand liep qua grootte, wist ik zeker dat ik verder wilde met 
onderzoek, en het was  ontzettend fijn om dit onder jouw begeleiding te kunnen doen. Ik 
vind het bewonderenswaardig hoe je altijd voor mij klaar stond en klaar staat, ook als jouw 
thuissituatie het eigenlijk niet altijd toe laat, of als ik ’s avonds om 22.00 een artikel probeer 
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te submitten en toch nog ineens iets van je nodig heb. Ik hoop dat we nog vele jaren mogen 
samenwerken en de ‘Friese vibes’ op de afdeling hoog kunnen houden!
I want to sincerely thank all the wetlab members in the Max Planck Institute, for helping me 
out and introducing me to the fantastic world of molecular genetics. I have to admit I was 
a bit nervous, at my first morning, when I arrived in the lab around 8.30. But that changed 
immediately after I met all my new colleagues, and discovered the common lab working 
ours started around 9.30-10.00, what a blessing! Pela, I could not have wished for a better 
supervisor in the first year of my PhD. Although I did not even know what a plasmid was 
when I started, you patiently helped me and your knowledge and experience, alternated 
with a great sense of humour (and many comments on the Dutch food and healthcare 
system), made it a pleasure to work with you. I’m still sad that you left me, but I’m very glad 
you’re living the good life now in the UK and you still support me via Whatsapp messages 
now and then! 
Sara, such a pity our time together in the lab was too short, but the ‘Lanterneta Paranoica’ 
labels at my bench have always reminded me of our good times (and PLA struggles). I’m 
looking forward to visiting you (and my best friend Ona!) in Badalona, I’m sure that will 
happen again someday. Elliot, thank you for all your help and positivity, especially with 
setting-up BRET experiments. Ary, I would simply not have survived in the lab without you. 
You are the corner stone of the protein group, always close by to help out, when I couldn’t 
find something, had no clue what I was doing or get the best tips & tricks to do everything 
faster/smarter/better (or to provide me with Taralli or self-made cake). Your creativity with 
cooking skills/birthday surprises/experiment solutions is unbelievable. And outside the lab 
we had so many good times too, with the ‘Dutch songs playlist’ at your wedding in Italy as 
one of the highlights. Laura, thank you for being a great desk-neighbor and a Pancake Day co-
organizer. We should still start filming for our ‘do’s and don’ts series’; great lab life hacks (by 
Laura) and how to screw up your co-IP or western blot (by Lot). Joery, of course you deserve 
a very special thanks too. As a Master student, and later as a PhD colleague, you have taught 
me so much about lab skills and experimental designs (and about ants, not to forget). After 
Pela left, I appointed you as my ‘lab supervisor’ and you took that job seriously. You are a 
great colleague and friend, and I’m sure you will have a great career ahead of you, with lots 
of ‘kwark’ and peanut butter! Maggie, I am so happy that you decided to join our group 
too. Although I still cannot handle the idea of ‘Essence of Chicken’ or ‘BBQ-fried dough’, it 
was great to have you around and to have so many funny discussions on science or life in 
general. Roos, although our time in the lab together was short, I am grateful for all the cells 
you split for me (and the good conversations of course), and I’m sure we will see each other 
in future, either on a bike or maybe as a new colleague? I also want to thank many other MPI 
colleagues: Fabian, Midas, Paolo, Elpida, Kai, Moritz, Janine, Ine, Jelle, Cleo, Karthik, Jasper, 
Jurgen, Else, Ellen, Martina and ………. (please fill in you own name if I accidentally forgot 
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you), for all the help, for great collaborations, fun Christmas parties, Friday pizza events, 
random ice cream moments and so much more! 
Het voordeel aan twee werkplekken is dat je ook dubbel zoveel leuke collega’s kunt hebben. 
De sectie Genetica in het Radboud is een warm bad waarin ik me ontzettend thuis voel, en 
dat komt vooral door al die leuke mensen die daar rondlopen. Ik wil alle onderzoekers van 
de Klinische Genetica bedanken: Linde, Elke, Chantal, Janet, Joost, Jeroen, Dmitrijs, Bianca, 
Sandra, Jolijn, maar ook iedereen die al lang weer weg is en natuurlijk de nieuwe lichting 
die nu de onderzoekskamer bemant. Linde, ik hoop dat onze speciale samenwerking (L&L 
voor al uw DNA en neuropsychologie-vragen) nog lang in stand blijft! Janet, dank voor al je 
betrokkenheid en ondersteuning bij Biobank-, Castor- of ethische commissie-vragen. Elke, 
wat een heerlijk persoon ben jij, jammer dat onze kamer zo plotseling werd opgeheven, ik 
mis de stapels Autodrop en verse dadelvoorraad! Jolijn, jij hebt als student fantastisch werk 
verricht voor de WDR5 studie, hopelijk mogen we je in de nabije toekomst als arts-assistent 
of arts-onderzoeker verwelkomen.
En ook al heb ik alle AIOS/ANIOS voor meer dan vier jaar in de steek gelaten, ik wil jullie 
toch ook bedanken voor alle support. Lex, Ozlem, Illja, Anneke, Femke, Inci, Milou, Jeroen, 
Erika, Nynke en Thatjana (voor mij hoor je er nog steeds bij hoor!), wat hebben we een 
fijne groep samen, hopelijk snel weer meer borrels en ‘buitenschoolse’ activiteiten! Bregje, 
heel veel dank voor je steun en flexibiliteit als opleider, waardoor ik later terug kon komen 
als AIOS dan oorspronkelijk gepland. Mede door jou ben ik als student ooit helemaal 
enthousiast geworden over Genetica, en daar heb ik nog geen moment spijt van gehad. 
Ik vind het fantastisch dat ik nu onder jouw hoede (en die van Yvonne!) mijn opleiding tot 
klinisch geneticus mag afmaken. Corrie, ik hoop dat we snel weer eens kunnen lunchen 
samen, om alle roddels van de afdeling te kunnen doornemen 😉. En natuurlijk voor alle 
stafleden, PAs/genetisch consulenten, ons fantastische (staf)secretariaat en de onmisbare 
maatschappelijk werkers, en iedereen die ik nu vergeet: dank voor jullie mental support, 
inhoudelijke bijdragen, gezellige lunches en voor de altijd fijne sfeer op route 836. Door al 
dat thuiswerken besef ik des te meer hoe gezegend ik ben met zulke fijne collega’s. Laten we 
snel weer de dansvloer onveilig maken met z’n allen, ‘klinische genetica-style’!
Een speciaal bedankje ook voor alle Klinisch Genetiski-deelnemers van de afgelopen jaren. 
Wat begon als een spontaan plan in de Aesculaaf, is geëindigd in een jaarlijkse traditie die 
(na een onderbreking in 2021) hopelijk nog héél vaak plaats gaat vinden. Ik kan niet wachten 
op de volgende Genetiski editie met foute skipakken, heuptasjes en haarbanden, een goede 
après ski-ski ratio, op slippers naar het ‘galadiner’ en natuurlijk vele andere legendarische 
momenten en anekdotes waar we weer een jaar op kunnen teren, maar waar is Joost?
Naast de collega’s van de sectie Klinische Genetica zijn er nog heel veel andere geniale 
Genetica collega’s die hebben bijgedragen aan het tot stand komen van mijn proefschrift. 
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Rolph en Nicole, wat fijn dat ik jullie altijd kan bellen als ik even twijfel over een variant of 
weer een query wil doen voor een nieuw kandidaat-gen. De afdeling Genetica is nergens 
zonder jullie! Christian, wat fijn dat ik altijd bij je kan binnenlopen (of eigenlijk loop jij altijd 
bij ons binnen) om te sparren over van alles en nog wat, variërend van nieuwe ideeën over de 
novo varianten of reduced penetrance tot inspiratie voor vakantieplannen of leuke borrels. 
Lisenka, dank voor al je hulp en kennis over o.a. CMO aanvragen, het is altijd leuk om met 
jou naar Hinxton of andere congressen te gaan, en ik hoop dat we in de toekomst meer 
kunnen samenwerken! Alex, jouw kennis over Genetica-land en sequencing-technieken is 
fantastisch, maar de vele borrels bij jou met over-the-top borrelplanken of versgemaakte 
pizza’s en (te veel) wijn zijn minstens zo fantastisch 😊 . 
Ik weet nog goed hoe ik na mijn afstuderen twijfelde of ik wel bij de afdeling Genetica 
wilde gaan werken, want ‘daar werken vast alleen maar saaie mensen’, dacht ik. Maar na 
het eerste dagje uit met een afterparty in de Sjors en Sjimmie was ik he-le-maal om. Ik 
denk met een grote glimlach terug aan alle borrels, uitjes en congressen die mijn PhD tijd 
hebben verrijkt: het Airbnb huis op een vakantiepark in Orlando (met lichtgevende koelkast 
en de partybus naar een vakantiehuis-feest), de nachtelijke fietstocht door Göteborg na 
een prachtige ESHG-feestavond, de ‘Nijmegen houses’ met bijbehorende ‘house parties’, de 
kerstdiners met afterparty in de Malle Babbe, het jaarlijkse dagje uit (maar zo leuk als het 
dagje uit 2015 wordt het helaas nooit meer, toch Martijn?), ‘spontane Genetica avonden’ 
tijdens de Vierdaagse en natuurlijk de vrijdagmiddagborrels in de Aesculaaf. Ik kan me niet 
meer voorstellen dat ik ooit dacht dat Genetica-mensen saai waren. A big thanks for all 
current or former Human Genetics colleagues making this all possible: Marloes, Martijn, 
Margot, Laurens, Stefan, Petra, Manon, Jakob, Judith, Ideke, Roos, Ralph, Susanne, Silvia, 
Laura, Ralph, and all the others I forget now: whether it’s in a serious Theme Discussion, at 
the dancing floor, in the Aesculaaf, or another random place: It’s always fun with you guys 
around! 
Margot, ik ben ontzettend blij dat wij elkaar gevonden hebben in onze beginjaren op de 
afdeling. Wat hebben we veel meegemaakt samen, daar kunnen we wel een boek over 
schrijven (hoewel ik nu wel even klaar ben met boeken schrijven). Ik weet nog goed hoe we 
samen onze eerste artikelen gingen submitten (eindeloze lijsten met co-auteurs invullen) 
en ons eerste praatje op een congres gingen geven (“haploinsufFICiency”). Ik hoop dat ik 
tijdens mijn promotie net zo relaxed kan zijn als jij tijdens de jouwe, en vind het fantastisch 
dat jij als paranimf naast me zult staan. Ik weet zeker dat we elkaar nog heel vaak gaan zien, 
niet alleen in Genetica-land maar ook daarbuiten! 
Karen en Leenke, wat fijn om met jullie samen te kunnen werken, ik kan me geen beter 
logopedistenteam wensen. Of het nou over wetenschap, promotiefrustraties of niet-werk 
gerelateerde onderwerpen gaat, het is altijd leuk met jullie! Ik hoop dat we ook de komende 
jaren nog samen kunnen werken aan research of in de kliniek, en ik weet jullie te vinden als 
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ik weer eens niet snap wat precies het verschil is tussen verschillende fasen of processen 
van de spraakmotoriek. Max, wat goed dat jij ons uit de brand kwam helpen toen we hard 
op zoek waren naar een psycholoog voor ons project. We gaan elkaar vast nog zien als jij je 
vervolgstudie uit gaat voeren!
Aardbananen, lievelingsmensen, Sjoeke, Afke, Lotver, AJ en Jildou: we kennen elkaar al meer 
dan twintig jaar, en nooit is het saai! Elk etentje, weekendje of reisje met jullie is fantastisch 
en o zo grappig, een heerlijke afwisseling van het soms serieuze leven. Ook al lopen onze 
levens soms aardig uiteen en wonen we niet bij elkaar om de hoek, ik weet zeker dat we 
elkaar altijd zullen blijven vinden, zullen blijven trakteren op random gadgets met aardbeien 
en bananen, en ooit gaat het lukken met die lustrumreis naar IJsland hoor, ik kijk er naar uit!
Ireen, Yoen, Helma, Dieke, Kars-Jan, Floor, Bob en vele andere oud MFVers en Formosa-
vrouwen, wat fijn om jullie nog steeds om mij heen te hebben als vrienden. Thee-avondjes, 
lunches en borrels zijn altijd een goede afwisseling van werkgerelateerde zaken. Floor, al 
vanaf het moment dat we samen meekeken bij Formosa hadden we elkaar gevonden. Ook 
al zijn we zo verschillend, we weten elkaar altijd weer te vinden voor wijze raad, fietsdates of 
kopjes thee. Ireen, Laura, Marleen, ook al wonen we allemaal niet meer bij elkaar in de buurt, 
het is altijd leuk om met jullie te zijn! Leonie, ik waardeer je niet-aflatende enthousiasme en 
positiviteit over zo ongeveer alles, en hoop dat we nog vele fietsuitjes of andere spontane 
activiteiten kunnen ondernemen. Heleen, Maaike, Leonie: ik heb de Tajine dates gemist 
in Corona-tijden, ik zal er snel weer een organiseren! Maaike, wat fantastisch om zoveel 
verschillende dingen met jou te kunnen delen: van hockeyteamgenoten tot huisgenoten, 
van samen reisleider zijn nu wekelijks samen op de tennisbaan. Ik weet zeker dat je een 
fantastische paranimf gaat zijn, en kom je ooit nog bij ons werken? 😉
De laatste vijf maanden van mijn PhD contract bestonden met name uit thuiswerken tijdens 
de ‘Corona-lockdown’, niet helemaal hoe ik het me had voorgesteld. Maar gelukkig waren 
daar de online pubquizzes, veel dank Martijn, Remi, Alex, Simon, Maaike, Martin en Marloes 
voor het wekelijkse enthousiasme, en voor het toevoegen van alle kennis over acteurs en 
films die bij mij (nog steeds, sorry!) ontbreekt. En gelukkig was fietsen nooit verboden tijdens 
Corona-tijden, en is dat altijd een prachtige afleiding van alles waar je maar afgeleid van wil 
worden, dus veel dank ook alle KEKkies en andere fietsmaatjes voor de mooie avonturen op 
de racefiets. Of het nou in de Ooijpolder is, in Girona, de Heuvelrug of Italië, op de fiets is 
het altijd genieten en zijn ‘PhD problemen’ ver te zoeken.
I want to thank all clinical geneticists and other collaborators that have contributed to all 
the studies in this thesis. Working in rare disease genetics can only be a success if there is 
collaboration and trust in each other, and I am very grateful the worldwide Human Genetics 
community is a great example of this.
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Daarnaast kan onderzoek in zeldzame ziekten niet plaatsvinden zonder families die bereid 
zijn hun eigen gegevens of de gegevens van hun kind te willen delen ‘voor de wetenschap’, 
bereid zijn om extra naar het Radboudumc te komen voor een studie, die ons op het spoor 
zetten van een nieuw gen of een nieuwe bevinding bij een bestaand gen… Daarom bij deze 
voor alle MED13, CHD3, POU3F3, WDR5, FOXP4 en SATB2 families die hebben meegewerkt, 
en ook de families die nog steeds deelnemen aan de GENTOS studie: Mijn dank is groot, 
zonder jullie bijdrage had dit proefschrift nooit geschreven kunnen worden! 
En als laatste wil ik mijn familie bedanken. Merel en Arjen, Wender en Janneke, ook al 
wonen we niet super dicht bij elkaar in de buurt, ik ben blij dat ik altijd bij jullie terecht 
kan voor fietsuitjes, logeeruitjes, om even te blijven eten of gewoon lekker sport kijken 
op de bank! Ik denk overigens dat Maren, Elin en Tessel misschien wel voor de meeste 
afleiding hebben gezorgd tijdens de laatste maanden van mijn PhD in het voorjaar van 2020 
waarin de wereld vrij klein werd en ik de hoeveelheid schrijfwerk voor mijn proefschrift 
nog groot was. De wekelijkse speel- en oppasdagjes in Bunnik waren een mooie afwisseling 
van het serieuze schrijfwerk, en ik ben trots dat ik tante mag zijn van zulke lieve, stoere en 
schattige nichtjes! Pap en mam, ook voor jullie heel veel dank. Thuiskomen in Sneek voelt 
altijd nog als thuiskomen, ook al is het huis niet meer hetzelfde. Wat ik ook doe, waar ik ook 
heen ga, ik weet dat jullie me altijd steunen en trots op me zijn. Mam, ook al weet je soms 
even niet meer het verschil tussen een ethische commissie of een manuscriptcommissie, 
je bleef altijd geïnteresseerd informeren naar hoe het met het onderzoek (en vooral met 
mij) ging. En pap, ik waardeer enorm hoe je altijd probeert te begrijpen wat ik precies heb 
gepubliceerd (en hoe je mijn artikelen van Twitter plukt als ik er zelf niet over begin!). Maar 
mijn allergrootste fan is misschien wel mijn oma: Oma Joke. Oma, als er iemand de afgelopen 
jaren vaak vroeg hoe het met mijn proefschrift ging dan was jij het wel! Je hebt altijd gezegd 
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